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Abstract 
Asthma is a common disease of the large airways and the airway epithelium has a sentinel 
role in the initiation of the disease. Interleukin-33 is located in the nucleus of airway 
epithelium and is increased in asthmatic airway epithelium. Furthermore the gene has been 
reproducibly associated with asthma by genome wide association studies. Originally 
identified as a nuclear factor, interleukin-33 was found to act as a cytokine via the receptor 
ST2. Since this point the majority of research on interleukin-33 has focused on its role as a 
cytokine. Studies of its nuclear role have investigated the expression of a handful of 
inflammatory genes. This thesis examines the role of nuclear interleukin-33 in the airway 
epithelium using a functional genomics approach.  
The alveolar A549 cell line and normal primary bronchial epithelial cells were found to 
express full-length interleukin-33 mRNA. Both were taken forward for interleukin-33 
knockdown studies using enzyme-linked immunosorbent assays to measure relevant 
cytokines in supernatants. Upon interleukin-33 knockdown, interleukin-1ß-induced 
interleukin-6 and interleukin-8 secretion was reduced in both A549 and primary cells. 
Microarray analyses of gene expression showed interleukin-33 affected genes involved in 
differentiation, cell-substrate adhesion and extracellular matrix organisation. In contrast, ST2 
knockdown resulted in increases in cytokine secretion upon interleukin-1ß stimulation with 
global gene expression analyses showing little overlap with interleukin-33-effected genes. 
Taken together, this suggests that the gene expression changes found upon interleukin-33 
knockdown were due to a nuclear role. Finally, chromatin-immunoprecipitation sequencing 
was used to determine genome wide the DNA-binding sites of interleukin-33. Transcription 
factor binding motifs and preferential binding near promoters and exons were found but 
further replicates are required for confidence in these results.  
This work shows that interleukin-33 has an important nuclear role that appears to regulate 
gene expression in a manner that could mediate the changes seen in the asthmatic lung.  
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1. Introduction 
1.1 Asthma  
Asthma is a chronic disease of the large airways and has a substantial morbidity and 
mortality, resulting in an estimated 15 million life years lost worldwide, similar to diabetes1. 
In the United Kingdom, 9.1% of the population have asthma costing the National Health 
Service over £1.1 billion in 2010-20112. Whilst the majority of asthma is well controlled, 5 to 
10% of patients with the most severe disease are refractory to treatments, have frequent 
exacerbations3 and are responsible for a disproportionate amount of the overall costs4. In 
order to adequately treat all cases of asthma, novel treatment methods and further knowledge 
of the mechanisms underpinning the disease are required.  
The large airways are covered in of a layer of epithelium upon a basement membrane of 
connective proteins below which connective tissue (lamina propria) and a layer of smooth 
muscle are found. The pathology of asthma manifests itself across these layers where the 
airways themselves are in a chronic state of inflammation, immune cell influx (Section 1.1.1) 
and structural cell remodelling (Section 1.1.2). In addition, a consistent feature of asthma is 
reversible airway constriction (airway hyper-responsiveness), where the airway smooth 
muscle contracts in response to bronchoconstrictors such as histamine.  
Current opinion is that asthma is an umbrella term for a number of disease subtypes with a 
similar phenotype. These can have distinct or overlapping causes, triggers, pathologies and 
patient-characteristics (reviewed by Hekking and Bel5). Subtypes include but are not limited 
to atopic, occupational, exercise-induced, non-eosinophilic, steroid-refractory and adult-onset 
asthma. The majority of asthmatics are atopic to common aeroallergens (skin-prick positive to 
any one allergen including cat fur, dog dander, grass pollen and house dust mite [HDM] 
extract)6 and to date the majority of research into asthma has been focussed on the atopic 
form.  
Atopy (known as allergy) is a form of hypersensitivity reaction where the immune system 
inappropriately responds to a benign foreign body, known as an allergen. This immune 
reaction is characterised by a chronic T-helper type 2 (TH2)-skewed response, usually 
reserved for defence against helminth infection. The mutually exclusive model of TH1 and 
TH2 is a simplification of T-helper type responses (reviewed by Hirahara7). This paradigm 
however, is still useful in order to understand the immune-skew in many atopic diseases. 
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Classically both types of T-helper response suppress the other, with TH1 responses being 
characterised by interferon (IFN)-γ and TH2 being characterised by a cytokine milieu of 
interleukin (IL)-5 and IL-13. A TH2 environment also skews the isotype of antibodies 
produced by B cells in response to allergens, with increased levels of immunoglobulin E (IgE) 
and decreased levels of IgG48. This is important as IgE activates cells involved in the 
pathology of atopic diseases whereas IgG4 competitively binds to the allergen, allowing for 
clearance without pathology (further details in Section 1.1.1 below).  
1.1.1 Airway inflammation 
The human body has two interacting populations of cells that protect the body (against 
viruses, bacteria, parasites or cancer). The adaptive immunity is composed of T and B cells 
and possesses the ability to “remember” previous infections and specifically target epitopes 
on the pathogen for clearance, as in vaccination. The innate immunity is composed of cells 
that instead recognise general components of pathogens via pathogen-associated molecular 
pattern receptors (PAMPs) and are not activated by specific antigens. Structural cells as well 
as haematopoietic cells make up the innate immune system. In order for an adaptive immune 
response to be generated, antigen-presenting cells of the innate immune system (canonically, 
dendritic cells and macrophages) must be activated by PAMPs or host inflammation (i.e. 
cytokines released from nearby cells). These activated antigen-presenting cells then migrate to 
the secondary lymphoid organs to present antigens to T cells (reviewed by Paul9).  
Airway inflammation in atopic asthma is characterised by a chronic TH2 response and IgE in 
the lungs, usually with an influx of eosinophils, activated mast cells, macrophages and T 
cells10,11. The innate immune system is required to prime the adaptive immune systems 
towards allergens:  dendritic cells and macrophages (antigen presenting cells) present 
allergens to naive T cells and polarise the T cells towards a TH2 response, which then interact 
with B cells. In this TH2 environment B cells undergo class switching and produce IgE against 
the presented allergen. When the allergen is encountered again it crosslinks mast cell-bound 
IgE and causes mast cell degranulation. This releases bronchoconstricting factors and 
chemoattractants resulting in recruitment of inflammatory cells. Although this section will 
focus on the TH2 skew in asthma, evidence of a TH17 skew in asthmatic patients has been 
identified12 and may cause a distinct subtype of asthma. 
The maintenance of the TH2 response requires cytokines such as IL-5 and IL-13, which are 
secreted by TH2 cells. Once a TH2 response is initiated, a positive feedback-loop maintains the 
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environment but importantly structural cells are required for the initiation. In mouse models 
of asthma, using either HDM (Dermatophagoides pteronyssinus) or extract from the fungus 
Alternaria alternata as the allergic trigger, the airway epithelium has been shown to be 
critical for initiation and it has a sentinel role. In the HDM model of asthma, STAT3 (signal 
transducer and activator of transcription 3) an innate immunity transcription factor was shown 
to be crucial for the asthma model by epithelium-specific knockout of the Stat3 gene13. The 
HDM model of asthma showed that the expression of the PAMP, toll-like receptor 4 (TLR4), 
on the surface of the airway epithelium is critical for the induction of the model14. Likewise, 
the A. alternata model requires protease activated receptor-2 (PAR-2) signalling from the 
epithelium15. These findings have shown that the epithelium, as the first line of defence 
against allergens, is key to activating the innate immune system and does so by releasing the 
“innate TH2 cytokines” IL-25, thymic stromal lymphopoietin (TSLP) and IL-33. These 
cytokines then activate the innate immune system, including dendritic cells, mast cells, 
basophils and type-two innate lymphoid cells (ILC2s). ILC2s represent a small proportion of 
haematopoietic cells but secrete high levels of the TH2 cytokines, IL-5 and IL-13.  ILC2s have 
been shown to be particularly important for priming the TH2 response16,17.  
Airway inflammation and remodelling can occur before clinical manifestations of asthma 
have become apparent18. These early changes have raised questions over the progression of 
pathogenesis, as it is not clear whether airway inflammation or airway remodelling occur at 
the same time or if one induces the other. An intrinsic increased sensitivity of the airway 
epithelium to allergens or an exaggerated response would induce stronger TH2 priming. The 
immune system could be responsible for the initiation of remodelling. For example immune 
cells secrete IL-13 which increases the number of mucus-secreting goblet cells in the 
airways19 and IL-13 also increases the sensitivity of airway smooth muscle to 
bronchoconstrictors20.  
1.1.2 Airway remodelling 
The structural changes seen in asthma occur in the larger airways. Many structural cell types 
are involved in the airway remodelling (Figure 1.1) resulting in increased airway smooth 
muscle21, sub-epithelial fibrosis (basement membrane thickening)22, an increase in the number 
of fibroblasts22, angiogenesis23 and epithelial changes (discussed further in Section 1.1.2.1). 
Each of these features is thought to contribute to the pathogenesis of asthma and they have a 
network of interactions that makes dissecting the individual role of a cell type complicated.  
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The airway smooth muscle of the asthmatic airway, which contracts to constrict the airways 
in an asthma exacerbation, is not only increased but it has also been shown to be hyper-
contractile in cell culture24. The basement membrane thickening occurs below the true 
basement membrane and is due to a deposition of extracellular matrix (ECM) proteins. This is 
a reservoir for secreted proteins such as growth factors although the ECM proteins alone can 
activate extracellular signalling between epithelial cells and underlying mesenchymal cells 
(these two cell types make up the epithelial mesenchymal trophic unit [EMTU]25 discussed in 
Section 1.1.2.1). Bronchial fibroblasts or fibroblast-like cell types are thought to cause the 
basement membrane thickening and in tissue culture, asthmatic fibroblasts appear to have an 
altered ECM deposition:breakdown ratio26, supporting this hypothesis. The increase in the 
bronchial blood vessels of the asthmatic airway has been associated with disease severity, 
eosinophil recruitment and oedema, with the latter considered to restrict the airways23.  
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Figure 1.1 Schematic illustrating the structural cell changes in the airways of asthmatics 
compared to healthy airways. 
The structures of healthy (left) and asthmatic (right) airways are shown. Labels indicate where 
cell type or feature is increased. 
1.1.2.1 Airway epithelial remodelling 
The airway epithelium is the first cell type that viruses, bacteria, fungi and noxious substances 
encounter in the lung.  Consequently it acts as a barrier as well as being the starting point of 
the innate immune response via PAMPs and other receptors known as damage-associated 
molecular patterns. Additionally, the airway epithelium secretes factors which produce a 
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chemical barrier, these include anti-bacterial peptides, anti-oxidants and protease inhibitors 
(reviewed by Swindle and colleagues27). The airway epithelium consists of three cell types: 
basal cells that are undifferentiated, goblet cells and ciliated cells. Goblet cells are found on 
the apical aspect of the epithelium and produce mucus that traps foreign particles. Ciliated 
cells are also apical and through cilia beating, push the mucus layer out of the airways. 
Together they form the mucocilliary escalator that clears the lungs of foreign bodies.  
There are several structural differences seen in the asthmatic airway epithelium when 
compared with healthy epithelium (illustrated and summarised in Figure 1.2). In asthmatic 
lungs, a notable increase of mucus is found, the major component of which is mucin (MUC) 
5AC28. This increase in MUC5AC is due to an increased number of goblet cells in the 
airways, a phenotype known as goblet cell hyperplasia. The TH2 cytokine, IL-13, induces 
goblet cell hyperplasia and increases MUC5AC levels through increasing levels of SAM 
Pointed Domain Containing ETS Transcription Factor (SPDEF)19. SPDEF is a critical 
transcription factor that controls goblet cell hyperplasia of the epithelium29. This transcription 
factor is a key regulator of the increased goblet cell number and mucin production found in 
asthmatics30,31.  
Asthmatic airway epithelium responds to injury, stimulation and infection with a more 
substantive increase in IL-6 and IL-8 release than that observed for normal airway 
epithelium31. Furthermore there is some evidence that the structural integrity and barrier 
function of epithelium from severe asthmatics is inherently compromised. Biopsies from the 
bronchi of asthmatics show an increased loss of the apical, differentiated cells32,33. This loss 
of apical epithelium may be due to the decreased expression of tight-junction proteins in 
asthmatic airways31,34. Tight-junction proteins are involved in the barrier function of the 
epithelium as they anchor cells together. Asthmatic epithelia also appear to be more 
susceptible to oxidative stress-induced apoptosis35, with airway biopsies from mild asthmatics 
having notably increased epithelial denudement32,33. This is somewhat controversial as 
Ordoñez et al.36 showed that in controlled mild asthmatics, bronchial biopsies had similar 
levels of epithelial denudement to controls.  This was in contrast however to work conducted 
in mild asthmatics by Barbato et al.32 and Lackie et al.33. Therefore the level of desquamation 
(hence denudement) may be affected by how well controlled the asthma is rather than being 
part of airway remodelling in asthma. Finally, the basal cells of the airway epithelium have 
been shown to be hyper-proliferative in asthmatics31, with undifferentiated basal cells forming 
a larger proportion of the airways.  
 23 
Another process may be involved in epithelial-remodelling in asthma. Epithelial-
mesenchymal transition (EMT) is a process whereby epithelial cells differentiate into 
fibroblast-like cells. This process is regulated by the EMTU interaction with growth factors 
(such as transforming growth factor ß1 and epithelial growth factor) and extracellular matrix 
(the latter via adhesion molecules) and additionally the process is altered by inflammation25. 
EMT may cause altered epithelial differentiation with increment of fibroblast markers such as 
vimentin, alpha smooth muscle and fibronectin rather than epithelial markers such as E-
cadherin. Ultimately this may lead to the increased numbers of fibroblast-like cells seen in 
asthmatic airways37. Indeed, when bronchial epithelium is grown at the air-liquid interphase 
(ALI, see further details below in Section 1.1.3), a higher proportion of asthmatic cells 
undergo EMT upon stimulation with a potent inducer of EMT, transforming growth factor-
ß138. Furthermore, using epithelial-specific LacZ reporter expression, Johnson and 
colleagues39 showed that chronic exposure of HDM in a mouse model induced EMT in the 
large airways thereby contributing to airway remodelling. The EMT process is regulated and 
involves the pathways of wound-healing, cell adhesion, inflammation, migration and 
extracellular matrix deposition.  These are all key pathways that are altered in asthma22,25,34.  
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Figure 1.2 Airway epithelial differences between healthy and asthmatic lungs 
Simplified phenotypes of healthy (left) and asthmatic (right) airway epithelium are shown. 
Labels indicate where cell number or function is increased.  
1.1.3 Methodological approaches for the investigation of asthma 
Asthma has been investigated using a wide range of methods from demographic studies and 
patient biopsies, to mouse models of asthma. Epidemiological studies have identified an 
increase in the occurrence of asthma and atopic disease in westernised countries40. Early twin 
studies had made clear that both a heritable component and an environmental factor explained 
the risk of developing asthma41. One of the most recent large studies involving Dutch twins 
indicated 63% heritability, though other estimates vary from 50-90%42. Early studies on post-
mortem biopsies from asthmatic airways showed the phenotype of airway remodelling and 
immune cell infiltration43. Exposure to aeroallergens such as HDM and A. alternata, along 
with “westernisation”, early-years respiratory virus infections and not drinking unpasteurised 
milk are associated with the risk of developing asthma (Reviewed by Martinez44) .  
Initial in vivo models were set up using ovalbumin (OVA, egg white protein) as the allergen, 
with intra-peritoneal sensitisation and subsequent inhaled challenge in mice. Although these 
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models induced inflammation of the airways, Johnson et al. established a mouse model using 
the relevant allergen, HDM45. The HDM model has since been adopted as a more specific 
model of allergic airway inflammation. Further models using A. alternata as the allergen have 
been investigated and appears to model steroid-resistant, severe asthma46. Using chronic OVA 
or HDM mouse models of asthma has shown that whilst airway remodelling does not resolve 
after cessation of allergen dosage, airway inflammation and airway hyper-responsiveness do 
resolve, although for the HDM model the induced airway hyper-responsiveness is in fact only 
partially resolved45,47. It should however be noted that the allergens used in mouse models of 
asthma have proteolytic properties. For example A. alternata activates PAR-2 signalling15 
whilst HDM cleaves tight junctions, both of which result in an increase in epithelial 
permeability48 hence properties of the allergens themselves may play a direct role in 
sensitisation.  
Cell culture techniques have allowed the culture of cell lines and primary cells from healthy 
and asthmatic patients. Cells can be grown as a monolayer submerged in growth media, in co-
culture with other cell types or in the case of epithelial cells in ALI. ALI culture has the 
drawback of being more costly, requiring a relatively high cell number and 21-28 days of 
differentiation.  Its biggest advantage however is that the culture enables the epithelium to 
differentiate into a pseudo-stratified model with basal un-differentiated cells and apical 
ciliated and goblet cells49,50. This culture method therefore more closely resembles the 
differentiated epithelium structure found in vivo in human lungs. ALI culture allows for 
comparisons to be made between disease states of patients because differentiated phenotypes 
are developed and trans-epithelial electrical resistance (TEER) established. TEER is a 
measure of the total conductivity and therefore the permeability of the barrier31,51. The ability 
to culture human cells has allowed the functional roles of these cell types to be assessed in 
isolation.   
Asthma is a complex disease, involving a number of genetic factors as well as environmental 
exposure resulting in the susceptibility to the disease. Historically, for many monogenic 
disorders, linkage analysis followed by positional cloning has been successful (e.g. 
Huntington’s disease52), yet this has proved more difficult in complex diseases. This may be 
due to linkage requiring large pedigrees or a collection of families that all have the same 
underlying genetic factors. Candidate gene studies were biased towards the known biology 
and were labour intensive, thus with the large number of potential candidates reproducible 
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results were difficult to obtain53. Since the advent of the human genome project, human 
genetic diversity has been opened up for study in new ways.  
Single nucleotide substitutions are one of the many sources of genomic variation and when 
these occur frequently they are known as single nucleotide polymorphisms (SNPs). SNPs may 
themselves have a functional impact (i.e. be a disease causing variant) or they can be in 
linkage disequilibrium with the disease causing variants and therefore act as a marker aiding 
the identification of the causal variant. The International HapMap Project54 has catalogued 
SNPs across different ancestries resulting in the generation of high-density SNP arrays. These 
arrays have been used in genome-wide association studies (GWAS) to identify SNPs 
associated with diseases. Thanks to the density of the SNPs genotyped across the genome, 
cases of disease with carefully matched controls in large numbers can be used in contrast to 
the earlier linkage studies where family pedigrees were required.  
The largest published GWAS for (doctor diagnosed) asthma was conducted by the GABRIEL 
consortium that genotyped 582,892 SNPs in 10,365 asthmatics and 16,110 controls55. The 
study identified 6 loci associated with asthma, implicating HLA-DQ (major histocompatibility 
complex, class II DQ), SMAD3, GSDMA (gasdermin A), ORMDL3 (sphingolipid biosynthesis 
regulator 3)/GSDMB (gasdermin B), IL2RB (interleukin 2 receptor subunit beta), 
IL18R1/IL1RL1 (interleukin 1 receptor-like 1; coding for ST2, the IL-33 receptor) and IL33. 
The association with IL33 has been further validated in another study of 5,416 asthmatics and 
12,649 controls across three ancestries in North America56. IL-33 was already of interest in 
asthma due to its role as a TH2 cytokine via ST2 signalling57 and an observed increase of IL-
33 in the asthmatic bronchial epithelium58.  Indeed, ST2 was already shown to be expressed 
on TH2 cells and absent on TH1 cells59,60. Furthermore, administration of IL-33 had been 
shown to induce goblet cell hyperplasia in mice that lacked an adaptive immune system61. 
1.2 IL-33 
IL-33 was originally discovered as a nuclear factor in canine and human endothelium (as 
DVS2762) and IL-33 in humans is constitutively expressed in barrier cells such as the 
epithelium63, endothelium64 along with other structural cells such as airway smooth muscle65 
and fibroblasts63. As mentioned in Section 1.1.1 above, IL-33 acts as ligand for ST257. ST2 
had already been established as an important receptor involved in TH2 responses66,67 and more 
recently noted for expanding ILC2s 68.  
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1.2.1 Localisation and release 
IL-33 was first discovered and characterised as a nuclear protein62. The homology-predicted 
nuclear localisation sequence (IL-3361-78) is now known to be unnecessary for translocation to 
the nucleus69 and instead amino acids 1-65 are required. Unlike most cytokines, IL-33 does 
not have a secretion sequence and is not cleaved within the cells in order to mediate secretion. 
For the majority of cell types, IL-33 is released upon non-apoptotic cell death70,71 and has 
been characterised as an alarmin63 i.e. a cytokine released upon necrosis.  
Fibroblasts upon stretching forces72 and normal human bronchial epithelial cells (NHBEs) 
upon A. alternata stimulation have been shown to secrete IL-33. NHBE stimulation with A. 
alternata was found to induce the release of ATP (adenosine triphosphate) and extracellular 
ATP caused IL-33 secretion73. Work from others have shown that A. alternata-induced ATP-
release is independent of PAR-274, contrasting murine models with A. alternata where PAR-2 
is critical for the release of IL-3315. Additionally, IL-33 can move from the nucleus to the 
cytoplasm upon A. alternata-induced ATP stimulation of NHBEs73. Kakkar and colleagues 
showed that IL-33 appears to be in a permanent flux in and out of the nucleus of fibroblasts72. 
Taken together these studies suggest that ATP signalling may cause the re-entry of IL-33 to 
the nucleus to be blocked, although as yet this has not been shown directly. Finally, co-
incubation of human corneal epithelial cells with ATP and Poly(I:C) 
(Polyinosinic:polycytidylic acid)  or flagellin caused an increase in IL-33 in the media, but it 
was not clear whether this induced cell death. In all other studies investigating human 
structural cells, increases in extracellular IL-33 have not been shown to be due to active 
secretion nor ruled out necrotic release of cellular contents. 
It appears that the pro-inflammatory environment of chronic diseases may cause the cellular 
localisation of IL-33 to change. For example, Prefontaine et al. showed that the bronchial 
epithelium in healthy patients had clear evidence of IL-33 in the epithelial cell nuclei, 
whereas the epithelium from severe asthmatics appeared to have more diffuse and 
cytoplasmic IL-3358. Staining for IL-33 has led to a number of contradictory results due to the 
paucity of robust antibodies (see discussion in Section 1.2.1.4 below) and it is therefore 
important that the detection of IL-33 is shown to be robust for localisation to be determined.   
1.2.2 Cleavage  
IL-33 is a member of the IL-1 family of cytokines and based on protein homology was 
predicted to be cleaved from an immature “pro-IL-33” form to a bioactive “mature” IL-3357. 
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Caspase-1 was predicted to cleave IL-33 at amino acid 112 and the majority of commercial 
recombinant IL-33 sources supply this “mature” IL-33 (IL-33112-270). Work by Cayrol and 
Girard however has shown that caspase-1 cleaves IL-33 at amino acid 178 and ablates IL-33’s 
cytokine activity70. Further work has shown that full length IL-33 (fl-IL-33) is bioactive 
although “mature” IL-33 is more potent in inducing inflammatory responses71. Within 
ionomycin-treated epithelium and endothelium, the calpain family of proteases can cleave IL-
33 within 30 residues upstream of serine 111, but this has not been shown to form a bioactive 
product75. Here ionomycin was used to raise the intracellular calcium levels, acting as an 
unspecific stimulation. There is more clarity with regard to the effects of IL-33 processing by 
the extracellular proteases, neutrophil elastase and neutrophil derived cathepsin G.  Both have 
the capability of cleaving full length IL33 (fl-IL-33) at amino acids 99 and 109 respectively, 
yielding products that are more pro-inflammatory than fl-IL-3376. It is unclear whether 
extracellular IL-33 is cleaved into a more active product or an inactivated product.  
Current literature suggests that the “mature” form of IL-33 does not occur in vivo, yet 
“mature” IL-33 (referred to as cytokine fragment IL-33, cf-IL-33) is almost exclusively used 
in stimulation experiments. Direct comparisons of these two versions of IL-33 have shown 
that fl-IL-33 is not as potent a cytokine as cf-IL-33, suggesting that the current literature may 
be skewed towards an artificially large response. This has further repercussions in its use as a 
stimulant for inducing ILC2s in humans and mice as this may further skew the importance of 
ILC2s by increasing their number to levels that would not be achieved in vivo.  
1.2.3 Functional domains and splice variants 
In addition to its role as a cytokine, studies of the protein sequence of IL-33 have revealed 
that it contains a prokaryotic helix-turn-helix DNA binding domain (IL-3328-68)64. Several 
studies have investigated the functional domains of IL-33 through transfection of truncated or 
mutated versions of IL33 (summarised in Figure 1.3). Of these, Carriere et al.69 showed that 
amino acids 1-65 are crucial for the nuclear localisation of IL-33 in Human embryonic 
kidney-293 cells (HEK293 cells) as assessed by confocal microscopy. This was further 
reduced to amino acids 40-53 through similar methods by Roussel and colleagues77. Roussel 
et al. showed that immunoprecipitation of a GST-tagged IL-3340-58 pulled down H2A and 
H2B histone proteins, and that mutation of the H2A acidic pocket abrogated the pull-down. 
This suggests that IL-33 may bind directly to the H2A-H2B dimer, although the pull-down 
using full length IL-33 was not demonstrated.  
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By over-expressing murine IL-33 in HEK293 cells, Ali et al.78 have shown that FLAG-tagged 
murine IL-33 immunoprecipitates with p65 and p50 of nuclear factor κB (NF-κB). 
Truncations of IL-33 revealed that amino acids 66-175 are required for this interaction. The 
authors, using electrophoretic mobility shift assays (EMSAs) and luciferase reporter assays, 
showed that IL-33 reduced NF-κB’s interaction with its binding sites. They found that 
transfection of full length murine IL-33 slightly delayed the inflammatory response of 
HEK293 cells to IL-1ß stimulation at the mRNA level. At the time of writing, there have been 
no studies showing an interaction with human IL-33 and NF-κB.  
 
Figure 1.3 The functional domains of IL-33 
Exons skipped in splice variants of IL-33 are shown in the context of functional domains of 
IL-33. Amino acid numbers are shown in italics and each exon or functional domain is shown 
relative to the full-length protein. Nuclear localisation69 and chromatin binding domains77 
overlap with exon 3, NF-κB interaction in murine IL-33 spans the end of exon 3 and extends 
into exon 678. The cytokine domain of IL-33 spans exon 5 to exon 857 and although this 
domain is not cleaved as previously assumed, the recombinant proteins that have been made 
and are available commercially code for this region.  
The IL33 gene has 8 exons. The first exon of the gene is not translated and this has led to 
some discrepancy in the numbering of exons. For clarity, exon 2 is defined as the first 
protein-coding exon of IL33. Several splice variants of IL33 have been reported using the 
methods of polymerase chain reaction (PCR) and Sanger sequencing. Variants missing exon 
3, exon 4, exon 5 or a combination of these exons have been found79 and this impacts the 
functional domains that are expressed (see Figure 1.3). Tsuda et al.79 transfected FLAG-
tagged IL-33 lacking exon 3 and detected FLAG bands only in the cytoplasmic compartment 
as expected from previous truncation experiments. Similarly, lacking exon 4 or exon 5 could 
potentially abrogate the NF-κB interaction shown previously in studies using murine IL-3378. 
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All isoforms of IL33 identified and reported to date contain exons 6-8.  It is important to note 
that cell lines appear to be more likely to express splice variants instead of full-length IL-3379. 
Therefore the choice of cell type for experimentation is important to recapitulate the in vivo 
role of IL-33, as highlighted by investigations using a hepatocellular carcinoma cell line 
(HuH-7). HuH-7 cells were found to express a splice variant lacking exon 4, stimulation with 
this variant on A549 cells induced IL-8 secretion whereas full length IL-33 did not 80.  
1.2.4 Detection of IL-33 
The detection of human IL-33 and in particular, which cellular compartment it is expressed in 
is contradictory. In epithelial cells, studies have reported detection of IL-33 in the nucleus 
alone58,73,81-87 or in the nucleus and cytoplasm20,88,89, with few finding IL-33 staining in the 
cytoplasm alone90,91. These discrepancies occur despite some studies using the same 
antibodies (Nessy-1 and polyclonal antibody from Medical and Biological Laboratories 
International), without any clear reason for the discrepancies seen. It is possible that the 
antibodies are not robust to minor variation in methodologies, yet there has been no direct 
comparison of this.  
Considering the published studies listed above, there is a general trend for IL-33 to be 
expressed in the nucleus of epithelial cells from healthy donors. Upon inflammation or a 
chronic inflammatory disease the protein appears to be both in the cytoplasm and nucleus or 
the cytoplasm alone. This is not consistent across all studies, for example in the nasal 
epithelium of allergic rhinitis patients. This is the site of inflammation for these patients and 
IL-33 has been found either in the nucleus alone92 or in the cytoplasm and nucleus89. Overall 
it seems that IL-33 is located in the nucleus for the majority of staining, with some 
cytoplasmic staining being possible, however the inconsistency in detection makes it difficult 
to draw firm conclusions and likewise have confidence with regard to which antibody is 
showing IL-33-specific staining.  
Enzyme-linked immunosorbent assay (ELISA) detection of IL-33 appears to be widely 
variable with serum levels of IL-33 in healthy patients either being undetectable91,93 or 
detected at high levels90. In allergic rhinitis, nasal IL-33 upon pollen stimulation remained 
below the detection threshold94, yet others have found basal levels of nasal IL-33 to be 
detectable95. This lack of detection has led some authors to concentrate supernatant and detect 
IL-33 using a Western Blot approach46,70,96. Recently, authors have called into question the 
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ability of current IL-33 ELISAs to be sensitive and specific when used to quantify serum 
levels of IL3397,98. 
1.2.5 Cytokine function 
IL-33 signals through the heterodimeric receptor of ST2 and IL1RAP (interleukin 1 receptor 
accessory protein) which ultimately leads to NF-κB, activator protein-1 (AP-1) or both factors 
being activated and inducing gene expression as summarised in Figure 1.4. The IL1RL1 gene 
codes for the membrane bound receptor ST2 (also known as ST2L) and an alternative splice 
variant produces a truncated version of the protein, soluble ST2 (sST2)99. Both variants 
contain the immunoglobulin-like repeats that allow for IL-33 binding. sST2 however lacks the 
transmembrane domain and the intracellular domain required for signalling. This causes sST2 
to be secreted and it acts as a decoy receptor for IL-33 signalling99,100.  
Pfeffer et al.101 Vitamin D in vitro appears to increase sST2 secretion from epithelial cells and 
lymphocytes, thereby reducing the effects of IL-33 stimulation. If this follows through in 
vivo, this would be an interesting mechanism of feedback.  Mast cells may regulate the 
cytokine function of IL-33 by several disparate mechanisms. When stimulated by IgE-
crosslinking or IL-33 stimulation, they increased the release of sST2 in vitro102, thereby 
limiting IL-33’s stimulatory capacity. Mast cells also secrete chymase that degrades IL-33 
and renders it inactive103 yet also can secrete cathepsin G which cleaves full-length IL-33 into 
a more active cytokine76. Mast cells are also responsive to IL-33, releasing Th2 cytokines104 
and increasing degranulation upon stimulation105. 
Interaction between IL-33 and ST2/IL1RAP causes a kinase-signalling cascade starting with 
the adapter proteins MyD8857 or MAL (MyD88-adapter-like)100. IL-33 stimulation causes 
activation of interleukin-1 receptor-associated kinases that activate mitogen-activated protein 
kinases and lead to AP-1 activation and nuclear translocation57. IL-33 stimulation also causes 
TRAF6 (TNF receptor-associated factor 6) activation, leading to inactivation of IκB (inhibitor 
of κB)106, thereby activating of NF-κB100. A simplified schematic of these pathways is shown 
in Figure 1.4.  
IL-33 stimulates a wide range of immune and structural cells altering their adhesion, cytokine 
secretion, proliferation and survival. Much of IL-33’s role has been investigated in relation to 
ILC2s. IL-33, along with IL-25 and TSLP, from structural cells has been shown to be 
important in the activation and proliferation of ILC2s in mice68 and in humans107. ILC2s were 
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investigated in murine helminth infection models, where they induced IL-13 secretion, goblet 
cell hyperplasia, eosinophilia and a TH2 response68. Other TH2-mediated mouse models have 
shown extracellular IL-33 to be important in activating ILC2s and leading to disease 
pathogenesis, e.g. the A. alternata mouse model of asthma46 although IL-33 has important 
roles in stimulating other innate immune cells and the adaptive immune system. 
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Figure 1.4 Summary of IL-33 cytokine signalling pathways 
Simplified schematic of IL-33:ST2 signalling57,100,106. Extracellular IL-33 binds to the 
heterodimeric receptor composed of ST2 and IL1RAP, which interacts with MyD88 or MAL 
and induces the intracellular signalling pathway shown, leading to AP-1 and NF-κB nuclear 
translocation. Soluble ST2 (sST2) acts as an inhibitor by competitively binding IL-33, thereby 
preventing IL-33 binding to the membrane receptor. Arrowed lines show activation, blunt-
ended lines show inhibition and dashed lines represent multiple possible steps. MAL: 
MyD88-adapter-like, IRAK: interleukin-1 receptor associated kinase, TRAF6: TNF receptor 
associated factor 6, IκB: Inhibitor of κB, MAPK: mitogen-activated protein kinase, JNK: c-
Jun N-terminal kinase, ERK: extracellular signal-related kinase.  
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1.2.6 Nuclear role  
1.2.6.1 Roles of proteins interacting with DNA or chromatin 
DNA within the nuclei of eukaryotes is bound to proteins and is collectively known as 
chromatin. Chromatin is formed by a repeating nucleosome unit, 146 bp of DNA wrapped 
around a protein-complex108, separated by 200 bp of nucleosome-free DNA. These 
nucleosomes can form “condensed” or “open” chromatin and this is a dynamic process that 
affects the transcription of DNA (reviewed by Berger109). Active transcription of DNA 
requires an open conformation of chromatin, allowing factors to access the DNA. This 
conformation is known as euchromatin, where nucleosomes are loosely bound to DNA. 
Conversely, transcription cannot take place in tightly bound (condensed) nucleosomes known 
as heterochromatin.  
The protein component of a nucleosome is an octamer of proteins known as histones, 
canonically two copies each of H (histone) 2A, H2B, H3 and H4110. The amino-termini of 
histones protrude from the surface of the complex and post-translational modifications can be 
introduced by histone modifying enzymes110. Many modifications are known, lysine 
modifications have been most studied, examples of post-translational modifications are 
acetylation, methylation and ubiquitination. Strahl and Allis first proposed the histone code 
hypothesis, where a combination of histone modifications determines the state of the genomic 
DNA111. Histone modifications can affect the chromatin conformation in two ways. First, they 
can directly reduce the binding of DNA to histones, as with histone acetylation which 
neutralises the positive charge of the N-terminal lysines and therefore reduces the binding to 
negatively charged DNA112. Second, histone modifications can recruit chromatin-remodelling 
proteins. As an example, heterochromatin protein 1 recognises H3 lysine 9 trimethylation 
(H3K9me3) and causes silencing by inducing a heterochromatin conformation113. It is worth 
noting that the genomic region of the histone modification appears to be important in altering 
the transcriptional status. Transcriptional repression is associated with H3K27me3 across the 
promoter (5’ to the transcription start site of the gene) and gene body, yet with H3K9me3 
only the promoter-region histones are modified in transcriptionally-repressed genes109.  
DNA forms a 3D structure, with euchromatin regions interacting to set up active transcription 
zones114. These interactions involve promoters and enhancers; enhancers can interact with 
promoters over long distances (often 1 Kb – 1 Mb) or even between chromosomes. Here, an 
interaction between transcription factors, the epigenetic state of the chromatin and the 
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transcriptional machinery is thought to govern transcription. Whilst transcription factors 
themselves can bind directly to DNA through recognition of a DNA-sequence (known as a 
binding motif) they may be part of a complex of proteins that require an epigenetic 
environment to alter gene expression.  
1.2.6.2 Nuclear role of IL-33 
IL-33 expression in vivo was first found in the nuclei of endothelial cells64 and further work 
has shown that it was expressed by barrier cells in humans and mice115. There is fairly rare for 
a cytokine, however IL-5 has been shown to be a nuclear cytokine116, though there has been 
little follow-up from this observation. As reviewed in Section 1.2.3, the presence of a helix-
turn-helix domain64 suggested that IL-33 had the capability of binding directly to DNA and 
subsequent work by Roussel et al. revealed that amino acids 40 to 53 of IL-33 were key for 
the binding to the H2A-H2B acidic pocket77. More recently the work of Shao et al. in 2014, 
found IL-33 co-immunoprecipitated with the histone methyltransferase SUV39H1 
(suppressor variegation 3-9 homolog 1)117. This suggests that IL-33 may potentially directly 
interact with histones and alter chromatin structure.  
So far one genomic locus has been reported to show significant evidence of IL-33 binding. 
Epitope-tag pull-down of IL-33 overexpressing HEK293 cells showed a 4-6 fold enrichment 
at the IL13 locus by ChIP (chromatin immunoprecipitation)-qPCR118. In addition, there is 
some suggestive evidence for IL-33 binding to the promoter of the p65 subunit of NF-κB119. 
By conducting knockdown and over-expression experiments, Choi et al. found that IL-33 
increased the luciferase activity of a p65 (RELA of the NF-κB dimer) promoter luciferase 
assay. This was followed up with ChIP-PCR showing enrichment at the p65 promoter but was 
not validated by ChIP-qPCR as enrichment was less than four-fold. A four-fold enrichment 
threshold is currently the best practice guidelines by the ENCODE (Encyclopaedia of DNA 
Elements) project120. 
Studies of human IL-33 that have compared the effects of intracellular IL-33 levels with ST2- 
or extracellular IL-33-mediated effects have suggested the presence of a specific nuclear role. 
Functional genomics studies of IL-33 have been focused on conducting investigations in the 
context of IL-33’s impact on cytokine secretion and less frequently, its role in adhesion and 
proliferation. Importantly, all studies carried out investigating the nuclear role of IL-33 have 
focused on the regulation of a subset of NF-κB target genes. Over-expressing IL-33 in tumour 
necrosis factor-α (TNF-α) stimulated rheumatoid arthritic synovial fibroblasts was found to 
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result in an increase in IL-6 and IL-8 expression compared to controls, the converse was seen 
when knockdown was performed121. In addition prostaglandin E2 in the supernatant was 
increased by IL-33 overexpression and decreased by IL-33 knockdown in the study. However, 
some proteins did not show reciprocal expression patterns, for example MMP-3 (matrix 
metalloproteinase-3) increased upon IL-33 over-expression but did not change upon 
knockdown and CCL2 (chemokine C-C motif ligand 2) decreased upon IL-33 knockdown but 
did not change upon over-expression. Knockdown of IL-33 in TNF-α stimulated human 
umbilical vein endothelial cells (HUVECs) showed a similar role, causing a decrease in 
ICAM-1 (intracellular adhesion molecule-1), VCAM-1 (vascular cell adhesion molecule-1) 
and NF-κB p65119. Finally human fibroblasts over-expressing IL-33 showed an increased 
SMAD2/3 phosphorylation122, which would lead to an increase in NF-κB targets. One study 
does suggest an opposing effect of IL-33. In TNFα-stimulated normal human epidermal 
keratinocytes, IL-8 secretion was increased upon IL-33 knockdown123.  
Investigations of the role of IL-33 in cells from rodents provide less clear evidence of it 
having a nuclear role although the number of studies is somewhat limited. In rat glioma cells 
(note however these are malignant cells), knockdown of IL-33 and ST2 both resulted in a 
decrease in proliferation124. Similarly, IL-33 knockdown in murine macrophages resulted in a 
reduction in peptidoglycan- and lipoteichoic acid-induced nitric oxide synthase expression, an 
NF-κB mediated inflammatory response gene. This was shown to be inducible by exogenous 
IL-33 stimulation and was reduced by ST2 knockdown. At the time of writing this thesis there 
are only two published studies purporting to show evidence of nuclear-specific roles for full 
length IL-33 in mice.  
In 2011, a study conducted by Ali et al. found that over-expressed murine IL-33 in HEK293 
cells co-immunoprecipitated with NF-κB and delayed the increased expression of NF-κB 
target genes78. Subsequently using murine lung fibroblasts, Luzina et al. found transfection of 
full length IL-33 in murine fibroblasts resulted in an increase in heat shock protein mRNA 
(Hspa1a and Hspa1b) that was not observed when only the cytokine-fragment of murine IL-
33 was transfected122. In the same study, the authors went on to conduct adenoviral-over 
expression of IL-33 in combination with a bleomycin-injury mouse model and found that 
together this resulted in an increase in lymphocytes and collagen within the lung, independent 
of ST2122.  
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1.2.7 IL-33 in disease 
The evidence for IL-33 having a role in disease can be divided into 3 types: mouse models 
using knockout (Il33 or Il1rl1) or dosing (recombinant cf-IL-33 or anti-IL-33 antibodies), 
increased IL-33 or ST2 in patient samples and GWASs of SNPs near IL33 or IL1RL1. The 
role of IL-33 in asthma will be reviewed separately and in further detail in Section 1.2.7.1. 
Several mouse models of intestinal helminth infection have revealed that IL-33 aids clearance 
of the parasite, perhaps to be expected when one takes in to consideration the recognised role 
of IL-33 in inducing TH2 responses. Il1rl1 knockout125 and Il33 knockout126 mice infected 
with Nippostrongylus brasiliensis were found to have a reduced inflammatory response and 
increased worm burden compared to wild-type mice. In Strongyloides venezuelensis infection, 
IL-33 was increased both at the protein and mRNA level in the intestine with Il33 knockout 
mice also showing a decreased immune response127. A further example is in Trichuris muris 
infection, where Il33 mRNA was observed to increase over the course of infection and dosing 
with IL-33 decreased disease severity and worm burden128.  
The majority of disease-states investigated are mediated by TH2 responses and in chronic 
diseases all 3 types of evidence are often found. Unfortunately, as outlined in Section 1.2.4, 
detection of IL-33 in the serum is generally at the lower limit of detection and in several 
diseases a reported increase in patients has the potential to be artifactual97,98. Increases near 
the threshold of detection have been observed and reported for serum measurements of 
patients with inflammatory bowel disease (IBD)91, atopic dermatitis129, allergic rhinitis89,130, 
asthma130 and  idiopathic pulmonary fibrosis131.  
GWASs have associated the IL1RL1 locus with allergy132,133 and allergic diseases: allergic 
rhinitis134, atopic dermatitis135, IBD91,136 as well as coeliac disease137. Similarly the IL33 locus 
by GWAS has been found to be associated with allergy133 and allergic rhinitis134. In allergic 
rhinitis, IL-33 is increased in the nasal epithelium at the mRNA level and by 
immunohistochemistry (IHC), along with ST289. Mouse models of allergic rhinitis have 
shown that Il33 knockout mice have reduced sneezing, serum IgE and inflammatory cell 
influx92,138. Similarly, in lesions from atopic dermatitis patients, IL-33 is increased139-141 
compared to healthy controls. In addition to TSLP, IL-33 appears to be involved in the 
induction and maintenance of the TH2 response in this atopic dermatitis via dendritic cells and 
ILC2s140,141. Studies investigating IBD have found that IL-33 is increased at both the mRNA 
and protein level in the intestinal mucosa91,142. In a mouse model of IBD (dextran sulphate 
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sodium-induce colitis) chronic intra-peritoneal injection of IL-33 increased the severity of the 
disease143. 
Diseases associated with a TH1 response have likewise shown that IL-33 can play a role in the 
resolution of inflammation. In a murine model of destructive arthritis where TNF-α is 
overexpressed, dosing with IL-33 decreased bone destruction, shifting the differentiation of 
osteoclast precursors (monocytes) towards alternatively activated macrophages144. In contrast, 
however, in a K/BxN serum transfer-induced model of arthritis Il1rl1 knockout mice showed 
a decrease in clinical score and bone erosion145. In this model, Il33 knockout showed no 
difference to wild-type mice, suggesting that the effects seen may be due to another ligand for 
ST2 or that the nuclear role of IL-33 may have opposing effects to the cytokine role145. This 
may be due to rheumatoid arthritic synovial fibroblasts since for this cell type, nuclear IL-33 
was found to increase pro-destructive proteins such as MMP1 and MMP3121. Another 
example of this remedial response of IL-33 has been found in a murine spinal cord injury 
model, where IL-33 notably increased in the cerebrospinal fluid after injury146. The increase 
of IL-33 was thought to be from glial cells and Il33 knockout mice in the study were found to 
have a notable decrease of type 2 macrophages at the site of injury and consequently impaired 
recovery.  
Finally, IL-33 has been investigated in unpolarised inflammatory responses. For example, 
patients with reflux esophagitis have be shown to have an increase in IL-33 both at the 
mRNA and protein level in the oesophageal epithelium147. A subsequent study has shown that 
IL-33 stimulation does not induce IL-6 or IL-8 and IL-33 knockdown reduced IFN-γ-induced 
IL-6 and IL-8 in oesophageal epithelium148.  
1.2.7.1 Evidence for IL-33 having a role in asthma 
1.2.7.1.1 Murine data 
Mouse models have shown that IL-33:ST2 signalling is important in the induction of 
asthmatic inflammation. In the A. alternata model of asthma, PAR-2 on epithelial cells was 
activated by the proteolytic activity of the allergen, leading to an increase in bronchial-
alveolar IL-33 which then primed the immune-system15. Comparing a variety of studies 
including Il33 knockout with Il1rl1 knockout, anti-IL-33 antibody treatment or sST2 
treatment in models of asthma infection, the majority of the impact of IL-33 appears to be 
through its cytokine function.  
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In OVA models of asthma, Il33 knockout has been shown to result in a reduction not only of 
total cell numbers in BAL, but also eosinophils and neutrophils149 with anti-ST2 or anti-IL-33 
antibody treatment showing the same effects150. The TH2 cytokines IL-4, IL-5 and IL-13 were 
also found to be decreased in an OVA model with Il33 knockout mice151 and with anti-IL-33 
treatment150. Similarly Il33 knockout and antibody administration resulted in comparable 
histological inflammatory score and airway hyper-responsiveness149,150,152.  
In the HDM mouse model of asthma, Il33 knockout was found to reduce immune cell 
infiltration149 as did Il1rl1 knockout153.  Although airway hyper-responsiveness and collagen 
deposition were not measured in the Il33 knockout study, in the Il1rl1 knockout both were 
found to be reduced154.  
Using adenoviral overexpression of murine IL-33 to form an airway inflammation model, 
Luzina et al. showed that similar effects were observed when different IL-33 variants were 
compared131. By overexpressing full-length IL-33 and a fusion product (consisting of full-
length IL-33 with a secretory signal peptide), Luzina et al. showed that full length IL-33 
resides in the nucleus and that it is not secreted.  In contrast, the fusion peptide was 
distributed between the nucleus and cytoplasm and secreted at high levels. Both constructs 
resulted in an increase in immune cells and cytokines. Over expression of murine IL-33109-266, 
showed some differences compared to both full-length constructs with increases in the total 
inflammatory cell numbers and in particular eosinophils, as well as increases in the mediators 
IL-4, IL-5, IL-13 and KC (keratinocyte chemoattractant) in the BAL and decreased BAL IFN-
γ when compared to control-transfected mice. Prior to the study of Luzina et al., the cytokine-
fragment of IL-33 had already been reported to have more potent effects than full length71 and 
this is the most likely explanation for the differences found. As detailed earlier in Section 
1.2.3, murine IL-33 transfected into HEK293 cells appeared to have a modest effect on NF-
κB, delaying the inflammatory response by binding to NF-κB and reducing its ability to bind 
to target DNA sequences78.  
It is worthwhile noting that in mice, IL-33 is only expressed in Type II pneumocytes of the 
alveoli whereas in humans it is constitutively expressed in the airway epithelium of the large 
airways (bronchial epithelium)58,155. Furthermore, whether human and murine IL-33 act in 
similar ways is not entirely clear, especially as the level of homology is 52% at the amino 
acid level156. Consequently it is important to be cautious about the data generated in mouse 
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models and how it relates to the role that IL-33 plays in healthy individuals and asthmatic 
patients.   
1.2.7.1.2 Human data 
GWASs have linked SNPs near IL33 and the IL1RL1/IL18R1 locus to asthma55,56 suggesting 
that IL-33’s cytokine function, nuclear role or both play a role in the disease. 
Immunohistochemistry studies of airway biopsies, have found IL-33 to be increased both in 
the bronchial epithelium20,58 and airway smooth muscle20,65 of asthmatics. Furthermore, in 
paediatric severe therapy-resistant asthma (PSTRA), an increase in airway smooth muscle and 
fibroblasts expressing IL-33 has been found157. These three cell types; epithelial, smooth 
muscle and fibroblasts are all structural cells involved in the characteristic feature asthma 
lung remodelling.  
IL-33 stimulation has been shown to induce collagen secretion from PSTRA fibroblasts but 
not healthy adult fibroblasts154. Whether this is due to the disease status or age of the patients 
is unknown. ILC2s are thought to have a critical role in human asthma and the cytokine role 
of IL-33 is a major player in the expansion, recruitment and activation of these cells95,107,141. 
Other important immune cell types involved in asthma have been shown to be affected by IL-
33 stimulation. For example polarisation of alternatively activated macrophages158, eosinophil 
survival159 and activation of eosinophils and basophils160. 
Current knowledge of the nuclear role of IL-33 (discussed in detail in Section 1.2.6 above) 
fits well with the airway epithelial cell remodelling observed in asthma and yet to date this 
has not been fully investigated. The phenotypes shown in other cells types: increased 
proliferation of the basal epithelium, decreased adhesion and pro-inflammatory nature of 
asthmatic epithelium realistically could be a result of the nuclear role of IL-33. 
1.3 Hypothesis 
The hypothesis of this thesis is that nuclear IL-33 alters the inflammatory response of the 
airway epithelium. The simplest explanation for this would be that IL-33 binds directly to 
DNA and in doing so alters gene expression. In addition to its role in inflammation, IL-33 is 
expected to affect additional functions of the epithelium.  
 41 
1.4 Aims 
1. To determine basal expression of IL-33 in airway epithelial cell types and validate 
robust detection methods. 
2. To investigate the role of IL-33 in the inflammatory response of the airway epithelium 
by stimulation and siRNA knockdown of IL-33 and its receptor, ST2.  
3. To elucidate global gene expression targets of IL-33 by microarray profiling and 
chromatin immunoprecipitation.  
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2. Materials and Methods 
2.1 General equipment 
The Allegra X-12 centrifuge (Beckman Coulter; Brea, CA, USA) was used for centrifugation 
of samples in 15 mL and 50 mL tubes, including bacterial culture samples. For samples in 
microcentrifuge tubes at room temperature a Mikro 220R microcentrifuge (Hettich; 
Tuttlingen, Germany) was used and for those requiring 4ºC microcentrifugation, the 
Eppendorf (Hamburg, Germany) 5427R microcentrifuge was used. The Labnet (Edison, NJ, 
USA) P2 plate shaker was used for shaking of microscopy slides.  
2.2 Generic methods 
2.2.1 Agarose gel electrophoresis 
Unless otherwise stated a 1.2% (w/v) agarose (Bioline; London, UK) gel was used for all 
nucleic acid gels. Agarose was weighed into a conical flask and 100 mL of 1x TBE (Sigma; 
Gillingham, UK) was added. This was heated in the microwave, swirling every 30 seconds 
until all agarose had melted. The gel was allowed to cool to 60ºC before 3 µL of gel red 
(Biotium; Hayward, CA, USA) was added. The gel was mixed well and poured into a gel tray 
and the comb added and the gel left for 30 minutes to set. Typically 10 µL of samples were 
mixed with 2 µL of loading dye (New England Biolabs, NEB; Ipswich, MA, USA), loaded 
into the set gel and run for 1 hour at 120V. Gels were imaged using an ultraviolet 
transilluminator (UVP; Cambridge, UK).  
Where applicable, gel extraction was carried out preparing the gel as above, but using low 
melting temperature agarose (Cambio; Cambridge, UK). Gel slices were extracted using gel-
extraction tips for P1000 pipettes (Alpha laboratories; Eastleigh, UK) and the standard gel 
extraction protocol, as per manufacturer’s instructions, was followed using the QIAquick Gel 
Extraction Kit (Qiagen; Hilden, Germany). This step-wise protocol dissolves the excised gel 
slice after which a spin-column matrix allows the DNA to be captured, washed and then 
eluted. 
2.2.2 Plasmid growth and harvesting 
Growth media used was Luria-Bertani (LB, Sigma) broth with 50 µg/mL of ampicillin or 
kanamycin as appropriate for the antibiotic resistant gene within the plasmid. Transformed 
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Escheria coli (One Shot Mach1, Thermo Fisher; Waltham, MA, USA) colonies were cultured 
for 16 hours at 37ºC with shaking at 200 rpm. For mini-prep extractions, 3 mL of growth 
media was used whilst for midi-preps, 100 mL of growth media was used. Qiagen mini- and 
midi-prep kits were used to lyse the bacteria and purify the plasmid DNA following the 
manufacturer’s recommendations. Briefly both kits alkaline lyse the cells, neutralise the lysate 
pH and in the process precipitate genomic DNA. The latter and the cellular debris is then 
pelleted by centrifugation, after which the supernatant is loaded onto a spin column resulting 
in binding of the plasmid and after a wash step the plasmid is then eluted. For the midi-prep, 
due to volume a spin column was not used and was replaced as per the manufacturer’s 
recommendations by an isopropanol precipitation step, followed by a 70% ethanol wash of 
the plasmid DNA pellet. The latter was allowed to air dry before being re-suspended in kit 
supplied 1X Tris-EDTA buffer (TE, Tris: Tris(hydroxymethyl)aminomethane, EDTA: 
Ethylenediaminetetraacetic acid).   
2.2.3 Polymerase chain reaction 
For polymerase chain reactions (PCR) 10 µL of Extensor Hi-Fidelity PCR Master Mix 
(Thermo Fisher), 1 µL of 10 µM of forward and reverse primers and template DNA were 
diluted in water to make a 20 µL reaction volume. The following cycling conditions were 
used, setting the annealing temperature to the optimal temperature for the primers used (listed 
with primers in Appendix I). An initial denaturation for 5 minutes at 94ºC was then followed 
by cycles of 10 second of 94ºC (denaturation), 30 seconds of annealing and 1 minute of 
extension (68ºC). After the cycles there was a final extension step of 7 minutes at 68ºC.  
2.3 Cell Culture 
A549, BEAS-2B, 16HBE cell lines (American Type Culture Collection, ATCC; Manassas, 
VA, USA) and primary NHBEs (Lonza; Basel, Switzerland and Promocell; Heidelberg, 
Germany) were grown in a 37ºC incubator with 5% CO2 (Appendix II). For general passage, 
all cells were grown in T150 flasks (Corning; Corning, NY, USA) until approximately 80% 
confluent at which stage cells were washed with warm 1X PBS (phosphate-buffered saline, 
Sigma), then detached using 1X Trypsin (Sigma). Trypsin was neutralized with growth 
media, the detached cells harvested by centrifugation at 300 g for 3 minutes and resuspended 
in growth media for seeding into new T150 flasks. For seeding in experiments, cells were first 
counted using an improved Neubauer haemocytometer and then seeded at an optimal density 
(specified in Appendix II) to achieve 80% confluence for stimulation or transfection. Unless 
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otherwise stated, 4 hours after seeding the growth media was replaced with un-supplemented 
media to starve cells overnight. 
2.3.1 Transfection 
siRNAs used for transfection were ON-TARGETplus SMARTpool (Dharmacon; Lafayette, 
CO, USA) and the ON-TARGETplus non-targeting pool negative control #1 (Dharmacon) 
was used as the non-silencing control (NSC).  For all siRNA transfections 24-well plates were 
seeded with cells in growth media (for seeding density, see Appendix II) to reach 60-70% 
confluence overnight before transfection, to achieve 80% confluence at time of RNA 
harvesting. Optimised siRNA transfection conditions differed for IL33 and ST2 and are listed 
separately (Sections 2.3.1.1 and 2.3.1.2) and are based upon the different protocols of the 
lipofectamine reagent used in each knockdown. Plasmids used for over-expression 
experiments were constructs created as detailed in Section 3.2.3.1. 
2.3.1.1 IL-33 siRNA knockdown 
On the day of transfection, starving media was replaced with growth media and incubated at 
37ºC with 5% CO2 until transfection reagents were added. DharmaFECT transfection reagent 
1 (lipofectamine, Dharmacon) was diluted 1:60 in un-supplemented media and pipetted up 
and down to mix. In a separate tube, siRNAs were diluted to 50 nM in un-supplemented 
media and again pipetted up and down to mix. Both solutions were left to incubate for 5 
minutes at room temperature, then mixed 1:1 and incubated for 20 minutes at room 
temperature. Lipofectamine-siRNA mix was then added to the media of the cells at a ratio of 
1:5, giving a final siRNA concentration of 5 nM. Cells were incubated for 48 hours, after 
which they were harvested for mRNA analyses or used in stimulation experiments.  
2.3.1.2 ST2 siRNA knockdown 
ST2 siRNA was carried out in 24-well plates; siRNA pools were diluted in a total of 97 µL of 
un-supplemented media to achieve 50 nM (per well to be transfected) and mixed well by 
pipetting. Per well, 3µL of HiPerFect Transfection reagent (Qiagen; Germantown, MD, USA) 
was added to each dilution of siRNA. After mixing well by pipette, siRNA complexes were 
left to incubate at room temperature for 10 minutes. Media was aspirated from the cells to be 
transfected and 100 µL of siRNA complexes were added per well. The culture plate was then 
placed in the incubator. After 3 hours of incubation, 400µL of growth media was added per 
well giving a final siRNA concentration of 10 nM. Samples were incubated for a further 45 
hours to complete transfection.  
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2.3.1.3 Plasmid overexpression 
Once cells reached 70-80% confluence, media was aspirated and replaced with fresh growth 
media. Lipofectamine2000 Transfection reagent was diluted in Opti-MEM media at 1:25 
(both from Life Technologies; Carlsbad, CA, USA). Plasmids were diluted to a concentration 
of 1 µg/mL; lipofectamine and plasmid were then added together in a 1:1 ratio and mixed 
well by pipetting. After 5 minutes incubation at room temperature, the lipofectamine-plasmid 
mixture was added to the cells at a 1/10 dilution; per well in LabTek (for confocal microscopy 
in Section 2.5.4) or 24-well plate this gave 0.5 µg in 500 µL and per 100 mm dish (for cell 
lysate in Section 2.5.2.1 or chromatin in Section 2.7.1), 5 µg in 10 mL.  
2.3.1.4 MTS assay 
The MTS assay allows for the metabolic activity of cells to be measured, which is a proxy to 
determine the cytotoxicity of a treatment, how viable the cells are post treatment. This is 
similar to the MTT assay, yet does not require permeabilising the cells. Metabolically active 
cells reduce MTS tetrazolium to a formazan dye that absorbs light at 490-500 nm.  
Cell culture was set up in triplicate in 24-well plates with untreated cells, treated cells and 
wells with no cells. MTS (Promega; Madison, WI, USA) was added to the cells at a 1/10 
dilution in growth media and cells were incubated for 1-4 hours in culture conditions. After 
incubation, media was transferred from 24-well plates to 96-well plates to measure 
absorbance at 490 nm using the Tecan Infinite M200 Pro plate reader (Männendorf, 
Switzerland). Absorbance readings were corrected by removing the absorbance of cell-free 
wells and normalised to the untreated cells.  
2.4 mRNA quantification 
2.4.1 RNA extraction 
Cells were lysed in situ using Qiagen RLT+ Lysis buffer (with 1% v/v ß-mercaptoethanol 
added) and frozen at -80ºC for extraction at a later date. Beta-mercaptoethanol was added to 
the RLT+ Lysis buffer to denature and inactivate any RNase activity, allowing the RNA to be 
stored without degradation.  
RNA extraction was carried out using the RNeasy plus kit (Qiagen), according to the 
manufacturer’s protocol and eluted in 30µL of kit supplied RNase free water. Briefly, these 
kits use a genomic DNA spin column to specifically capture the genomic DNA, leaving pure 
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RNA to be bound to a spin column, washed and eluted using RNase free water. RNA yield 
was quantified using a Nanodrop spectrophotometer (Thermo Fisher).  
2.4.2 cDNA library synthesis 
RNA was converted to cDNA using the High Capacity cDNA Reverse Transcription kit 
according to kit recommendations (Applied Biosystems; Warrington, UK). Depending on 
experiment, RNA was used at concentrations ranging from 2 ng/µL to 200 ng/µL in final 
reaction volumes of 20 µL and all cDNA reactions were 20 µL in final volume. Before RT-
qPCR (Real-Time quantitative PCR), cDNA from all samples within an experiment were 
diluted to an equal concentration using RNase free water. 
2.4.3 Primer design 
All primers were designed to span adjacent exons in order to detect all known splice variants 
of a gene using Primer3161. Primers were designed to have a length between 75 – 200 bp for 
RT-qPCR. Potential primers were checked for similar melting temperatures, GC content, 
complementarity and 3’ complementarity161. Three pairs of primers were tested in preliminary 
experiments and were chosen based on their creation of a product of the correct size with no 
product in the non-template control, this was done using the ViiA 7 Real-Time PCR System 
(Life Technologies). Final primer sequences used are shown in Appendix I. An example of 
primer testing is shown in Figure 2.1: no amplification in the non-template control, i.e. 
amplification which does not reach the threshold for the Ct values (Figure 2.1-A) and a single 
product as shown by the melting curve (Figure 2.1-B) with robust detection were required for 
the primers to be selected for further experiments.   
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Figure 2.1 qPCR test results of primers 
Amplification plot (A) and melt curve (B) of non-template control (purple) and positive 
cDNA (orange) are shown for primer testing. The threshold for determining the Ct value is 
shown as a red horizontal line. The non-template ideally does not reach the Ct threshold in 
amplification, and there should be a single peak in the melt curve of the positive control 
samples.  
2.9 
1.9 
0.9 
0 
65 75 85 95 
Temperature (ºC) 
D
er
iv
at
iv
e 
R
ep
or
te
r (
-R
n’
) 
2.9 
1.9 
0.9 
0 
2 12 22 32 
Cycle 
ΔR
n 
40 
A) 
B) 
 48 
2.4.4 Real-Time quantitative PCR  
RT-qPCR was carried out using the ViiA 7 Real-Time PCR System (Life Technologies) using 
Sybr Fast qPCR Mix (rox low, Kapa Biosystems; London, UK). The relative quantification 
(ΔΔCT) method was used for mRNA quantification. Whilst there is no single gene that will 
always maintain the sample abundance upon any possible stimulation, the ribosomal protein 
S13 gene  (RPS13) has been identified as having very low variation upon a meta-analysis of 
13,629 human gene arrays162. For this reason RPS13 was used for an endogenous control for 
gene specific RT-qPCR (see Chapters 3 and 4).  
2.5 Protein Detection 
2.5.1 Custom polyclonal antibody generation 
A literature review of antibody staining (Section 1.2.4) as well as information from colleagues 
at the National Heart and Lung Institute (NHLI) suggested that commercial antibodies have 
variable success in reproducible staining. For this reason, Cambridge Research Biochemicals 
(http://www.crbdiscovery.com/) were consulted to create three polyclonal antibodies for 
detection of IL-33 protein. Epitopes from IL-33 were selected by prediction of having good 
surface probability and antigenicity prior to synthesis. Since methionine can oxidise to 
methionine sulfoxide, norleucine (Nle) was used in place of methionine. This is common 
practice in raising antibodies against small epitopes as the similar amino acid, Nle, gives a 
consistent epitope of an un-oxidised methionine.  A cysteine residue was added to the 
terminus of the peptide if none were present in the sequence, in order to allow for coupling to 
carrier proteins. Table 2.1 shows the epitopes used for Cook-3, Cook-4 and Cook-5 
production.  
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Table 2.1 Custom antibodies and epitopes 
Affinity purified polyclonal antibodies were created by immunising rabbits to the peptides 
shown. Cook-3’s epitope is at the N-terminal of IL-33, Cook-4 targets near the N-terminal 
and Cook-5 targets the C-terminal of IL-33. Residues that have been altered from the 
reference sequences are framed in square brackets.  
Antibody Epitope peptide sequence IL-33 Amino acid residues 
Cook-3 KPK-[Nle]-KYSTNKISTAK-W-[C] 2-17 
Cook-4 CYFRRETTKRPSLKTGR 58-74 
Cook-5 [C]-KDNHLALIKVDSSENL 243-258 
 
2.5.2 Lysate protein 
2.5.2.1 Protein Extraction 
For protein extraction, cells were seeded in 100 mm diameter tissue culture dishes (Nunclon 
treated, Thermo Fisher) and harvested when at 80% confluence. The Active Motif Nuclear 
Extract Kit (Active Motif; Rixensart, Belgium) was used according to the manufacturer’s 
instructions for whole cell lysate or for separating the nuclear and cytoplasmic compartments. 
Media was removed from the cells, and they were washed with ice cold PBS/phosphatase-
inhibitor (kit supplied) and then harvested by scraping into PBS/phosphatase-inhibitor. 
Scraped cells were centrifuged at 500 g for 5 minutes at 4ºC. The supernatant was removed 
leaving a cell pellet, which was either lysed immediately on ice, or frozen at -80ºC for 
processing at a later date.  
For whole cell lysis, a complete lysis buffer was used to lyse the cells on ice. This contains 
protease inhibitors, DDT and phosphatase inhibitors to reduce proteolysis, oxidation and 
phospholysis by endogenous enzymes within the lysis buffer. The lysis buffer (AM1) contains 
detergent and salt to break down the cell and nuclear membranes by hypo-osmolarity. After 
30 seconds of vortexing at the highest setting, 30 minutes incubation on ice and 30 seconds of 
further vortexing, cellular debris was pelleted by centrifugation at 14,000 g for 20 minutes at 
4ºC. The supernatant was then kept on ice if used that day or frozen at -80ºC for later use.  
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When sub-cellular components were prepared the cells were resuspended in a hypotonic 
buffer, making them fragile by osmotic-swelling, detergent was then added to lyse the cell 
membranes whilst leaving the nuclear membranes intact. Nuclei were pelleted at 14,000 g, 
4ºC for 30 seconds and the supernatant was removed but retained as it contained the 
cytoplasmic extract. The nuclei were then lysed with the complete lysis buffer (constituents 
detailed above) and then cell debris was pelleted at 14,000 g at 4ºC for 10 minutes before 
collection of the supernatant, which contained the nuclear extract.  Extracted proteins were 
stored frozen at -80ºC if not immediately used in downstream experiments.  
2.5.2.2 Protein Quantification 
Extracted protein was thawed on ice and measured using the Bio-Rad Protein Assay 
(Hercules, CA, USA), which is a colourimetric assay based on the Bradford assay, as per the 
manufacturer’s recommendations. Briefly, a Coomassie Brilliant Blue G-250 solution is 
prepared and when protein is added, a colour change occurs with the Coomassie dye changing 
from brown to blue depending on amount of protein present. A standard curve of known 
quantities of bovine serum albumin (BSA; Thermo Scientific) and 1 µL of samples were 
diluted in the Coomassie solution and the absorption of light at 590 – 600 nm was measured 
using the Tecan Infinite M200 Pro plate reader. A Polynomial regression line was fit to the 
standard curve, with an R2 >0.99 as a threshold for the use of the standard curve in 
quantifying sample protein concentration.  
2.5.2.3 Western Blotting 
Western blotting was carried out using 10-40 µg of cell lysate per well. SDS-polyacrylamide 
gel electrophoresis was used in order to separate the proteins using NuPAGE Bis-Tris gels 
(Thermo Fisher) and NuPAGE MES SDS running buffer (Thermo Fisher). Samples had 
NuPAGE LDS sample buffer (Thermo Fisher) added for loading. Denatured samples had ß-
mercaptoethanol added to the LDS, giving a final concentration of 2.5% (v/v) once the sample 
was added to the buffer. Denatured samples were then incubated at 70ºC for 10 minutes. 
Semi-native samples were not heated and only NuPAGE LDS sample buffer was added to 
them prior to loading onto the gels.  
Separated proteins were transferred to a nitrocellulose membrane (iBlot Transfer Stack) using 
the iBlot Gel Transfer Device (both by Thermo Fisher). This is a dry blotting system that 
allows efficient and fast transfer of proteins. Membranes were blocked with milk (5% low fat 
milk w/v, 0.1% Tween-20 v/v in TBS: tris-buffered saline) for 1 hour at room temperature. 
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Primary antibodies were diluted in 5% milk in TBS and blots were probed overnight at 4ºC. 
Blots were washed three times for 5 minutes in TBS-T (0.1% Tween-20 in TBS) and probed 
with secondary antibodies conjugated to alkaline phosphatase (diluted in TBS milk), then 
washed 3 times in TBS-T for 5 minutes each except for the final wash which was extended to 
15 minutes. ECF (GE Healthcare; Chalfont St Giles, UK) was added on top of dry blots on a 
clean, flat surface for detection. ECF is a solution and a substrate for alkaline phosphatase. 
The latter dephosphorylates ECF to produce a product that fluoresces at 540 – 650 nm when 
excited by 440 nm light. Chemifluorescence images were taken using the Storm Scanner 
System (GE Healthcare). Antibodies used and concentrations can be found in Appendix III.  
2.5.3 Enzyme-linked immunosorbent assays 
IL-6, IL-8, CCL2 and IL-33 ELISAs were purchased from Peprotech (Rocky Hill, NJ, USA) 
and an additional IL-33 ELISA was purchased from R&D Systems (DuoSet; Minneapolis, 
MN, USA). All ELISAs were carried out according to manufacturers’ instructions.  
Briefly, the protocol for ELISA involved several steps separated by washes. For each wash 
the Maxisorp 96 well plate (Thermo Fisher) was emptied by inverting and flicking the plate 
over a sink, followed by the addition of 300 µL PBS-T (Sigma) to each well to wash, and 
repeating for a total of three times. The plate was then inverted on to absorbent paper and 
tapped to dry the wells. The plate was then filled with the appropriate solution (described 
below) for the next step.  
The steps involved in an ELISA were as follows: to each well 100 µL of capture antibody in 
PBS was added and then incubated overnight at room temperature. Blocking was carried out 
for 1 hour at room temperature using 300 µL of 1% (w/v) BSA in PBS, stopping any non-
specific binding of detection antibodies or streptavidin-HRP. Standards were made up by 
serially diluting 500 µL of recombinant protein in 1.5 mL micro-centrifuge tubes in diluent 
(0.1% BSA in PBS-T for Peprotech, and 1% BSA in PBS for R&D), vortexing for 10 seconds 
per dilution to ensure mixing. Standards and samples were added in duplicate and incubated 
for 2 hours at room temperature. In order to achieve detection within the range of the standard 
curve, samples that fell above the top standard they were diluted and re-run. After this 
incubation 100 µL of detection antibody was added per well and incubated for 2 hours at 
room temperature. The detection antibody was conjugated to biotin, which allowed HRP-
streptavidin to specifically bind to the detection antibody through streptavidin:biotin 
interaction. One hundred µL of streptavidin-HRP was added for 30 minutes and then the 
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substrate solution was added. For the Peprotech ELISA, ABTS (2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid), from Sigma) was used as a substrate. HRP catalyses 
the conversion of ABTS to a green solution and was read using an absorbance of 405 nm with 
wavelength correction at 650 nm. In the R&D Systems ELISA, the substrate used was TMB 
(tetramethylbenzidine, Sigma) where similarly HRP catalyses a reaction with TMB. This 
forms a blue product with the reaction being stopped by adding 50 µL of 2N sulphuric acid 
(Sigma), turning the solution yellow. The plate was then read at an absorbance of 450 nm 
with wavelength correction at 540 nm. Plate reading was done using the Inifite M220 Pro 
plate reader (Tecan) and analysed using a polynomial regression to fit the standard curve.  
2.5.4 Confocal microscopy 
Cells were seeded in Nunc LabTek II 4 chamber slides (Thermo Scientific) and were cells 
were transfected as per Section 2.3.1. Once cells were ready for fixation, the media was 
aspirated and each chamber was washed with PBS. The PBS was aspirated and replaced with 
10% formalin solution (neutral buffered; Sigma) for 15 minutes at room temperature. 
Formalin was then removed, the chambers washed with PBS, and then stored in PBS at 4ºC in 
the dark until staining.  
For staining, chambers were aspirated and washed with PBS (shaking at 300 rpm at room 
temperature for 15 minutes using the plate shaker). The PBS was replaced with 
permeabilisation buffer (see Appendix II) and shaken (300 rpm at room temperature for 1 
hour). Three hundred µL of primary antibody diluted in permeabilisation buffer (see 
Appendix III for optimal dilution of each antibody) was added to the chamber which was then 
incubated overnight at 4ºC. The next day, primary antibodies were aspirated and chambers 
were washed with PBS-T four times (each wash involves adding 500 µL of PBS-T and 
shaking at 300 rpm for 20 minutes at room temperature). Three hundred µL of secondary 
antibody (see Appendix III for optimal dilution) in permeabilisation buffer was added per 
chamber and shaken at 300 rpm for 1 hour at room temperature in the dark. Secondary 
antibodies were aspirated and chambers washed again with 1 mL of PBS-T four times for 20 
minutes. Cells were then mounted using Vectashield with DAPI (Vector Laboratories; 
Peterborough, UK) and imaged using a Leica SP5 MP/FLIM inverted confocal microscope 
(Leica; Wetzlar, Germany). Images were processed using FIJI software163 (Version 2.0.0-rc-
43).  
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2.5.5 Flow cytometry 
Live/dead fixable aqua dead cells stain (405nm excitation, Life Technologies) was made up in 
50 µL of DMSO. This stain was diluted 0.1% in FACS buffer (Appendix II). After 
transfection, 3 wells of a 24-well plate were pooled into a 50 mL tube, detaching from culture 
plates using 1X Trypsin (Sigma). Pooled cells were centrifuged at 800 g for 5 minutes and 
resuspended in 100 µL of FACS buffer with live/dead stain and incubated for 30 minutes on 
ice. GFP and live/dead stain single positive populations were used to set up compensation of 
the flow cytometer. Positive control cells for live/dead cells were dislocated from the plate 
and resuspended in culture media, then heated at 60ºC for 5 minutes followed by incubation 
for 20 minutes at 37ºC before being pelleted and resuspended in live/dead stain. Flow 
cytometry was carried out using the FACS Canto II machine (BD Biosciences; San Jose, CA, 
USA) and data analysed with FlowJo (Ashland, OR, USA; Version 10.0.8r1). Positive and 
negative gates were set up using un-transfected and the heat-treated cells for the GFP and 
live/dead channels respectively.  
2.6 Global gene expression 
2.6.1 RNA quality control 
RNA quality was determined with the Agilent 2100 Bioanalyzer (Agilent; Santa Clara, CA, 
USA). Samples with an RNA Integrity Number (RIN) of 7 or above were used in microarray 
analyses. Similar to gel electrophoresis, the RNA is separated by size and driven by a voltage 
through a sieving polymer matrix. Fluorescent dye is intercalated within the RNA and the 
fluorescence intensity over time gives an electrophoretic trace. The 2100 Bioanalyzer 
software determines a RIN score, based on ribosomal 18S and 28S RNA degradation levels. 
RINs range from 1 to 10, where 1 has the highest degradation and 10 has no degradation 
giving the highest RNA quality possible. Figure 2.2 shows electrophoretic traces of RNA at 
different states of degradation.  
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Figure 2.2 Bioanalyzer RIN examples 
RNA Integrity Number (RIN) is a quantification of RNA quality. The RIN for the sample is 
shown at the right of each subgraph and the baseline is shown as an orange line. A) Shows the 
highest RIN score possible of 10, with intact 18S and 28S RNA peaks at 1,800 and 2,700 nt 
respectively. Subgraph B) shows slight degradation with intact 18S and 28S peaks and C) 
shows highly degraded DNA. Images are based upon real traces from the Bioanalyzer (Piatek 
unpublished).  
2.6.2 Microarray cDNA library synthesis 
To ensure no confounding batch effects, RNA samples for microarray experiments were 
randomized and prepared in batches of 8 to 18 samples. This ensured that important 
groupings of samples (e.g. control versus knockdown or time points) were not prepared in 
independent batches.  
RNA was processed into sense-stranded cDNA using the Ambion WT Expression Kit 
(Applied Biosystems), as it required a relatively low input RNA per sample (100 ng used). 
Figure 2.3 shows a schematic of the steps involved in preparation of cDNA from RNA 
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(adapted from the Ambion kit flow chart). RNA is processed, a strand at a time, into cDNA 
using random primers containing the T7 promoter. Double stranded cDNA is then converted 
into anti-sense strand cRNA using T7 RNA polymerase overnight, which is then purified 
using magnetic beads. Anti-sense strand cRNA is then used as a template for sense-strand 
cDNA and the RNA is degraded using RNase H. This is then fragmented and labelled with 
biotin using the Affymetrix GeneChip Terminal Labelling Kit. Finally, the labelled fragments 
were denatured for 5 minutes at 95ºC and 5 minutes at 45ºC before hybridisation (Section 
2.6.3)  
Purified cRNA and sense-stranded cDNA was quantified using the Nanodrop ND 1000 UV-
Vis spectrophotometer (Thermo Scientific), with 550 ng/µL and 200 ng/µL (of each nucleic 
acid stage respectively) being taken through the subsequent preparation steps. Purified cRNA 
and sense-stranded cDNA quality was determined using the RNA 6000 Nano Assay kit with 
the Agilent 2100 Bioanalyzer. If the yield was lower than this threshold, or the distribution of 
nucleic acids was distinct from the usual distribution, the sample preparation was repeated 
accordingly.  
Exogenous controls were added before any processing of input RNA, these were Bacillus 
subtilis genes containing poly-A ends that are not present in eukaryotes (lys, phe, thr and 
trpn). These controls are added at staggered concentrations and are used to monitor the 
efficiency of the sample processing.  
The hybridisation cocktail is spiked with hybridization controls; bacterial bioB, bioC, bioD 
and cre genes. These controls do not cross-hybridize with human transcripts, and are added at 
staggered concentrations allowing hybridisation efficiency to be evaluated.  
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Figure 2.3 Schematic of cDNA preparation for microarray analyses.  
Overview diagram adapted from Ambion WT Expression Kit manual workflow, with key 
enzymes and states of RNA and DNA shown. RNA is shown in purple, DNA is shown in red.  
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2.6.3 Gene expression profiling 
According to the Affymetrix protocol, before use the stain trays and covers for use in the 
GeneTitan were static neutralized and the Affymetrix GeneTitan machine was set up for the 
Human Gene ST 2.1 Array Plates. Stain buffers and array holding buffer were loaded into the 
trays and then into the GeneTitan. The hybridisation plate was loaded with denatured, biotin 
labelled samples, and the plates then loaded into the GeneTitan along with the array plate and 
scan tray. As with processing of samples, the samples were randomised across arrays to 
minimize potential batch effects. All details in relation to batches, dates processed, reagents 
and arrays were recorded in order to estimate the batch effect of potential sources of error.  
2.6.4 Data analysis 
2.6.4.1 Quality control and normalisation 
Unless otherwise stated, analyses were carried out in the R statistical programming 
environment (Version 3.1.0164) with core and Bioconductor packages165. Raw data was 
imported into R and quality control carried out using arrayQualityMetrics (Version 3.20.0166), 
detecting outlier arrays that are likely to skew data upon normalisation. Mean absolute 
distance, principal component analysis and array intensity distributions were compared 
between arrays. Individual array quality was assessed by determining increased intensity 
across the physical location of the probes on the array. Any outlier arrays were excluded and 
the corresponding RNA re-processed and run on arrays until all samples had successfully 
passed quality control.  
Robust Multichip Average (RMA) pre-processing appeared to be the best choice of 
normalisation for Affymetrix arrays167 and was  carried out using Affymetrix Power Tools 
(Version 1.12.0). This pooled individual probes into transcript probesets, normalised quantiles 
and medians, and corrected for background fluorescence. This data was then imported into R 
and control array probesets were removed. Probesets that had below-median levels of 
expression in all arrays were removed, as this level of expression is likely to be too low to be 
accurately quantified by microarrays168 .  
The variability of the data explained by each batch effect (reagents and processing) and 
phenotype was determined using the PVCA (Principle Variance Component Analysis) 
package (Version 1.6.0169). This uses both a linear model (as in variance component analysis 
methods) to estimate the magnitude of variability explained by the factor as well as reduces 
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the data dimensions, maintaining the majority of variation (as in principle component 
analyses). 
2.6.4.2 Differential expression 
Differential expression was determined using linear modelling, comparing the non-silencing 
control and siRNA knockdown per time point collected using the Limma (Linear models for 
microarray data) package (Version 3.20.0170). Per probeset, t statistics and p values were 
computed from pairwise comparisons and combined into a moderated t statistic using a 
Bayesian model. This moderated t statistic gives p values where the degrees of freedom are 
increased due to smoothed standard errors in the model. The p values were then corrected for 
multiple testing, using a method derived from Benjamini and Hochberg’s method to control 
the false discovery rate171.  
Gene ontology was determined by the HOMER (Hypergeometric Optimization of Motif 
EnRichment, Version 4.7172) program, which calculates statistics based upon a 
hypergeometric test. Homer uses the Gene Ontology Consortium Database 
(http://geneontology.org/) for its source of gene ontology terms and NCBI Entrez Gene 
Database (www.ncbi.nlm.nih.gov/entrez/) for chromosomal location. The output p value was 
corrected for multiple testing using Benjamini and Hochberg’s method171. Fold-change per 
gene ontology term was determined by: (number of target genes in term / total number of 
target genes) / (total number of genes in term / total number of genes in background list). This 
gives the relative increase in background compared to what we would expect from all genes 
that were passed into the analysis. Gene ontology was verified by DAVID (Database for 
Annotation, Visualization and Integrated Discovery) which uses Fisher’s exact test173,174. 
Both tools were given transcripts passing the threshold for significance (further details of 
thresholds used given in Chapters 5 and 6) and were compared to a background list of all 
transcripts used in the differential expression analysis.  
2.6.4.3 Weighted Gene Co-expression Network Analysis  
Network analyses allow for the enrichment of genes that are biologically relevant to each 
other: this can be by known protein interactions, transcription factor interactions or co-
expression. Whilst known interactions and regulation are important, they are based on prior 
research, which can skew towards highly studied targets. An unbiased approach is to create 
networks of co-expression based on the relative change in the expression levels of each 
sample without discrimination between conditions or phenotypes until the network has been 
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created. This is carried out using Weighed Gene Co-expression Network Analysis (WGCNA) 
the WGCNA package in R175.  
A signed co-expression network was created using a Pearson correlation matrix, determining 
paired comparisons between all transcripts. Using a soft threshold method, the co-expression 
similarity was converted to adjacency. The WGCNA package calculates the weighted 
adjacency between two genes from their similarity using a logarithmic scale; high correlations 
between genes are enriched at the expense of low correlations. The use of a signed co-
expression was chosen as it distinguishes between co-expression and inversely correlated 
expression, which has found novel modules compared to unsigned networks176.  
2.7 Chromatin immunoprecipitation  
Optimised chromatin immunoprecipitation (ChIP) was carried out using the Millipore EZ-
Magna ChIP A/G kit. Kit instructions were followed but with incorporation of the 
optimisations detailed below.  
2.7.1 Cell fixation and harvesting 
Cells were seeded into 100 mm dishes and once they had reached 80% confluence, the media 
was replaced with 10 mL of un-supplemented media. One dish was reserved and used for a 
cell count (Section 2.3), giving an estimate of cell number taken into each experiment. The 
remaining dishes were placed in a fume cupboard and had 275 µL of 37 % molecular-biology 
grade formaldehyde (Sigma) added, resulting in a 1% formaldehyde concentration. The dishes 
were placed in a box that was then sealed and placed on a rotating platform at 15 rpm for 10 
minutes. One mL of kit-supplied glycine was added to each dish with dishes then returned to 
the rotating platform for a further 5 minutes. After this incubation, dishes were placed on ice, 
quenched formaldehyde was removed and dishes washed three times with 10 mL of ice cold 
PBS. To each dish 3 mL of PBS containing 1X kit protease inhibitor cocktail II (kit-supplied) 
were added and cells harvested with scraping into a 15 mL tube. Cells were pelleted by 
centrifugation at 400 g for 5 minutes at 4ºC. The supernatant was aspirated and cell pellets 
snap frozen in liquid nitrogen and stored at -80ºC until required. 
2.7.2 Chromatin shearing  
Each cell pellet was thawed on ice and resuspended in kit-supplied cell lysis buffer, (500 µL 
per 1 x 107 cells) in a 1.5 mL microcentrifuge tube. Cells were incubated on ice for 15 
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minutes and vortexed for 5 seconds every 5 minutes before being centrifuged at 800 g for 5 
minutes at 4ºC. Supernatant was removed and the pellet was resuspended in sonication buffer, 
using 500 µL per 1 x 107 cells.  
Chromatin shearing was performed using the Covaris S2 or Covaris M220 focused-
ultrasonicator system (Covaris, Woburn, MA, USA). These hold Adaptive Focused Acoustic 
(AFA) 130 µL microTUBEs (Covaris) in a cold water bath during shearing and use a focused 
ultrasonicator. The resulting shearing is consistent and avoids sample heating. Sonicated 
samples (sheared DNA) were then centrifuged at 10,000 g for 10 minutes at 4ºC to pellet any 
insoluble material and supernatants then transferred to pre-chilled 1.5 mL microcentrifuge 
tubes.  
2.7.3 Immuno-precipitation  
In 1.5 mL Safe-Lock microcentrifuge tubes (Eppendorf), per immuno-precipitation (IP), 1 x 
106 cell equivalents of sheared chromatin were diluted in ice-cold dilution buffer (kit-
supplied) to a final volume of 500 µL. Twenty µL of a mixture of resuspended protein A/G 
magnetic beads and IP antibody were added per condition. For monoclonal antibodies, 1 µg 
was added and for polyclonal antibodies, 6 µg was added. In addition, 1 x 106 cell equivalents 
of sheared chromatin without any magnetic beads or antibody was taken through the protocol, 
without washes to serve as the input control DNA. Tubes were rotated for 16 hours at 4ºC to 
allow binding of the beads to the antibody and for the antibody to capture their targets.  
After 16 hours, the chromatin-bead mix was incubated for 5 minutes on a 1.5 mL magnetic 
stand separator (DynaMag-2, Invitrogen) and the supernatant removed and discarded. Next a 
series of washes were performed with each wash consisting of the addition of 500 µL of the 
appropriate ice-cold buffer and removal from the magnetic stand where the beads were 
resuspended by pipetting. Tubes were incubated on ice (on a rocking platform at 70 rpm) for 
5 minutes then returned to the magnetic stand separator for 5 minutes after which the 
supernatant was removed and discarded. The kit-supplied buffers were used in the order: low 
salt wash buffer, high salt wash buffer, LiCl wash buffer and TE buffer.  
After the final wash, beads were resuspended in 100 µL of kit-supplied ChIP elution buffer 
with 500 ng of RNase A (Roche; Basel, Switzerland) and incubated in an INCU line ILS-6 
(VWR) incubator at 62ºC for 16 hours with shaking at 200 rpm. The heat reverses the 
formaldehyde cross-links, whilst the RNase A digests any contaminating RNA. After the 
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incubation, 1 µL of kit-supplied Proteinase K was added per tube followed after which tubes 
were incubated for a further 2 hours at 62ºC in the shaking incubator. Tubes were then 
incubated for 10 minutes on a heat block set to 95ºC. Tubes were left to cool to room 
temperature in a rack and then briefly centrifuged and placed on the magnetic stand to 
separate the magnetic beads. The supernatant was retained.  
The kit protocol was followed to purify from the supernatant the DNA using spin columns 
and kit supplied reagents. ChIP DNA was finally eluted using 50 µL of kit-supplied Elution 
Buffer “C”. Purified ChIP DNA was kept on ice for RT-qPCR validation of successful ChIP 
(Section 7.2.2.3) and PicoGreen (Thermo Fisher, Section 2.7.4) DNA quantification after 
which it was frozen at -80ºC until library preparation.  
2.7.4 PicoGreen DNA quantification 
The Quant-iT PicoGreen dsDNA assay kit was used to quantify ChIP and input DNA. This 
method uses a standard curve of known concentrations of DNA and dye that emits light at 
520 nm upon excitation at 480 nm when intercalated with dsDNA. This method allows for the 
quantification of low concentrations of DNA and the assay was adapted to extend the serial 
dilution (1/2) of the standard DNA to 10 dilutions to allow quantification of DNA from 100 
ng – 0.195 ng per well. The DNA standards and 4 µL of each sample were measured in 
duplicate, using the Tecan Infinite M200 Pro plate reader, excited at 485 nm and read at 535 
nm. The DNA standard was used to create a linear model of the DNA quantity from the 
emission intensity. All linear models had an R2 > 0.99.    
2.7.5 ChIP sequencing 
2.7.5.1 Library preparation 
Library preparation was carried out using the NEXTFlex ChIP-Seq library preparation kit 
(Protocol version 15.07, Bioo Scientific; Austin, Texas, USA). Five ng of either ChIP or total 
DNA (for input-control) were used as summarised in Figure 2.4. This protocol involved end 
repair followed by Ampure XP (Beckman Coulter; Brea, CA, USA) bead size selection, 3’ 
adenylation and ligation of barcoded adapters (single indexed primers from Bioo Scientific). 
After adapters were ligated, two rounds of Ampure XP bead clean up were carried out to 
remove any adapter dimers that may have formed. Purified, adapter-ligated DNA was then 
amplified by PCR, followed by a further two rounds of Ampure XP clean up. The final 
libraries were eluted in 15 µL of kit-supplied resuspension buffer. The only modification to 
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this protocol was that all bead purification were done in 1.5 mL microcentrifuge tubes instead 
of within a 96 well plate. Consequently washes were done using 500 µL of 80% (v/v) ethanol 
instead of 200 µL. 
2.7.5.2 Bioanalyzer-determined size of libraries 
The size distribution of libraries was determined using the Agilent 2100 Bioanalyzer with the 
High Sensitivity DNA kit (Agilent). A fluorescent dye is intercalated with double stranded 
DNA and separated by electrophoresis through a matrix. Fluorescence intensity over time was 
measured. Size was determined using two reference peaks added to each sample and 
comparison to a reference ladder. The average length of DNA in each library was determined, 
which allowed for library concentration calculation (along with RT-qPCR readings, Section 
2.7.5.3). In addition, the absence of adapter dimer was confirmed.  
2.7.5.3 RT-qPCR quantification of libraries 
Library concentrations were determined by RT-qPCR using the Kapa Biosystems Library 
Quantification Kit for Illumina platforms. The kit contains 6 DNA standards (452 bp in size), 
following a 10-fold dilution from 20 pM to 200 aM. Aliquots of each library (samples) were 
diluted to 1/1,000, 1/2,000, 1/4,000 and 1/8,000 for quantification. Standards, non-template 
controls and libraries were run in triplicates in a 96-well plate and kit-defined cycling 
conditions were followed. Experiments where the standard curve achieved an efficiency of 
90-110% were used for quantification. If the efficiency was not in this range, the RT-qPCR 
experiment was repeated. Standard-curve determined concentrations were corrected for 
dilution factor and adjusted to take into account the average size of the library the latter 
having already been determined previously by Bioanalyzer measurement (Section 2.7.5.2).  
RT-qPCR quantification was used to ensure equi-molar pooling of libraries and on the day of 
the sequencing run for the pooled library quantification.  
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Figure 2.4 Overview of library preparation 
Schematic of the main steps involved in the Bioo Scientific NEXTflex ChIP-Seq library 
preparation kit. Five ng of DNA purified from ChIP and input samples were taken through to 
library preparation.  
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2.7.5.4 Sequencing run 
Libraries per experiment were equi-molar pooled and sequenced on an in-house MiSeq 
sequencer (Illumina; San Diego, CA, USA), using 150 cycle (2x75 paired-end) V3 kits 
(Illumina). The sequencing run was set up according to the latest guidelines. The flow cell 
was rinsed well with lab-grade water, dried using microscopy tissues (Fisher Scientific) and 
given a final clean with ethanol-impregnated microscopy tissues (Bollé Safety; Villeurbanne, 
France). MiSeq cartridges were thawed for 1 hour in a water bath set to 21ºC, then dried and 
inverted 5 times to ensure thorough mixing of contents. Only once the MiSeq set up was 
complete, were the libraries denatured thereby ensuring the amount of time from denaturation 
to the start of the sequencing run was minimised.  
Libraries were denatured by adding 5 µL of library to 5 µL of 0.2 N of fresh NaOH (Sigma), 
and incubated for 5 minutes at room temperature. After denaturing, libraries were placed on 
ice, diluted with kit supplied ice-cold HT1 buffer (Illumina). Concurrently, PhiX control 
DNA (Illumina) was denatured and diluted to the same loading concentration as the library. 
Nine hundred and 50 µL of library was mixed well with 50 µL of diluted PhiX, giving a 5% 
spike of PhiX. The final concentration of NaOH in the sample to be loaded was less than 1 
mN. Six hundred µL of this was loaded into the MiSeq cartridge and the cartridge  loaded into 
the MiSeq.  Initial sequencing was optimised and revealed that 12.5 pM of library loading 
achieved an ideal cluster density of 800-1,000 x103 clusters per mm2.  
  
 65 
2.8 Statistical analysis 
Data with fewer than 8 data points was assumed to be non-parametric as there were too few 
data points to reject this assumption and non-parametric is the more conservative approach.  
Consequently for these points the median and range is shown. Per chapter the statistical 
approach chosen will be outlined, as will how it was carried out either using Prism software 
(Version 5, Graph Pad; San Diego, CA, USA) or the R environment (Version 3.1.0164). 
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3. Detection of IL-33 
3.1 Introduction 
Tsuda et al. have previously shown that cell lines vary in their expression of IL33 splice 
variants79. This has the potential to impact on the results generated from functional genomic 
experiments of IL-33 as, pending on splice variants expressed this would influence the ability 
of IL-33 to carry out hypothesised roles. Whether IL-33 acts as a chromatin-binding factor77, 
localises in the nucleus69, interacts with NF-κB78 or induces signalling as a cytokine can all 
vary with known variants57. Therefore it is prudent to determine the variant expression in 
NHBEs and cell lines before any functional approaches are carried out.  
IL33 is reproducibly detected at the mRNA level where precisely designed primers allow for 
confidence in the specificity of detection. At the protein level however, detection of human 
IL-33 has been found to be inconsistent. Using microscopy and Western blotting, IL-33 is 
usually found only in the nucleus or in the nucleus and cytoplasm of cells20,73,83,87. It is not 
clear whether the discrepancy in subcellular localisation is due to species, cell type or 
antibody. Nessy-1 and the R&D mAb (monoclonal antibody) clone 390412 (referred to as 
R&D mAb) are commonly used antibodies for detection, with Nessy-1 often showing strong 
nuclear staining and R&D mAb detecting IL-33 in both the nucleus and cytoplasm. In 
addition to these two commercial available antibodies, specifically for this thesis project three 
polyclonal antibodies were raised against peptides of IL-33 that were predicted to be the most 
immunogenic: Cook-3, Cook-4, Cook-5 (see Chapter 2, Table 2.1 their epitopes).  
Many authors have commented on IL-33 ELISAs being unable to detect any signal, and 
papers have shown limited detection in supernatant of stimulated cells177, serum91,93 and in 
clinical lavage84,131. Others in contrast, have occasionally reported notably higher values such 
as 1,000 ng/mL90. Conducting a survey of publications to date, the R&D DuoSet IL-33 
ELISA is most commonly used and all ELISAs, to the author’s knowledge, have a standard 
curve based on “mature” IL-33 (referred to as cytokine fragment IL-33, cf-IL-33, for clarity). 
There have been no published attempts to determine whether the current ELISAs detect the 
full-length IL-33 and yet full-length is seen in the majority of published Western blots for IL-
33 with few finding a lower molecular weight band. 
The aims of this chapter were to: 
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1. Determine the IL33 splice variant repertoires of a number of airway epithelial cell 
lines in order to identify those expressing an identical or as similar as possible 
repertoire to that of NHBEs. 
2. Validate antibodies and ELISAs for IL-33 by using recombinant IL-33 variants and 
tagged IL-33 constructs.  
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3.2 Materials and Methods 
3.2.1 Cell culture 
The airway epithelium cell lines A549 (passages 19-52), BEAS-2B (passages 6-17), 16HBE 
(passages 10-35) were passaged as per Section 2.3. For baseline expression; these cells were 
harvested without being starved overnight. For mRNA and flow cytometry; cells were seeded 
in 24 well plates, for confocal microscopy; cells were seeded in LabTek II slides and for 
protein measurements; cells were seeded in 100 mm dishes.  
3.2.1.1 Overexpression optimisation using Turbofect 
When cells were 70% confluent, media was aspirated and replaced with 450µL of growth 
media. Turbofect (Thermo Fisher) lipofectamine was diluted in un-supplemented media at a 
ratio of 2:25 and mixed well. Plasmids were diluted in order to be the specified (see Section 
3.3.4.2) final concentration when added 1:1 with the diluted lipofectamine. After 15 minutes 
of incubation at room temperature, 50 µL of lipofectamine-plasmid solution was added to the 
cells. Cells were incubated for 24 or 48 hours before harvesting. The optimised 
overexpression conditions are given in Section 2.3.1.3.  
3.2.1.2 MTS assay 
The mitochondrial activity of cells was measured using the MTS assay as per Section 2.3.1.4. 
This was used as a surrogate for cell viability, in order to determine the conditions for 
transfection that were least toxic. Supernatants from cell culture individual wells were 
transferred into technical triplicates for plate reading; these technical triplicates were then 
averaged.  
3.2.2 Quantification of IL33 mRNA 
RNA was lysed and extracted using the Qiagen RNeasy plus kit (Section 2.4.1). After 
Nanodrop quantification, RNA was reverse transcribed to cDNA (Section 2.4.2). Relative 
quantity of mRNA was determined by RT-qPCR, using RPS13 as the endogenous control 
(Section 2.4.4). Relative expression was calculated from the control sample, which was 
arbitrarily set to a value of 1.  
3.2.3 Cloning 
Cloning was carried out using the PCRII TOPO vector (Thermo Fisher) and chemical 
transformation using the One Shot Mach1 (Thermo Fisher) competent E. coli. The standard 
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method of transformation was used and involved heat shock of the bacteria, followed by 
growth in unselective media for 1 hour at 37ºC. Bacteria were then spread using 3mm glass 
beads onto plates containing LB agar containing 50 µL/mL ampicillin until colonies formed 
(16 hours at 37ºC). Colonies were picked and grown in liquid selective LB media (50 µL/mL 
ampicillin) for 16 hours shaking at 200 rpm at 37ºC after which plasmids were purified using 
the mini-prep kit (Section 2.2.2). Gene incorporation was determined by double digest and 
running the digest on an agarose gel. Plasmids with the correct size inserts were sent for 
external Sanger sequencing (Eurofins; Luxembourg City, Luxembourg) to verify insert 
correct and with no base errors.  
3.2.3.1 IL-33 construct development 
Molecular cloning was carried out to generate tagged-versions of IL33. Vectors used were the 
pEGFP-C1 (C’ terminal EGFP tag. Clontech; Mountain View, CA, USA) pEGFP-N1 (N’ 
terminal EGFP tag; Clontech) and an altered plasmid based upon pcDNA3 (Invitrogen, 
received with thanks from Dr. Paul Lavender). For the altered pcDNA3 plasmid, Sanger 
sequencing was required to determine the features present around the multiple cloning site. 
This was done by sequencing outwards from the current insert (GATA3) using primers listed 
in Appendix I. This showed FLAG-tag, 2x TEV cleavage sites and an HA (human influenza 
haemagglutinin) tag 3’ of the insert. The map of this plasmid is shown in Figure 3.1, and was 
created using SnapGene Viewer (Version 2.7.1. GLS Biotech; Chicago, IL, USA).  
To prepare the plasmids for ligation, 4 µg of plasmid was added to a total reaction volume of 
80 µL, with 4µL of restriction enzyme and 8 µL of enzyme (New England Biolabs, NEB; 
Ipswich, MA, USA) buffer, as shown in Table 3.1. These were kept for 2 hours at 37ºC and 
heat inactivated at 80ºC if appropriate. Ten units of shrimp alkaline phosphatase (NEB) was 
added to the reaction and carried out at 37ºC for 1 hour then heat inactivated by holding at 
65ºC for 5 minutes. Dephosphorylating the plasmid at the restriction site reduces ligation of 
the plasmid without an insert being inserted. The plasmid was then purified using the Qiagen 
PCR clean up kit.  
Inserts for each construct were generated by 30 cycles of PCR (Section 2.2.3) using 50 ng of 
cloned IL33 plasmid (generated in Section 3.3.2, primers and annealing temperatures are 
listed in Appendix I). From 5’ to 3’, PCR primers were created to produce: an additional four 
nucleotides of the required restriction site and to amplify IL33 or a truncated version of IL33. 
The additional 5’ nucleotides allow the restriction enzyme to cleave more effectively as they 
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do not always have high efficiency at the ends of DNA. If required, a start codon at the 
beginning of the variant sequence was added. These were all designed to have the tag and 
IL33 in the same open reading frame. One µg of PCR product for each variant was digested 
under the same conditions as the vector, using 1 µL of each restriction enzyme and 4 µL of 
NEB buffer in a final reaction volume of 40 µL.  
Fifty ng of plasmid was used in the ligation reaction, and the PCR product was used at a 
molar ratio of 3:1 (PCR product: plasmid). The ligation was carried out using 1µL T4 ligase 
with T4 ligase buffer (NEB) in a total reaction volume of 20 µL, incubated for 16 hours at 
16ºC and then heat denatured for 10 minutes at 65ºC.  
Transformation of E. coli and confirmation of correct insert (in frame and expected sequence) 
was carried out using the method described in Section 2.2.2, using ampicillin 50 µg/mL or 
kanamycin 50 µg/mL for the C’ HA and GFP plasmids respectively.  
  
 
Figure 3.1 Map of altered pcDNA3 plasmid 
Map of custom HA tagged plasmid based on the original pcDNA3 map and Sanger 
sequencing outwards from current insert to determine the restriction sites available and 
features added previously. The figure was created using SnapGene Viewer.  
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Table 3.1 Digestion conditions 
For each tagged-plasmid the restriction enzymes, buffer and use of heat inactivation is shown. 
4µg of each plasmid and 1µg of PCR product containing the restriction site were used in the 
digestion reactions. 
Plasmid 5' Restriction Enzyme 
3' Restriction 
Enzyme Buffer 
Heat 
Inactivation 
C' HA Eco RI Eco RV 3 + BSA Yes 
N' GFP Xho I Bam HI-HF Cutsmart No 
C' GFP Xho I Bam HI-HF Cutsmart No 
 
3.2.4 Protein detection 
Cells were harvested for their whole, nuclear or cytoplasmic lysates following the protocol in 
Section 2.5.2.1 before being used in Western blotting or ELISA. Recombinant cf-IL-33 was 
obtained from R&D Systems and GST-tagged recombinant fl-IL-33 was obtained from 
Abnova (Taipei, Taiwan).  
3.2.4.1 Western blot 
The Western blotting method in Section 2.5.2.3 was followed, originally only using 
denaturing conditions and where listed, semi-native conditions. Over-expressed IL-33 was 
first detected by the HA-tag on the construct. The anti-HA pAb details are listed in Appendix 
III. IL-33 was detected using the custom IL-33 polyclonal antibodies (pAb) Cook-3, Cook-4 
and Cook-5 (described in Section 2.5.1 and Appendix III). IL-33 was also detected using 
commercial anti-human IL-33 antibodies: Nessy-1 mAb (Enzo Life Sciences) and R&D mAb 
(clone 390412). 
3.2.4.2 Dot blot 
Recombinant proteins were diluted in PBS with 20% NuPAGE LDS (Thermo Fisher). Protein 
to be denatured had ß-mercaptoethanol (Sigma) to a final concentration of 2.5% added to it. 
Native samples were kept on ice; denatured samples were heated on a heat block to 70ºC for 
10 minutes and then left to cool on ice. Ten µl aliquots of the protein was then dotted onto to 
nitrocellulose membrane (Whatman; Dassel, Germany) and left to air dry. Once dried, blots 
were blocked and probed as per the Western blots protocol (Section 2.5.2.3).  
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3.2.4.3 Flow cytometry 
Transfected cells were detached using 1X Trypsin, pooled, live/dead stained and analysed by 
flow cytometry (Section 2.5.5). Live/dead cell and GFP cell gating was first determined using 
heat-killed cells and un-transfected cells respectively. 
For each sample, 10,000 unique live cell events were recorded. Data was analysed using 
FlowJo, first gating on single cells, then excluding dead cells and then determining the 
percentage of GFP positive cells.  
3.2.4.4 Confocal microscopy  
LabTek II 4 chamber slides were seeded with 16HBE cells and following transfection 
(Section 2.3.1.3) cells were fixed and stained (Section 2.5.4), using IL-33 antibodies (Section 
3.2.4.1). Cells were imaged using the Leica SP5 MP/FLIM inverted confocal microscope and 
processed using FIJI. For images shown, colours were chosen to allow for colour-blind 
distinction and contrast was enhanced by a saturation value of 0.35 for each channel. Finally 
speckles were removed by the remove outlier function whereby a pixel is replaced by the 
median value of the pixels surrounding it in a 3x3 pixel radius if its value is higher than 20 
intensity units than the median value. Co-localisation was quantified by Pearson r value using 
the Coloc 2 plugin for FIJI163. 
3.2.4.5 IL-33 ELISA 
Cell lysates were thawed on ice and quantified using the Bradford method (Section 2.5.2.2). 
One hundred ng and 1 µg of protein of separated lysates were added to the Peprotech and 
R&D DuoSet ELISA kits and processed (Section 2.5.3).  
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3.3 Results 
3.3.1 IL33 mRNA detection 
Several airway epithelial cell lines exist and in order to determine the most suitable cell line 
model to adopt, a number of cell lines were screened for levels of expression of IL33 
including splice variants. RT-qPCR using primers spanning IL33 exon-exon junctions 
determined that NHBEs and the A549 cell line express all protein coding exons (Figure 3.2, 
see Chapter 1, Section 1.2.3 for the IL33 gene structure and splice variants). As can be seen, 
BEAS-2B and 16HBE cell lines only had very low levels of detection for a few of the exon-
exon junctions of IL33. Compared to the endogenous control gene RPS13, IL33 had the 
highest level of mRNA expression in NHBEs, and this was approximately 100-fold higher 
than the levels seen for the A549 cell line.  
To further determine IL33 splice variant expression, primers spanning the second exon and 
the junction between exon 7 and 8 of the gene were used in a PCR reaction for each cell line.  
Primer sequences are listed in Appendix I and were previously used by Tsuda et al.79 in their 
investigation of IL33 splice variants. Only NHBE and A549s yielded PCR products using 50 
ng of cDNA of each cell line for 35 cycles (Figure 3.3). Full-length IL33 was predicted to 
give a PCR product of 550 bp. The amplicon obtained was confirmed to be the full-length 
variant of IL33 by gel extraction of the 550 bp products and Sanger sequencing (Section 
2.2.2).  
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Figure 3.2 RT-qPCR of exon junctions of IL33 in airway epithelial cell types 
Percent expression of IL33 per primer-pair, NHBE levels were arbitrarily set to 100%. 
Quantification of IL33 products spanning exon junctions shows that the A549 cell line and 
NHBEs express all protein coding exons of IL33. Positive detection of IL33 in BEAS-2B and 
16HBE cell lines only occurred with a few exon junction-spanning primers. Median and 
range is shown (N=3).  
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Figure 3.3 Agarose gel of IL33 PCR to determine splice-variants present 
Labels above lanes indicate ladder used or 50 ng of cDNA per cell type. Twenty cycles of 
PCR of RPS13, as a loading control are shown below the gel. Only cDNA from NHBE and 
A549 cells yielded an amplicon of the predicted size, which was confirmed to be IL33 by 
Sanger sequencing.  
3.3.2 Generation of IL-33 recombinant protein 
Twenty ng of cDNA from unstimulated A549 cell line was used in a PCR reaction with 
primers spanning the 5’ untranslated region (UTR) to the 3’ UTR of IL33 (30 cycles as per 
Section 2.2.3, primer sequences given in Appendix I). A 10 µL aliquot of the product was run 
on an agarose gel (Section 2.2.1) to confirm successful PCR and an amplicon of the expected 
size (Figure 3.4-A). It was then ligated into the PCRII TOPO vector for molecular cloning. 
Qiagen mini-prep extractions from 3 colonies found one plasmid with the correct insert size 
by double digest using Hind III and Not I in NEB Buffer2 with BSA (Figure 3.4-B). Sanger 
sequencing validated that the insert matched the full-length IL33 reference sequence and 4 
mismatches in the UTR of the mRNA, which may have been caused by a Taq polymerase 
error in PCR.  
The plasmid was given to Dr Rebecca Beavil (King’s College London Protein Production 
Facility) to enable two forms of recombinant proteins to be created in E. coli by cloning the 
inserts into the pET151 N-terminal his-tag vector for expression. The cytokine fragment (cf-
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IL-33) and the full-length (fl-IL-33) variants contained a coding sequence of amino acids 112-
270 and 1-270 respectively. The full-length protein had a much lower yield from pooling two 
preparations (0.3 mg/ml) compared to a single preparation of the cytokine-fragment (1.2 
mg/ml).  
 
Figure 3.4 Agarose gel images of IL33 cloning 
Images show agarose gels of PCR products from IL33 5’ UTR to 3’ UTR PCR (A) and 
digests of colonies from molecular cloning (B). Labels above lanes indicate the samples or 
ladders loaded, to the left of the images are the ladder sizes and to the right of the images are 
the approximate sizes of the products of interest. The predicted size of the PCR product in A) 
and digest in B) are 936 and 1,032 bp respectively.  In each case gels show a band of expected 
size.  
3.3.3 Detection of recombinant full length IL-33 requires ‘semi-native’ 
conditions  
In order to assess antibody sensitivity to IL-33, pure recombinant proteins were used in a 
standard denaturing Western blot method (Section 2.5.2.3). As Nessy-1, R&D mAb and 
Cook-5 have epitopes in the C-terminus it was anticipated that these antibodies would be able 
to detect the cytokine fragment as well as the full-length versions of IL-33. Cook-3 and Cook-
4 in contrast would only detect the full length. 
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After some initial issues with purity of commercial full length IL-33, detection was 
successful. Commercial cytokine fragment and fl-IL-33 recombinant proteins were both 
detected at 50 ng per well (Figure 3.5).  
Using the recombinant proteins generated by Dr Rebecca Beavil and under standard 
denaturing conditions, the cytokine fragment of IL-33 was successfully detected. The 
commercial full-length protein was also detected, this was tagged with GST: a large tag that 
roughly equals the molecular weight of the full-length protein. Custom fl-IL-33, which had a 
His-tag instead of GST, however was not detected (Figure 3.6). Similar results were seen 
using the R&D mAb and Cook-4 (data not presented).  
Several variations of the Western blot method (Section 2.5.2.3) were attempted including: 
using 1% BSA to block and dilute antibodies in place of 5% milk, using PBS-T in place of 
TBS-T, using PVDF membranes in place of nitrocellulose membranes and using primary 
antibodies at [1/500]. None of these changed the ability to detect custom fl-IL-33 with any of 
the antibodies used.  
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Figure 3.5 Commercial recombinant proteins are detected in western blots 
Western blots detected recombinant IL-33 protein using Nessy-1 (A) or Cook-3 (B). Proteins 
were from commercial sources: cytokine fragment IL-33 (cf-IL-33, IL-33170-270) or full-length 
IL-33 (GST-fl-IL-33). Bands are of expected size and intensity.  
In order to reduce the number of variables, a dot blot was carried out using recombinant 
protein in LDS buffer with denaturing or native conditions before loading. Figure 3.7 shows 
that the custom full-length IL-33 was only detected when samples were blotted in their native 
state. If samples were denatured before addition they were not detected. It is worth noting that 
the fl-IL-33 required 300 ng of protein for detection, whereas the cf-IL-33 or commercial 
GST-tagged full length only required 30 ng.  
Native Western blots were therefore attempted using the NativePAGE protocol (Thermo 
Fisher). After 5 unsuccessful attempts in detecting fl-IL-33, it was concluded that native 
Western blots were not sensitive enough to detect full length IL-33 and therefore a semi-
native approach was adopted. Figure 3.8 shows a representative Western blot with 
recombinant IL-33 being loaded in its native state or denatured prior to loading. cf-IL-33 both 
native and denatured was detected equally by Nessy-1. Both Cook-3 and Nessy-1 were unable 
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to detect fl-IL-33 when denatured before loading, even when using 3 µg of protein, yet both 
antibodies detected a band at approximately 30 kDa when fl-IL-33 was loaded without 
denaturation. The detection of fl-IL-33 was weaker in Nessy-1, but as the imaging software 
scaled the intensity compared to the highest level of signal, this could be an artefact of the 
high level of detection of the cf-IL-33.   
 
 
Figure 3.6 Full length IL-33 is undetected in denaturing Western blot 
Recombinant IL-33 variants were run by Western blot and detected by Nessy-1 (A) or Cook-3 
(B). Proteins used were: His tagged cytokine fragment variant of IL-33 (cf-IL-33, custom 
made), His-tagged full length IL-33 (fl-IL-33, custom-made), or GST-tagged full length IL-33 
(GST-fl-IL-33, commercial). Custom fl-IL-33 is not detectable under conditions that other 
variants are. Representative blot from N=3 (independent technical replicates).  
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Figure 3.7 Native IL-33 is detectable by dot blot but not detected when denatured 
His-tagged cytokine fragment (cf-IL-33, custom made) and full length (fl-IL-33, custom 
made) or GST-tagged full-length (GST-fl-IL-33, commercial) IL-33 recombinant proteins 
were added to nitrocellulose membranes for dot blot detection. They were added native or 
denatured as shown in blue and red respectively. cf-IL-33 and GST-fl-IL-33 were detected in 
both states whereas fl-IL-33 was only detected when in its native state. Blot is an example 
from independent technical replicates (N=2).  
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Figure 3.8 Full length IL-33 is detected by Western blot when loaded in native state 
Recombinant full length (fl-IL-33) or cytokine fragment (cf-IL-33) were run by Western blot. 
cf-IL-33 was detected whether denatured (in red) or native (in blue). fl-IL-33 was only 
detected when loaded natively. This was seen with blots probed with Nessy-1 (A) or Cook-3 
(B). Representative blots of independent technical replicates (N=3).   
3.3.4 IL-33 overexpression 
3.3.4.1 IL-33 construct development 
The IL-33 plasmid from Section 3.3.2 was used as a template for PCR with primers to give 
three variants of IL-33: Full-length (fl-IL33, IL-331-270), non-nuclear (nn-IL33, IL-3366-270) 
and cytokine fragment IL-33 (cf-IL33, IL-33112-270). Figure 3.9 shows the PCR products from 
this reaction and each product was specific for the plasmid it was later ligated into. IL-33 
variants were constructed as per Section 3.2.3.1. After digestion and ligation of the PCR 
product and plasmids, E. coli were transfected with the constructs and grown for 16 hours at 
37ºC on agar plates. Colonies from these plates were grown and their plasmids were 
harvested to confirm insert ligation by digestion. An example of this validation is shown in 
Figure 3.10. Nearly all variants were successfully ligated into all plasmids with the exception 
of fl-IL33 in C’GFP which, after 30 colonies, positive ligation was not detected. Sanger 
sequencing (Section 2.2.2) validated that all constructs were in-frame and had the correct 
sequence.  
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Figure 3.9 Agarose gel of IL33 variant inserts 
PCR products generated for each insert and variant were of the expected size. Lanes are 
labelled by their IL33-variant: 1: fl-IL33 (expected size of 813 bp), 2:  nn-IL33 (expected size 
of 618 bp) and 3:  cf-IL33 (expected size of 486 bp).  Each product had specific restriction 
sequences for the plasmid listed above the lane numbers.  
 
Figure 3.10 Agarose gel of digest-confirmation of constructs 
Individual colonies from IL33-HA variants were picked and their plasmid digests are shown 
as lane numbers. All colonies picked show positive insert ligation.  
3.3.4.2 Overexpression of IL-33 in airway epithelial cells 
Preliminary optimisation of IL-33 overexpression was carried out using fl-IL33-GFP 
constructs compared to the empty C’GFP plasmid. Lipofectamine2000 and Turbofect (2 µL 
of lipofection reagent, further details given in Section 2.3.1.3 and Section 3.2.1.1 
respectively) were used with 16HBE, A549 and BEAS-2B cells lines, varying the amount of 
plasmid per 500 µL. RT-qPCR showed that Turbofect achieved above 1,000 fold 
overexpression in all cell types at 4 µg of plasmid, whilst Lipofectamine2000 achieved this at 
0.5 µg of plasmid. For this reason Lipofectamine2000 was chosen as the method for 
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overexpression. Finally, 16HBE and A549 cell lines had high levels of overexpression at 0.5 
µg of plasmid, whereas BEAS-2B overexpression was reduced at 0.5 µg compared to 2 or 4 
µg plasmid (Figure 3.11).  
 
Figure 3.11 Preliminary optimisation of overexpression 
16HBE, A549 or BEAS-2B cell lines were transfected using 0.5, 2 or 4 µg of plasmid per 500 
µL and IL33 was quantified by RT-qPCR relative to empty plasmid per cell type. 
Transfection with Lipofectamine2000 yielded higher IL33 mRNA levels at lower amounts of 
plasmids compared to Turbofect. Median and range shown (N=3). 
Flow cytometry was used to determine the transfection efficiency per cell type and to validate 
that the relative increase in IL33 at the mRNA level was observed at the protein level. Figure 
3.12-A shows the transfection efficiency was fairly similar between cell types, however all 
the replicate BEAS-2B data had to be pooled in order to reach 10,000 events in the alive-cell 
gate. Whilst there was no difference in the alive-dead stain in the BEAS-2B cells, fewer cells 
were seen when inspecting the cells before typsin-detachment, suggesting that the BEAS-2B 
cells were less tolerant to the transfection and had undergone cell death and lysis over the 
transfection period. For this reason, BEAS-2Bs were excluded from further optimisations.   
The volume of Lipofectamine (per 500 µL media) was varied as a further condition for 
optimisation. 16HBEs had the highest overexpression at 1 µL of Lipofectamine whilst A549 
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cells achieved the highest overexpression using 2 µL of Lipofectamine (Figure 3.12-B). fl-
IL33-HA and fl-IL33-GFP had similar levels of overexpression within the same conditions. 
MTS absorbance was used as a surrogate measure of cell viability upon transfection of fl-
IL33-GFP and empty C’-GFP plasmid using 1 or 2 µL of Lipofectamine (Figure 3.12-C). 
This revealed that 16HBEs had higher mitochondrial activity than transfected A549s and that 
there was no difference in viability between the fl-IL33- and empty-plasmid. The 16HBEs 
were therefore taken forward using 1 µL of Lipofectamine in 500 µL of media and the 
duration of transfection was assessed.  
Figure 3.13-A shows that for fl-IL33-HA and cf-IL33-HA, the highest overexpression at the 
RNA level was achieved with incubation for 24 hours. The cf-IL33 variant starts at the 3’ end 
of exon 4 IL33 and stops at exon 8 of IL33. Primers spanning exons 3 to 4 showed a lack of 
overexpression of this region in cf-IL33 and robust overexpression of fl-IL33. Both variants 
showed overexpression using primers spanning exons 6 to 7.  The final over-expression 
method was based upon these optimisations: 0.5 µg of plasmid and 1 µL of 
Lipofectamine2000 in 500 µL with a 24-hour incubation for 16HBEs. For A549s, the method 
was almost identical but with 2 µL of Lipofectamine2000 being used.  
Lipofectamine concentration caused the greatest difference between 16HBE and A549 over-
expression, whilst all other optimisations gave similar results for the two cell lines. For this 
reason, Lipofectamine concentration was tested in NHBEs, with the highest overexpression 
found to be with 2 µL of Lipofectamine (Figure 3.13-B).  
16HBEs were used to verify over-expression at the protein level by loading 10 µg of whole 
cell lysate on a Western blot and probing with anti-HA pAb. Figure 3.14-A shows that fl-
IL33-HA and cf-IL33-HA were detected at 40 kDa and 30 kDa respectively whilst nn-IL33-
HA was weakly detected. Here, nn-IL33 was a construct developed expressing IL-3365-270, 
which was not used past this point. When IL33 overexpression constructs had their nuclear 
and cytoplasmic fractions isolated, cf-IL33-HA was only detectable in the cytoplasmic 
compartment. fl-IL33-HA had the greatest detection in the nuclear fraction, with some 
detection in the cytoplasm (Figure 3.14-B). 
 
 85 
 
Figure 3.12 Selection of cell type and Lipofectamine volume for overexpression 
A) Flow cytometry of fl-IL-33 overexpression. Due to cell death all BEAS-2B replicates had 
to be pooled to achieve the numbers of cells needed for a representative sample. 
Overexpression efficacy was similar across the cell types (median and range are shown, for 
16HBEs and A549s N=3). B) RT-qPCR quantification of fl-IL-33 overexpression varying the 
construct-tag (GFP or HA) and volume of lipofectamine. 16HBE cells transfected using 1µL 
of lipofectamine gave the largest increase in IL33. C) MTS absorbance of cell line 
transfection with fl-IL33-GFP or empty C’ GFP plasmid. 16HBEs showed the highest MTS 
absorbance. Median and range are shown (N=3).  
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Figure 3.13 Final optimisation of conditions for IL33 overexpression 
A) RT-qPCR quantification of IL33 overexpression in 16HBEs transfected for 24 or 48 hours. 
Primers detecting exons 3:4 (IL33 E3:4) only detected an increase by fl-IL33 overexpression 
and both variants were detected by IL33 E6:7. The largest increase in IL33 is found using 24-
hours of transfection. B) RT-qPCR quantification of IL33 overexpression in NHBEs. fl-IL33-
HA shows moderate overexpression at 2µL of Lipofectamine. Median and range shown 
(N=3).  
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Figure 3.14 Western Blot of IL33-HA constructs 
Molecular weight ladders are shown to the left of the blots and loading control bands are 
below the main blots. A) Western blot of whole cell lysate in transfected 16HBE cells. 
Probing with anti-HA pAb detects bands at the appropriate size for each variant. A non-
specific band at 80 kDa is present in all samples, including the mock transfection. 
Representative blot of N=3. B) Western blot IL-33 constructs with separated cytoplasmic 
(cyt, in green) and nuclear (nuc, in orange) compartments. fl-IL33 is detected at moderate 
intensity in the cytoplasmic compartment and at strong intensity in the nuclear compartment. 
cf-IL33 is only detected in the cytoplasmic compartment. Representative blot of N=2.   
3.3.5 Antibodies in confocal microscopy and Western blot show concordant 
IL-33 detection 
Using the IL-33 over-expression demonstrated in Section 3.3.4.2, each antibody was tested 
for its ability to detect IL-33 (sensitivity) and the level of off-target detection (specificity). 
The 16HBE cell line served as an ideal cell type for this, as they appeared not to express IL33 
in normal conditions (at the mRNA level, Section 3.3.1), thereby providing a negative control 
(for background). A Western blot loaded with 300 ng of native fl-IL-33 recombinant protein, 
30 µg of nuclear extract from fl-IL33-HA overexpression and mock-transfected 16HBEs 
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determined the ability of each antibody to detect IL-33 (Figure 3.15). Cook-3 and Nessy-1 
showed good sensitivity and specificity: the recombinant protein and fl-IL33-HA were 
detected and there was no detection in the mock-transfected extract. The sizes detected were 
those previously seen in earlier optimisations using the anti-HA pAb. Cook-4 showed good 
sensitivity for IL-33, it detected the recombinant protein, but it also detected several bands at 
the same intensity between the over-expression and mock-transfection making the specificity 
very low. Cook-5 did not detect any bands. The R&D antibody weakly detected bands in both 
the fl-IL33-HA and the mock construct, suggesting that it was not very sensitive or specific.  
The antibodies were tested again using confocal microscopy. Over-expressing fl-IL33-GFP 
and staining the cells was expected to show co-localisation of staining if the antibody was 
sensitive, and any staining where there was no GFP signal was a sign of lack of specificity. 
Figure 3.16 shows the same results as seen for the Western-blot test of antibodies. Nessy-1 
stained only where GFP signal was found and Cook-3 had the strongest staining where GFP 
staining was strong, with some low-intensity staining of the cytoplasm. As with the Western 
blots, Cook-4 and the R&D mAb had strong background staining and Cook-5 had no 
detectable staining. In order to quantify the over-expression, the Coloc2 plugin for FIJI was 
used to calculate the Pearson r value of per-pixel intensity between the GFP and antibody-
staining channel. The results of this analysis are shown in Figure 3.16-F. The quantification of 
co-localisation concurred with the visual inspection of each biological replicate, with Nessy-1 
having a very strong correlation (median r value of 0.88), Cook-3 a strong correlation 
(median r value of 0.77), and the other antibodies showing weak to no correlation.  
In one replicate of the R&D antibody staining, a different pattern of detection was observed 
with very little background staining and weak, specific staining for IL-33 where the GFP 
signal was most intense. The Pearson r value for this replicate was 0.41: whilst there was 
positive co-localisation in 1/10th – 1/5th of the cells, that the lack of staining in the other GFP 
positive cells meant that it correlated moderately with the IL-33-GFP. Images from this 
replicate are shown in Appendix IV and may be show auto-fluorescence.  
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Figure 3.15 IL33 antibody specificity by Western blot 
Recombinant fl-IL-33 (300 ng of native-state, fl-IL-33 in blue) or 30 µg of nuclear extract 
protein (orange) were loaded per lane. Molecular weight is shown to the left of the blots and 
primary blotting antibodies are shown below. Loading control bands are shown below. Cook-
3 (A) and Nessy-1 (D) show the best sensitivity and specificity for recombinant and over-
expressed IL-33. Representative blots from N=2.  
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Figure 3.16 Co-localisation of GFP-IL33 and antibody staining by confocal microscopy 
Each image is a representative confocal image (A-E). Sub-panels are of DAPI (top left), GFP-
fl-IL33 (top right), antibody stain (bottom left) and merged channels (bottom right). F) Co-
localisation quantified by Pearson r values of pixel intensity between channels (N=3, median 
and range shown). Cook-3 and Nessy-1 have the best co-localisation with GFP-IL33. 
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3.3.6 IL-33 ELISA 
In a similar way to the Western blot, two suppliers’ IL-33 ELISA kits (Peprotech and R&D 
DuoSet) were tested using recombinant protein. These are shown in Figure 3.17, where fl-IL-
33 and cf IL-33 were serially diluted and quantified. Whilst the relative decrease upon serial 
dilution followed the expected Log2 decrease, 5 ng/mL of cf-IL-33 was detected at similar 
levels to 250-500 ng/mL of fl-IL-33. Both suppliers’ kits showed the same preference to 
detect cf-IL-33 at 50-100 fold more than fl-IL-33 and this was also seen when commercial 
full length IL-33 was used (GST-fl-IL-33).    
 
Figure 3.17 IL-33 ELISAs are less sensitive to fl-IL-33 than cf-IL-33 
Serial dilutions of recombinant full length (fl-IL-33) or cytokine fragment (cf-IL-33) were 
detected by Peprotech (A) or R&D (B) ELISA kits. Both detected 500 ng/mL of fl-IL-33 
within a 2-fold range of 5 ng/mL of cf-IL-33. The Y-axis is a log2 scale for clarity of log2 
decrease in detection in the serial dilution. Median and range shown of independent technical 
replicates, N=2.  
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Alterations of the two ELISA kits were attempted but none abrogated the preferential 
sensitivity for cf-IL-33 over to fl-IL-33. The alterations attempted were to use a mix of the 
ELISA kits’ capture and detect antibodies to make a hybrid ELISA, or to use Cook-3 or 
Nessy-1 as the capture or detect antibody. Using Cook-3 or Nessy-1 as a capture antibody 
could only detect 2 ng/mL and 1 ng/mL of the supplied cf-IL-33 and was not viable for 
further use. Hybrid ELISAs did allow for the detection of the standard curve with the best 
polynomial fit having an R2 value of 0.999 (R&D capture and Peprotech detection 
antibodies), but the same preferential detection of cf-IL-33 over fl-IL-33 was still observed.   
Finally, cellular compartment extracts of IL-33 overexpression in 16HBE cells were loaded 
onto the two ELISAs. From the Western blot and confocal data (Section 3.3.5), fl-IL-33 was 
expected to show a large increase in the nuclear extract and a moderate increase in the 
cytoplasmic. A large increase in the detection of IL-33 in the cytoplasmic compartment was 
expected for cf-IL-33-transfected cells. Neither ELISA kit showed a detectable increase in IL-
33 in any cellular compartment for either constructs compared to the mock-transfection 
(Figure 3.18). The same lysates were used for the ELISA detection as for the Western blot 
validation for antibodies (summarised in Figure 3.15-F). 
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Figure 3.18 IL-33 ELISAs do not detect over-expression 
Using the Peprotech (A) or R&D DuoSet (B) ELISA, the level of IL-33 detected in 1µg of 
protein from mock-transfection was similar to overexpression of fl-IL33 or cf-IL33. Neither 
cytoplasmic nor nuclear compartments showed any difference in detection across 
transfections. Median and range shown, no significant differences by Kruskal-Wallis test 
followed by Dunn’s post-test, N=3.  
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3.4 Discussion 
3.4.1 IL33 mRNA expression in airway epithelium cell types 
Full length IL33 was expressed in both NHBEs and A549s and was the only splice variant 
detected when ran on an agarose gel. A549s are an adenocarcinoma cell line which have a 
Type II alveolar epithelium morphology178. Whilst being a different cell type from the 
bronchial epithelium, they will serve as a useful model in Chapter 4, to investigate the role of 
IL33 in inflammation. They will allow experiment optimisation in the cell line and NHBEs to 
be used to validate findings in the biologically relevant cell type. Tsuda et al.79 found that 
immortalised cells are more likely to express splice variants of IL33 and here two SV40 
(Simian vacuolating virus 40) immortalised bronchial epithelial cell lines (BEAS-2B and 
16HBE) did not express any detectable variant of IL33. This may be due to the SV40-virus 
immortalisation process or possibly by prolonged tissue culture. In BEAS-2B and 16HBE cell 
lines, the RT-qPCR was able to detect some products of IL33 exon junctions, but at 100-
10,000 fold lower levels than for NHBEs. This could be a very low level of transcription that 
does not yield enough mRNA to be detected by 35 cycles of PCR for the full-length IL33 
mRNA primers used. Being expressed at such a low level this was classified as a lack of 
expression in 16HBE and BEAS-2B cells.   
3.4.2 IL-33 detection at the protein level 
Full length IL-33 required a semi-native Western blot in order to be detected, however both 
the cytokine fragment and GST-tagged full length IL-33 did not require these conditions. 
Expression of cf-IL-33 in E. coli yielded high amounts of product, yet fl-IL-33 had a low 
yield; this may be accounted for by inclusion bodies found in fl-IL-33-expressing E. coli. 
Inclusion bodies are often made of insoluble aggregates and reduce yield of over-expressed 
protein179. In support of this, commercial fl-IL-33 has been produced with a GST tag, which 
is 26 kDa and would increase the solubility of the product.  
This lack of detection was specific to IL-33 expressed in E. coli because the requirement for a 
semi-native Western blot was not necessary to detect fl-IL33 constructs with an HA tag, 
suggesting that there may be a post-translational modification such as SUMOylation,  
ubiquitination or glycosylation, which may be required for fl-IL33 to be soluble. This does 
not explain why antibodies can bind to fl-IL-33 only when it is loaded in its native state, when 
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they can bind to cf-IL-33 when denatured. Both proteins have the same primary sequence of 
amino acids and when denatured this should be the epitope that is bound.  
In contrast to recombinant IL-33, over-expression of IL-33 constructs clarified the specificity 
and sensitivity of IL-33 antibodies. In both Western blot and confocal microscopy 
measurements, Nessy-1 mAb and Cook-3 pAb were able to detect IL-33 with little 
background. The R&D mAb had a high level of background staining, except for one replicate 
of the confocal staining where it had very little background staining and specific, weak 
staining for IL-33. Nessy-1 is a commonly used antibody for IL-33 detection and was found 
to be very specific and sensitive for IL-33. In addition, Cook-3 is sensitive and specific for 
IL-33, thereby providing uniquely an N-terminal antibody for detection of IL-33.  
Both the Western blot and confocal staining revealed that fl-IL33 is predominantly found in 
the nucleus when over-expressed. By Western blot there was some detection in the 
cytoplasmic compartment, and low-level staining in the cytoplasm found by confocal 
microscopy. This difference in cytoplasmic localisation of fl-IL33 may be because IL-33 is 
weakly localised to the nucleus. Ross et al.180 have shown using a flow cytometry method of 
nuclei extraction, that IL-33 was lost from the nucleus if the nuclei were not fixed, thus when 
cells are fixed immediately for confocal microscopy the true localisation of IL-33 is seen.  
As expected, cf-IL33 was localised to the cytoplasmic compartment in Western blots, but in 
confocal microscopy it was also found to be present in the nuclei. This might be another case 
where the cf-IL33 may be lost from the nucleus due to lack of immediate fixation in confocal 
microscopy. Another explanation is that eGFP multimers up to tetramers have been found to 
localise in the nucleus, and proteins smaller than 50 kDa can freely diffuse into the nucleus181, 
suggesting that the nuclear detection may be due to free diffusion of the cf-IL33 construct.  
ELISAs for IL-33 have been brought into question by the work contained within this Chapter. 
Experiments conducted have shown that both the R&D Duoset and the Peprotech IL-33 
ELISA kits detect recombinant cf-IL-33 at two orders of magnitude greater than fl-IL-33. 
This was seen with both the fl-IL-33 with a HA tag and the commercial GST-tagged IL-33. 
This suggests that the under-detection of fl-IL-33 was not due to the same requirement of fl-
IL-33 to be in a native state for Western blot, as both tagged versions of fl-IL-33 had similar 
detection issues. Both ELISA kits use polyclonal antibodies for the capture and detection 
stages. If the majority of the antibodies within the polyclonal mix detect epitopes that only 
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exist on the cf-IL-33 variant, due to folding of cf-IL-33 in the E. coli that does not occur in 
the fl-IL-33 protein, then this could account for a reduced binding to fl-IL-33. This could have 
been due to the capture, detection or both stages of the ELISAs. Hybrid ELISAs, using all 
possible combinations of IL-33 antibodies from the Western blot experiments and the ELISA 
antibodies, did not give appreciable detection of IL-33.  
Whilst the IL-33 ELISAs’ detection of recombinant fl-IL-33 was less sensitive than cf-IL-33, 
when overexpressing IL-33 constructs, no consistent change in detection was observed. Based 
on the findings from Western blot experiments, there should have been a similar increase of 
cf-IL33 in the cytoplasmic extract and an increase in fl-IL33, predominantly in the nuclear 
extract, when assayed using ELISA. Neither of these expectations were observed suggesting 
that the IL-33 ELISAs tested detect other intracellular components at a higher affinity than 
IL-33. This may be compounded by the lack of sensitivity for full length IL-33, especially as 
IL-33 in most human samples is detected as the full-length protein, making the off-target 
proteins more important in the signal from the ELISA. It is possible that if basal levels of IL-
33 were high, over-expression would not be detected. The RT-qPCR data however from 
16HBEs revealed that any exons of IL33 expressed were at extremely low levels, and there 
was no detection of a full length transcript. Moreover, both confocal and Western blot data 
show no detection of endogenous IL-33 in 16HBEs.  
As IL-33 is a necrosis-released factor, then the detection of endogenous proteins more 
sensitively than IL-33 by the ELISA kits poses a serious problem for the use of these ELISAs 
in both tissue culture-based and real human samples, as they may be detecting the off-target 
epitopes in place of IL-33. This would be plausible because IL-33 would be released into the 
extracellular milieu along with the off-target proteins.  
This Chapter has set up a panel of tests for a number of IL-33 detection methods, using over-
expressed IL-33 tagged for microscopy or cellular compartment extracts. The recombinant IL-
33 may serve as a useful test for sensitivity for full-length protein, however the specific 
conditions required for detection of the full-length protein may confuse issues. Ideally, other 
available reagents for IL-33 protein detection should be validated in a similar manner. 
3.4.3 Impact on current knowledge 
The R&D mAb has been used in several publications and often finds cytoplasmic and nuclear 
staining of IL-33182,183. From the data shown within this Chapter although the antibody is 
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capable of staining and detecting IL-33 it also detects many other proteins with a similar if 
not higher affinity. The cytoplasmic and nuclear staining seen in publications using the R&D 
mAb consequently is questionable and conclusions drawn should be viewed with caution. 
The Peprotech and R&D DuoSet ELISA kits have detected IL-33 in cell lysate184, serum185, 
bronchoalveolar lavage131 and cell culture supernatant20. As these ELISAs appear to be 
detecting other targets at much higher affinity than IL-33, these results may simply be that the 
off-target intra-cellular proteins are being released and detected. A recent paper has shown 
that the Biolegend IL-33 ELISA kit is prone to false positive results in human serum97.  
Nygaard et al.97 hypothesise that this is due to cross-linking of capture and detection 
antibodies by human anti-animal IgG antibodies. 
IL-33 ELISAs from Adipogen, Enzo and Boster use a monoclonal capture antibody and 
polyclonal detection antibody. These ELISAs could avoid the biases towards full-length IL-
33 for the capture stage, yet the detection may still be skewed towards detecting the cytokine 
fragment if the antibodies generated by immunising animals to the cytokine fragment of IL-33 
have epitopes that do not exist on the full length protein. It is too early to state that results 
published with the R&D DuoSet and Peprotech ELISAs are not detecting the true level of IL-
33. The findings of the experiments in this Chapter do however highlight that the use of these 
ELISAs for lysates and homogenates should be avoided, as it is likely that the off-targets will 
be detected in place of IL-33.   
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4. IL-33 and Airway Epithelial Cell Inflammation 
4.1 Introduction 
Intracellular IL-33 has been shown to alter the expression of NF-κB target genes across 
several cell types under various stimulations. The NF-κB targets IL6 and IL8 are the most 
studied and in humans IL-33 appears to have contrasting effects based on cell type or 
stimulation. IL-6 and IL-8 have been shown to be positively regulated by IL-33 in IFN-γ-
stimulated human oesophageal epithelial cells147. Similarly, Kunisch et al.121 used TNF-α-
stimulated rheumatoid arthritic synovial fibroblasts and found that IL-6 and IL-8 were 
decreased upon IL-33 siRNA. Contradictory results were found when stimulating the same 
cell type with a cocktail of TNF-α, IL-1ß, Poly(I:C) and LPS (lipopolysaccharide): Lee et 
al.177 showed an increase in IL-6 and IL-8 upon IL-33 siRNA knockdown, suggesting that the 
effect of IL-33 on IL-6 and IL-8 secretion is stimulation dependent. In addition, TNF-α-
stimulated human epidermal keratinocytes had increased IL-8 at both the mRNA and protein 
level in response to IL-33 knockdown123. Investigations by Shao et al.117 also revealed a 
potential repressive role of IL-33 whereby in unstimulated human pulmonary arterial 
endothelial cells IL-33 knockdown caused an increase in basal IL-6 levels.  
As a cytokine, IL-33 signalling occurs by binding to the heterodimeric receptor composed of 
ST2 (a product of the IL1RL1 gene) and the IL-1 receptor accessory protein. IL1RL1 has two 
isoforms. Full-length ST2 (referred to as ST2 or ST2L) is the membrane-bound receptor 
whilst soluble (sST2) is a truncated version of ST2 and acts as a decoy receptor by binding to 
IL-33 in the extracellular milieu99,186. ST2 is expressed by airway epithelial cells187 and given 
that these cells are a source for IL-33, this could potentially lead to autocrine signalling.  
Work conducted in Section 3.3.1 revealed that only A549 cells and NHBEs both express full 
length IL33. Although A549 cells are a small-airway cell type derived from an 
adenocarcinoma178, due to their easy set-up, robustness and low cost they have been used in 
this chapter as a model to first establish optimal experimental conditions. Subsequently these 
optimal conditions were used to determine the role of intracellular IL-33 on inflammation in 
NHBEs.  
The aims for this chapter were to: 
1. Optimise stimulation conditions for airway epithelial cells using A549 cells 
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2. Investigate the effect of IL-33 stimulation to determine the extra-cellular role of IL-33 
in terms of airway epithelial inflammation.  
3. Determine optimal conditions in A549 cells where IL-33 knockdown may cause 
differential secretion of IL-6, IL-8 or both cytokines.  
4. Validate IL-33 knockdown findings in NHBE cells using IL-33 knockdown, ST2 
knockdown and IL-33 overexpression.  
5. Harvest RNA from optimised experiments for subsequent global gene expression 
profiling. 
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4.2 Materials and methods 
4.2.1 Cell culture 
Cell culture, including IL-33 siRNA and IL-33 overexpression, was carried out as per Section 
2.3. A549 and NHBE cells were cultured in T150 flasks to 80% confluence before being 
seeded in 24-well plates. Four hours after seeding, media was replaced with conditioning 
media and left overnight before stimulation. Unless otherwise stated, conditioning media was 
un-supplemented growth media and stimulations diluted in conditioning media. Six hundred 
µL of stimulation or control (conditioning media alone) were added to each well in a 24-well 
plate. Supernatants were aliquoted and kept for ELISA quantification of cytokines and cells 
lysed in RLT plus buffer and RNA extracted per time point (as per Section 2.4.1).  
Human umbilical vein endothelial cells (HUVECs, Promocell) are responsive to IL-33 
stimulation187 and were used to validate recombinant IL-33 as bioactive. HUVECs were 
cultured in endothelial cell growth media (Promocell, Appendix II) and used at passages 3-4. 
A549 cells were used at passages 40-75 and NHBE cells were used at passages 2-4. For 
experiments investigating IL33 expression upon stimulation of NHBEs, basal epithelial 
growth media was supplemented with insulin-transferrin-selenium at 1% v/v (ITS, Sigma) in 
order to avoid starvation stress. 
4.2.1.1 ST2 siRNA optimisation 
ST2 knockdown was optimised using three Lipofectamine formulations: DharmaFECT 
(Section 2.3.1.1), HiPerFect (Section 2.3.1.2) and RNAiMAX (Invitrogen). The final ST2 
siRNA method adopted is detailed in Section 2.3.1.2.  
The RNAiMAX method for transfection was carried out on 60-70% confluent NHBEs in 24-
well plates. Media was aspirated and replaced with 480 µL of growth media. Per well, siRNA 
pools were diluted to 25, 50 or 100 nM in 60 µL of Opti-MEM media (Invitrogen) and mixed 
well by pipetting. Per well, 1.5 µL of RNAiMAX was diluted in 60 µL of Opti-MEM media 
and mixed well by pipette. Both solutions were incubated at room temperature for 10 minutes 
before being mixed 1:1 by pipette. Lipofectamine-siRNA mix was then added to cells (1:5) 
giving final siRNA concentrations of 2.5, 5 and 10 nM. Transfection was carried out for 24 
hours or 48 hours at 37ºC in a 5% CO2 incubator.  
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4.2.2 ELISA 
Supernatants from stimulated cells were kept at -20ºC until quantification of cytokines by 
ELISA. IL-6, IL-8 and CCL2 ELISAs were carried out as per Section 2.5.3.  
4.2.3 RNA extraction and RT-qPCR 
RNA was lysed and extracted using the Qiagen RNeasy plus kit (Section 2.4.1). After 
quantification using the Thermo Fisher Scientific Nanodrop, RNA was reverse transcribed to 
cDNA (Section 2.4.2). Relative quantity of mRNA was determined by RT-qPCR as per 
Section 2.4.4 .  
4.2.4 MTS assay 
The MTS assay was used to determine the mitochondrial activity of cells in a 24-well plate 
(Section 2.3.1.4). Readings were normalised to percent absorbance of untreated cells.  
4.2.5  Statistical analysis 
Data with less than 7 samples cannot be reliably determined as parametric so was assumed 
non-parametric. Non-parametric data with more than two conditions were assessed for 
statistically significant differences by a Kruskal-Wallis test followed by Dunn’s Multiple 
Correction. Two-way ANOVA with a Bonferroni post-test correction was used for data with 
multiple time points or concentrations, across multiple conditions. There is no non-parametric 
equivalent of this test so this was used even when the data normality could not be shown.  
Parametric data are presented as mean and standard error of the mean (SEM) for cell lines and 
mean and standard deviation (SD) for primary cells; non-parametric data are shown as median 
and range. SEM was chosen for cell lines as they represent a single population of cells, even 
with replicates taken as biological if they were seeded from separate flasks or passages.  
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4.3 Results 
4.3.1 Epithelial cell stimulation 
From work in Chapter 3, the A549 cell line was shown to be the only cell to express full 
length IL33 and consequently the most appropriate for conducting preliminary experiments of 
IL-33’s effect in inflammation. Using A549 cells, initial dose response experiments were 
carried out over a 24-hour time-course using three different and independent stimulations: the 
pro-inflammatory cytokines IL-1ß and TNF-α, and an extract from the A. alternata fungus.  
IL-1ß was chosen as a stimulus because it is a potent activator of NF-κB signalling and prior 
work in the group (Molecular Genetics and Genomics Group, NHLI) had characterised the 
responses of airway epithelium to IL-1ß. A 10-fold serial dilution (0.1 – 10 ng/mL) of IL-1ß 
was used to determine optimum stimulation conditions (Figure 4.1). In the supernatant of 
stimulated cells, IL-6 and IL-8 were increased compared to unstimulated cells during the time 
course (Figure 4.1-A and -B respectively). One ng/mL IL-1ß was the lowest concentration 
that produced an appreciable response for both cytokines, peaking at 24 hours with median 
values of 489 (485-503) pg/mL (p < 0.001) and 1.5 (1.0 – 3.8) ng/mL (p < 0.01) for IL-6 and 
IL-8 respectively. Using the optimum stimulation concentration of 1 ng/mL, IL33 increased 
over the time course showing a 7.1 (4.9 – 8.0) median fold increase (p < 0.01) compared to 
expression levels at baseline (0 hours) (Figure 4.1-C). For all further IL-1ß stimulation 
experiments 1 ng/mL was therefore used.  
IL-33 and IL-1ß both require the IL-1 receptor accessory protein co-receptor for signalling. 
To rule out any potential cross talk of co-receptors, a TNF-α stimulation was also performed. 
TNF-α is another potent activator of NF-κB-signalling. The dose response experiment for 
TNF-α (1 – 100 ng/mL) revealed that although stimulation using 1 ng/mL led to an increase 
in IL-6 secretion with the peak level occurring at 6 hours with a median change of 73 (56-
257) pg/mL of IL6 (p < 0.001, Figure 4.2-A), an equivalent increase in IL-8 (Figure 4.2-B) 
was not observed. Ten ng/mL TNF-α was the lowest concentration that gave rise to a 
significant response in IL-8 secretion, again with the peak level at 6 hours, median change 
702 (466 – 917) pg/mL of IL8 (p < 0.05, Figure 4.2-B). When IL33 expression was 
investigated with 1 and 10 ng/mL TNF-α stimulation, only 10 ng/mL TNF-α stimulation 
significantly increased IL33 compared to baseline, again with a peak in levels occurring at 6 
hours with a 3.2 (2.4 – 4.6) median fold-change (p < 0.05, Figure 4.2-C). Ten ng/mL was 
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taken forward as the optimum concentration for TNF-α stimulation, even though it did not 
significantly alter IL-6 secretion 
Exposure to A. alternata has been associated with asthma in a dose-responsive manner188. 
Extract from this fungus has since been used in human cell culture73 and mouse models of 
asthma15 as it induces a potent inflammatory response and an increase in IL-33. Stimulation 
using 0.2 – 20 µg/mL of A. alternata extract however, did not achieve detectable levels of IL-
6 in the supernatant of stimulated cells. IL-8 increased with the maximum dose of 20 µg/mL 
to a median of 384 (381- 440) ng/mL upon 24 hours of stimulation (p < 0.0001, Figure 4.3-
A). IL33 increased over the time-course with median fold change increases of 3.6 (2.3 – 3.8) 
and 3.0 (2.9 – 3.2) at 4 and 24 hours respectively (p < 0.05 for both, Figure 4.3-B) although a 
drop in the intervening six hours point was observed unlike that seen for the other 
stimulations (IL-1ß and TNF-α). Twenty µg/mL of A. alternata extract was deemed to be the 
optimal stimulation concentration and was used for all further stimulations.  
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Figure 4.1 IL-1ß stimulation dose response in A549 cells 
ELISA quantified IL-6 (A) and IL-8 (B) levels in supernatant over a 24-hour time-course of 
IL-1ß stimulation in A549 cells (N=3). Statistical significance was determined using two-way 
ANOVA with Bonferroni correction post-test, comparing each dose to un-stimulated per time 
point. For IL-6 (A), for both 1 ng/mL and 10 ng/mL stimulation with IL-1ß significant 
increment (p < 0.001) in levels was observed from 4-24 hours.  For IL-8 (B), significant 
increment (p < 0.01) was seen at 24 hours only for 1 ng/mL and 10 ng/mL IL-1ß stimulations. 
C) Relative IL33 mRNA expression for 1 ng/mL IL-1ß stimulation time-course (N=3). 
Significance was assessed by Kruskal-Wallis test with Dunn’s post-test comparing each time-
point to time 0. Median and range shown.  
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Figure 4.2 TNF-α stimulation dose response in A549 cells 
ELISA quantified IL-6 (A) and IL-8 (B) levels in supernatants over a 24-hour time-course of 
TNF-α stimulation in A549 cells. Statistical significance was determined using two-way 
ANOVA with Bonferroni post-test, comparing each dose to unstimulated per time point 
(N=3). One ng/mL stimulation with TNF-α led to a significant increase of IL-6 (A) at 6 & 24 
hours (p < 0.001). Ten and 100 ng/mL TNF-α led to a significant increase of IL-8 (B) at 6 & 
24 hours (p < 0.05). C) Relative IL33 mRNA expression for 1 and 10 ng/mL TNF-α 
stimulation time-course (N=3). Significance was assessed by Kruskal-Wallis test with Dunn’s 
post-test comparing each time-point to time 0. Median and range shown.  
0 2 4 6 24
0
1
2
3
4
5
Re
lat
iv
e I
L3
3 
Ex
pr
es
sio
n 
 (A
U
)
Time (hours)
p < 0.01
p < 0.05
1 ng/ml TNF-α
10 ng/ml TNF-α
2 4 6 24
0
500
1000
1500
IL
-8
 (p
g/
m
L)
Time (hours)
2 4 6 24
0
100
200
300
IL
-6
 (p
g/
m
L)
Time (hours)
Unstimulated
100 ng/ml TNF-α
10 ng/ml TNF-α
1 ng/ml TNF-α
2 4 6 24
0
200
400
600
800
IL
-8
 (p
g/
m
L)
Time (hours)
Unstimulated
100 ng/ml TNF-α
10 ng/ml TNF-α
1 ng/ml TNF-α
A) 
C) 
B) 
 106 
 
Figure 4.3 Alternaria alternata extract stimulation dose response in A549 cells 
A) ELISA-determined IL-8 in supernatant over a 24-hour time-course of A. alternata extract 
stimulation in A549 cells. IL-6 was undetectable in these samples by ELISA. Statistical 
significance was determined using two-way ANOVA with Bonferroni post-test, comparing 
each dose to unstimulated per time point (N=3). IL-8 was increased by A. alternata extract 
stimulation at 0.2 µg/mL (p < 0.01) and  20 µg/mL (p < 0.0001) from 4-24 hours. B) Relative 
IL33 mRNA expression for 20 µg/mL A. alternata extract stimulation time-course. 
Significance was assessed Kruskal-Wallis test with Dunn’s post-test comparing each time-
point to time 0 (N=3). Median and range shown.  
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4.3.2 IL-33 stimulation 
HUVECs are highly sensitive to cf-IL-33 stimulation, with secretion of high levels of CCL2 
and IL-8187. These cytokine responses and cells were used in the first instance to determine 
the stimulatory capacity of commercial and custom sources of cf-IL-33 and full-length (fl-IL-
33) recombinant proteins (described in Section 3.3.2).  
After 24 hours of stimulation with 100 ng/mL of IL-33, the sources of cf-IL-33 were 
comparable in their induction of CCL2 and IL-8 secretion (Figure 4.4-A and -B) with 
statistically significant increases in both cytokines being observed. Median CCL2 levels in 
unstimulated HUVECs were 469 (466 – 471) pg/mL and when stimulated with cf-IL-33 this 
increased to 30,885 (29,269 – 32,500) pg/mL using commercial sources and 87,536 (57,417 – 
150,096) pg/mL using custom recombinant protein (p < 0.0001 for both). For the custom cf-
IL-33, lower concentrations also resulted in significant increases. Stimulation with 10 and 1 
ng/mL was found to increase CCL2 to median values of 61,979 (52,949 – 69,278) and 18,736 
(12,664 – 21,427) pg/mL respectively (p < 0.0001 for both).  No significant increase in CCL2 
upon stimulation with commercial cf-IL-33 was seen.  
Full length IL-33 also elicited IL-8 and CCL2 secretion at 24 hours of stimulation (Figure 
4.4-C and -D), and whilst statistically significant, the levels were much lower than that 
observed for the cf-IL-33-induced secretion. For CCL2, 1 ng/mL resulted in an increase to a 
median of 756 (753 – 786) pg/mL when commercial fl-IL-33 was used (p < 0.01) and 834 
(600 – 1,031) pg/mL using custom fl-IL-33 (p < 0.01). Both fl-IL-33 sources increased IL-8 
at all doses tested (p < 0.05), whereas the commercial fl-IL-33 only significantly increased 
CCL2 at 1 ng/mL (p < 0.01) and custom fl-IL-33 increased CCL2 at all doses (p < 0.01). In 
summary, unlike the commercial forms the custom made versions of IL-33 appear to be 
folded correctly in order to stimulate HUVECs. The cytokine fragment of IL-33 was the most 
potent stimulant when compared to full length IL-33.  
Based on these HUVEC experiments, IL-33’s capacity to stimulate airway epithelial cells was 
determined using cf-IL-33. The A549 cell response to cf-IL-33 stimulation for 24 hours 
however, was found not to lead to an increase in either CCL2 or IL-8 (Figure 4.5-A and -B). 
NHBE cells were therefore stimulated with cf-IL-33. There was no detection of IL-6 or 
CCL2, and whilst IL-8 was detected, there was no significant increase from any dose used of 
IL-33 (Figure 4.5-C). Full length IL-33 stimulation of A549s for 24 hours also did not lead to 
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an increase in the secretion of either cytokine and was not taken forward to NHBE cell 
experiments (data not shown for brevity). 
 
Figure 4.4 Recombinant IL-33 dose response experiment in HUVECs  
HUVEC cytokine secretion (detected by ELISA) after 24 hours of stimulation with 
recombinant IL-33 – commercial or custom made. A) & B), cytokine fragment variant of IL-
33 from commercial and custom stocks significantly increased CCL2 and IL-8 using 100 
ng/mL of IL-33 compared to unstimulated cells. C) & D), stimulation using full length IL-33 
from commercial and custom stocks increased CCL2 and IL-8 secretion significantly. Data 
was analysed using a two-way ANOVA with Bonferroni post-test correction, comparing 
stimulation to unstimulated values. All points underneath horizontal lines reach the 
significance threshold stated and the single point underneath vertical lines reach the threshold 
(median and range shown, N=3).  
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Figure 4.5 Recombinant IL-33 dose response in A549 and NHBE cells 
ELISA detection of CCL2 and IL-8 in the supernatants of cells after 24 hours of stimulation 
using commercial or custom stocks of cytokine fragment IL-33. A549 CCL2 (A) and IL-8 (B) 
secretion showed no significant increase. CCL2 and IL-6 were undetectable in IL-33 
stimulated NHBEs and IL-8 (C) was not significantly increased upon stimulation. No 
statistical significance was found using a two-way ANOVA followed by Bonferroni post-test 
correction, comparing stimulation to unstimulated values (median and range shown, N=3 
except for C) where a single biological sample was used in technical triplicate).  
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4.3.3 IL-33 knockdown 
4.3.3.1 Knockdown of IL-33 in A549 cells  
Intracellular IL-33 has previously been shown to alter the inflammatory response of 
cells119,121,124,131. In order to define the role of intracellular IL-33 in airway epithelial cells 
during inflammation, siRNA knockdown of IL-33 in A549 and NHBE cells was undertaken.  
IL-33 knockdown was optimised at the mRNA level in A549 cells and primers spanning 
exons 6:7 were used to detect relative changes in IL33 mRNA by RT-qPCR as these exon 
junctions are in all known splice variants of IL33 (“IL33 all variants” in Appendix I). Using 5 
nM IL-33 siRNA and NSC, 24 and 48 hours of knockdown achieved similar efficiency 
(Figure 4.6-A). Forty-eight hours of knockdown was chosen for future experiments. 
Comparing 5, 10 and 15 nM of IL-33 siRNA, IL33 was most reproducibly reduced using 5 
nM of IL-33 siRNA reducing IL33 to a median of 15 (12 – 37) % of the NSC (Figure 4.6-B). 
Whilst optimising the concentration of siRNA to be used and time of knockdown, the MTS 
assay was used to determine changes in relative mitochondrial activity upon transfection. This 
gives a surrogate indication of cell viability, metabolism and cell number. Figure 4.6-C shows 
that after 48 hours of incubation, transfection with IL-33 siRNA did not affect the MTS 
reading more than NSC. Lipofectamine alone, as well as NSC and IL-33 siRNA transfection 
equally reduced the viability of the cells compared to un-transfected cells.  
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Figure 4.6 IL-33 siRNA knockdown optimisation 
A549 cells transfected with non-silencing control (NSC) or IL-33 siRNA to optimise IL33 
knockdown. A) 5 nM of IL-33 siRNA reduced IL33 to less than 10% of the NSC level with 
24- or 48-hour transfection. B) Optimum IL-33 siRNA concentration was determined at 48 
hours of transfection; IL33 was most consistently reduced at 5 nM of siRNA and control. C) 
Cell viability assessed by MTS assay shown as percent absorbance of un-transfected cells; no 
significant difference between lipofectamine alone, NSC or IL-33 siRNA (assessed by 
Kruskal-Wallis test with Dunn’s post-test). median and replicates shown  ( A and B, N=3;  C, 
N=5).  
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In order to identify conditions where the levels the cytokines, IL-6 and IL-8, were altered 
between NSC and IL-33 knockdown, ELISA analysis for the two cytokines was performed. 
A549 cells were used for preliminary IL-33 knockdown and stimulation experiments. IL-33 
knockdown and IL-1ß stimulation caused a statistically significant decrease in IL-8 secretion, 
at 24 hours of IL-1ß stimulation. The supernatant from NSC-treated cells contained a mean 
concentration of 12,197 (SEM = 876) pg/mL of IL-8 whilst in IL-33 siRNA-treated cells this 
level dropped to 9,098 (SEM = 1,012) pg/mL (p < 0.01, Figure 4.7-B). A non-significant 
trend towards reduced IL-6 secretion was also observed (Figure 4.7-A) when compared to 
NSC. Figure 4.7-C confirms an effective knockdown of IL33 mRNA, with 75-90% 
efficiency.  
IL-33 knockdown and TNF-α stimulation in A549 showed a decrease in cytokine secretion 
when compared to NSC-transfected cells. When biological replicates were pooled, IL-6 
showed a non-significant trend towards decreased levels in IL-33 siRNA treated cells (Figure 
4.8-A). IL-8 was significantly decreased in IL-33 siRNA-transfected cells, at 24 hours of 
stimulation NSC-treated IL-8 mean levels were 6,581 (SEM = 874) pg/mL compared to 2,462 
(SEM = 633) pg/mL in IL-33 siRNA-treated cells (p < 0.0001, Figure 4.8-B) and there was a 
reasonable efficiency of knockdown from 45%-85% (Figure 4.8-C).  
IL-6 was undetectable for all samples from transfection and stimulation with A. alternata 
extract. IL-8 secretion did not differ between IL-33 siRNA- and NSC-transfected cells (Figure 
4.9-A). This lack of difference was seen for time points with good knockdown efficiency (0-
12 hours, 90-95% efficacy (Figure 4.9-B)).  It should be noted that by the 24-hour time point 
unlike the other stimulation experiments, knockdown was no longer sustained and had 
recovered to NSC levels (Figure 1.9-B).  
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Figure 4.7 IL-33 knockdown and IL-1ß stimulation in A549 cells 
Non-silencing control (NSC) or IL-33 siRNA-transfected cells were stimulated with IL-1ß, 
IL-6 (A) and IL-8 (B) were measured by ELISA. IL-8 is significantly decreased in IL-33 
siRNA compared to NSC. C) IL33 expression as a percent of NSC-transfected levels per time 
point shows an efficient knockdown of IL33 (mean and standard error shown, two-way 
ANOVA with Bonferroni correction post-test per time point for A) and B), N=3).  
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Figure 4.8 IL-33 knockdown and TNF-α stimulation in A549 cells 
Supernatant IL-6 (A) and IL-8 (B) measured by ELISA over the TNF-α time-course of non-
silencing control- (NSC) or IL-33 siRNA-transfected cells. IL-8 was significantly decreased 
in IL-33 siRNA compared to NSC. C) IL33 expression as a percent of NSC-transfected levels 
per time point shows an efficient knockdown of IL33 (mean and standard error shown, two-
way ANOVA with Bonferroni post-test correction per time point for A) and B), N=2).  
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Figure 4.9 IL-33 knockdown and Alternaria alternata extract stimulation in A549 cells 
IL-6 and IL-8 were measured over an A. alternata time-course of NSC- or IL-33 siRNA-
transfected cells.  IL-6 was not detected and there was no significant difference in IL-8 (A). 
C) IL33 expression as a percent of NSC-transfected levels per time point shows an efficient 
knockdown of IL33 for the first 12 hours of stimulation (mean and SEM is shown, two-way 
ANOVA with Bonferroni post-test correction per time point for A), N=2).  
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4.3.3.2 Knockdown of IL-33 in NHBE cells  
Based on the results from the A549 knockdown and stimulation experiments above, IL-33 
knockdown with stimulation using IL-1ß in NHBEs was performed. In NHBEs IL-6 secretion 
was reduced by a third when cells were pre-treated with IL-33 siRNA compared to NSC 
(Figure 4.10-A) at both 12 and 24 hours of stimulation. NSC-treated cells at 24 hours had a 
mean IL-6 concentration of 324 (SD = 67) pg/mL whilst the siRNA-treated NHBE levels 
were 91 (SD = 37) pg/mL, p < 0.0001. IL-8 was also significantly decreased by IL-33 
knockdown at 24 hours of stimulation (Figure 4.10-B), NSC-treated cells had mean IL-8 
concentrations of 285 (SD = 127) pg/mL and in IL-33 siRNA-treated cells this reduced to 139 
(SD =122) pg/mL, p < 0.001. In NHBEs, a high knockdown efficiency of 75-98% was 
achieved throughout the time-course (Figure 4.10-C). A triplicate of RNA samples per each 
time-point and condition were prepared from this experiment for future global gene 
expression analysis by microarray (see Chapter 5).  
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Figure 4.10 IL-33 knockdown and IL-1ß stimulation in NHBE cells 
Secreted IL-6 (A) and IL-8 (B) were measured over an IL-1ß stimulation time-course of NSC- 
(non-silencing control) or IL-33 siRNA-transfected cells. IL-6 and IL-8 were significantly 
decreased in IL-33 siRNA compared to NSC. C) IL33 expression as a percent of NSC-
transfected levels per time point showing an efficient knockdown of IL33 (mean and SD 
shown, two-way ANOVA with Bonferroni post-test correction per time point, N=3).  
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a poor ST2 knockdown efficiency in NHBEs with only 40% knockdown achieved using the 
optimal conditions from IL-33 knockdown.   
In order to optimise ST2 knockdown in NHBE cells, three different commercially available 
lipofectamine reagents were tested using a range of concentrations (2.5-10 nM ST2 siRNA) 
and two time points (24- or 48-hour incubation) (Figure 4.11). Each supplier of lipofectamine 
had a different protocol for siRNA knockdown and each of these protocols was followed in 
order to give the same volume of lipofectamine and final concentration of siRNA in growth 
media. This optimisation found that 48-hours of transfection with 10 nM ST2 siRNA using 
the HiPerFect reagent gave the most efficient and effective knockdown, achieving a median 
knockdown efficiency of 86 (79 – 88) %.  
When NHBEs were stimulated with IL-1ß following transfection with ST2 siRNA or NSC no 
significant change in IL-6 secretion was observed (Figure 4.12-A). In contrast to IL-33 
knockdown, which caused a decrease in cytokine secretion, ST2 siRNA significantly 
increased IL-8 secretion (Figure 4.12-B).   Mean levels of IL8 for ST2 siRNA treated cells 
were 374 (SD = 105) pg/mL compared to 287 (SD = 71) pg/mL in NSC, p < 0.01. This was 
achieved with a moderate knockdown of ST2 at a mean efficiency of 40-60% (Figure 4.12-C).  
As with the NHBE IL-33 knockdown, triplicate RNA samples per time-point and condition 
were extracted and frozen at -80oC for subsequent use in global gene expression profiling 
with microarrays (see Chapter 6).  
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Figure 4.11 ST2 siRNA optimisation in NHBE cells 
ST2 expression as a percentage of non-silencing control levels. Cells were transfected with 
serial dilutions of ST2 siRNA for 24 or 48 hours using three formulations of lipofectamine 
reagent. Statistical significance was assessed by two-way ANOVA with Bonferroni post-test 
correction, comparing all conditions to NSC-transfected cells. All comparisons were 
significant, p < 0.0001.  HiPerFect with 10 nM ST2 siRNA for 48 hours gave the highest 
efficiency knockdown (mean and standard deviation shown, N=3) 
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Figure 4.12 ST2 knockdown and IL-1ß stimulation in NHBE cells 
ELISA measured IL-6 (A) and IL-8 (B) in NHBEs upon IL-1ß stimulation, showed an 
increase in IL-8 in ST2 siRNA-transfected cells. C) ST2 expression relative to NSC per time-
point reveals a moderate knockdown was achieved. Significance was assessed by two-way 
ANOVA followed by Bonferroni post-test correction, comparing NSC and ST2 siRNA per 
time point (mean and standard deviation shown, N=3).  
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4.3.5 IL-33 overexpression  
Western blotting and confocal microscopy in Sections 3.3.4 and 3.3.5 showed that fl-IL33 
localises in the nucleus and the cf-IL33 in the cytoplasm. In order to determine the role of 
each protein variant in the inflammatory response of the airway epithelium, over expression 
with IL-1ß stimulation was conducted using 16HBEs. The latter were chosen as they had 
proven to be the cell type most tolerant of transfection based on the prior work conducted in 
Chapter 3 (Section 3.3.4.2). Previous studies transfecting truncated versions of IL-33 have 
found that the N-terminus is required for nuclear localisation and nuclear function69,77,78, 
therefore it was expected that overexpression of fl-IL-33 would cause an increase in cytokine 
secretion and that cf-IL-33 would show no differential cytokine secretion upon IL-1ß 
stimulation. 16HBEs however secreted IL-6 and IL-8 at the same levels when either construct 
was over-expressed (Figure 4.13-A and -B). Over-expression was validated at the mRNA 
level using primers spanning exons 3:4. By RT-qPCR cf-IL33 was not detected and an 
increase in IL33 was only seen in fl-IL33-transfected cells (Figure 4.13-C). Primers spanning 
exons 6:7 detected both variants and RT-qPCR showed robust overexpression in fl-IL33- and 
cf-IL33-overexpressing cells (Figure 4.13-D). As discussed in Section 4.4, certain co-factors 
or the chromatin environment may be different in 16HBE cells than NHBEs and therefore 
may not alter the inflammatory response in these cells. It was therefore uncertain whether the 
transcriptome of 16HBEs overexpressing IL-33 would be comparable to NHBEs and was not 
investigated. Instead, gene expression changes upon IL-33 knockdown (Chapter 5) and ST2 
knockdown (Chapter 6) were prioritised. 
 
 122 
 
Figure 4.13 IL-33 overexpression and IL-1ß stimulation in 16HBE cells 
ELISA-measured IL-6 (A) and IL-8 (B) in IL-33 transfected 16HBEs followed by IL-1ß 
stimulation. No difference was found in either cytokine in the supernatant. RT-qPCR using 
primers spanning exons 3:4 of IL33 only detected an increase in fl-IL33 (full length IL-33) 
(C). RT-qPCR using primers spanning exons 6:7 of IL33 (D) show that cf-IL33 (cytokine 
fragment IL-33) and fl-IL33 were both overexpressed at the mRNA level. Significance 
assessed by two-way ANOVA followed by Bonferroni post-test correction, comparing cf-
IL33 and fl-IL33 per time point for A) and B). Mean and standard error shown, N=3.  
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4.3.6 Differential IL33 expression in airway epithelial cells 
The IL33 expression patterns observed over the 24-hour IL-1ß stimulation experiment were 
found to differ depending on cell type: A549s versus NHBEs. When stimulated with 1 ng/mL 
of IL-1ß in starving media, A549 IL33 mRNA increased over the time-course whereas NHBE 
IL33 mRNA decreased. When starving media alone was added as control it showed that at 12 
hours, IL33 remained unchanged in A549s but decreased in NHBEs, suggesting that the 
decrease seen was not related to IL-1ß stimulation (Figure 4.14-A). The Molecular Genetics 
and Genomics Group (NHLI) use overnight starving and stimulation in starving media as 
standard practice to enhance reproducibility189. In order to determine if starving stress altered 
the IL33 response complete growth media stimulation was also used.  
NHBEs stimulated in complete growth media showed an increase in IL33 mRNA by 2-fold at 
6 hours with a return to baseline at 24 hours of IL-1ß stimulation. In comparison, NHBEs 
stimulated in starving media showed a constant decrease in IL33 throughout the time-course 
(Figure 4.14-B). Insulin-transferrin-selenium (ITS) is a supplement for conditioning media. 
This was used as a minimal media to determine whether the difference in IL33 levels across 
the time-course was due to a starving stress. ITS-supplementation delayed the decrease in 
IL33 over a 24-hour time-course (Figure 4.14-C). At 24-hours of stimulation in ITS-
supplemented media, IL33 had a median value of 42 (32 – 44) % compared to a median of 8.6 
(8.5 – 11) % in un-supplemented media. This means that either growth alone or a specific 
factor in the complete growth media is required for IL-33 expression. The primers used to 
determine IL33 levels span exons 6:7 and therefore detect all known splice variants of IL33 
(Section 3.3.1).  
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Figure 4.14 Differential expression of IL33 mRNA over timecourse in A549 and NHBE 
cells 
A) A549 and NHBE expression of IL33 over a 24 hour time-course of IL-1ß stimulation.  
Included at the right side of the graph are levels per experiment for the 12 hour unstimulated 
control. In stimulated A549s, IL33 increased over the time-course (p < 0.05 for 6 hours and p 
< 0.001 for 12 and 24 hours of stimulation when compared to baseline [time 0 hours]). In 
contrast, in NHBEs IL33 decreased (p < 0.001 for 12 hours and 24 hours of stimulation when 
compared to baseline [time 0 hours]). B) NHBE cells stimulated in starving or complete 
growth media. IL33 mRNA increased when in complete media and decreased when in 
starving media. C) NHBE decrease of IL33 expression was delayed using insulin-transferrin-
selenium (ITS) supplemented media for stimulation. Statistical significance assessed by two-
way ANOVA with Bonferroni post-test correction, comparing all time points to the base line 
(time 0 hours) per condition, and values shown per group (median and range shown, N=3).  
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4.4 Discussion 
This chapter aimed to investigate the role of IL-33 in the inflammatory response of airway 
epithelial cells including differentiating between the role of intracellular IL-33 and 
extracellular IL-33. This was first carried out using the A549 cell line and then validated in 
primary NHBEs. The effect of extracellular IL-33 as a stimulation was also determined and 
airway epithelial cells appear to be unresponsive to IL-33 up to 100 ng/mL of recombinant 
IL-33.    
Of the three stimulations assayed, Alternaria alternata extract was the only stimulation not to 
show differential cytokine secretion upon IL-33 knockdown. Previous work in NHBEs has 
shown that A. alternata extract stimulation causes IL-33 to relocate from the nucleus to the 
cytoplasm73,190. It is expected that the intracellular effect of IL-33 is mediated by interacting 
with DNA, thus if IL-33 is located in the cytoplasm, it would not be able to alter the cellular 
response. Other authors have reported that different A. alternata extract batches produce 
different responses191. Therefore these conclusions are limited because, in this study, all 
experiments were carried out using the same batch of A. alternata extract.  
Using IL-33 stimulation in HUVECs, custom recombinant IL-33 was able to elicit the same 
or greater cytokine response for both the full-length and cytokine-fragment versions of IL-33. 
This final validation of the custom recombinant IL-33 (Section 3.3.2) indicated that the 
cytokine-domains are likely to be folded in the same conformation as commercial sources of 
IL-33. When stimulation using cf-IL-33 was taken forward into A549 cell lines and NHBE 
cells however, 100 ng/mL of cf-IL-33 was not able to elicit a significant cytokine response. 
This contradicts previous work from Yagami et al.187 that showed that cf-IL-33 stimulation 
at10 ng/mL for 24 hours, increased IL-8 secretion from NHBEs. The only difference between 
the methods of stimulation is that Yagami et al. stimulated NHBEs in complete growth 
media, which could potentially reduce the sensitivity of the NHBEs to IL-33 stimulation. If 
this was the case, complete media caused IL-8 to be secreted at 5,500 pg/mL instead of 40 
pg/mL observed in this current study. An alternative reason for this discrepancy is that there 
may be variability in an individual’s responsiveness to IL-33.  
Previous studies have described contradictory effects of intracellular IL-33, suggesting 
positive regulation of NF-κB targets121,124,147 or repression of NF-κB targets78,117,123. Different 
cell types, species, unstimulated or stimulated and stimulation cytokine have been used across 
this large range of studies. In the present study of A549 and NHBEs, all differential IL-6 and 
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IL-8 secretion suggested positive regulation of NF-κB by IL-33. IL-33 knockdown and IL-1ß 
stimulation was taken forward from the A549 inflammatory model to NHBEs where it was 
validated. Since IL-33 has shown to affect proliferation121,192, the MTS assay gave a surrogate 
measure of relative cell number and showed no difference between IL-33 siRNA- and 
control-transfected cells. This assumes that the basal level of metabolic activity in the 
mitochondria of cells in both conditions is not altered and therefore is not conclusive 
evidence.  
If IL-33 knockdown reduced extracellular IL-33 and thereby reduced autocrine signalling, 
then knockdown of the IL-33 receptor (ST2) would also show a decrease in IL-6 and IL-8. 
ST2 knockdown however caused an increase in cytokine secretion, ruling out a purely-
autocrine mechanism. Using over-expression of ST2 in HEK293 cells, Brint et al. have 
shown that ST2 negatively regulated IL-1RI signalling by sequestering MyD88 and Mal in 
unproductive interactions193.  
Using over-expression constructs (made in Section 3.3.4.1), it was expected that fl-IL33, 
which contains the N-terminus of IL-33 would cause the opposite response of IL-33 
knockdown. Over-expression of the cf-IL33, which does not contain the N-terminus of IL-33 
and resides in the cytoplasm, was not expected to affect the inflammatory response. When 
this was tested using 16HBEs and IL-1ß stimulation, there was no difference between the two 
construct-transfected groups. This could be because IL-6 and IL-8 are not directly regulated 
by IL-33 or cofactors or the chromatin environment required for their regulation are not 
present in 16HBE cells. It is also possible that the 24 hours of overexpression did not give 
enough time for IL-33 to mediate its effects on IL-6 and IL-8.  
In the A549 cell line, IL33 was increased from 6 hours of stimulation using IL-1ß or TNF-α. 
This relatively late transcription suggests that IL-33 may be a tertiary target of NF-κB 
signalling requiring the translation of a direct target that then promotes IL-33 transcription. 
This stimulation-dependent IL33 increase was not seen in NHBEs, which instead showed a 
steady decrease that occurred at a similar rate in unstimulated media. Stimulating in growth 
media fully abrogated the decrease in IL33 over 24 hours, whereas reducing the starving 
stress by using ITS-supplemented media for stimulation only delayed the decrease in IL33. 
Two constituents of the NHBE growth media are required for IL-33 expression in different 
cell types: human keratinocytes require epidermal growth factor (EGF) receptor-
stimulation184 and murine kidney epithelia require retinoic acid194. Both EGF and retinoic acid 
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are constituents of the basal growth media for NHBEs and not present in the starving media; 
A549s could have constituent activation of their targets and are thereby not affected by 
starvation. All knockdown and stimulation was compared to a non-silencing control so this 
does not change the conclusions from the work, but it could have under-estimated the effect 
of IL-33 knockdown. This finding was elucidated whilst carrying out the NHBE biological 
replicates and to keep the method consistent between the A549, 16HBE and NHBE 
experiments starving media was chosen. RNA extracted from IL-33 knockdown and IL-1ß 
stimulation (Section 4.3.3.2) and ST2 knockdown and IL-1ß stimulation (Section 4.3.4) was 
stored to allow use in subsequent global gene expression profiling (Chapters 5 and 6 
respectively).   
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5. Effect of IL-33 on gene expression 
5.1 Introduction 
The data generated in Chapter 4 suggested that the knockdown of IL-33 decreased the 
cytokine response of airway epithelium independently of ST2. To date there have been 
relatively few studies that have investigated the nuclear targets of IL-33. Studies that have 
focused on the impact of IL-33 on inflammatory genes have shown contradictory results.  
The majority of research suggests that intracellular IL-33 is pro-inflammatory. Kunisch et 
al.121 overexpressed and knocked-down IL-33 in rheumatoid arthritic synovial fibroblasts. 
Upon TNFα stimulation,  both transfections showed intracellular IL-33 increased levels of IL-
6, IL-8 at the mRNA and protein levels. MMP3 also increased in response to IL-33 
overexpression, but was unchanged when IL-33 was knocked-down. Similar effects were 
found in TNFα stimulated HUVECs with IL-33 siRNA resulting in a decrease of p65 of NF-
κB, as well as the latter’s targets, ICAM-1 and VCAM-1 at the mRNA and protein level119. 
Shao et al.117 found contrasting results, IL-33 knockdown in normal human pulmonary 
arterial endothelial cells caused an increase in IL6 and sST2 mRNA. There have been no 
global investigations into the intracellular role of IL-33. Instead studies have quantified NF-
κB target genes and proliferation. The main limitation of this approach is that by defining 
specific targets, novel functions cannot be discovered unless pre-defined by chance.  
Transcript levels ultimately affect protein levels in cells and as a result, the dynamics of the 
cells. Comparison of the transcriptomes from cells in two conditions (NSC and IL-33 siRNA) 
enables differentially expressed genes to be determined, highlighting the differences between 
conditions in terms of the cells’ activities. Methods to determine levels of RNA transcripts 
include RT-qPCR, cDNA microarrays and RNA sequencing (RNA-Seq).  
Transcript microarrays allow the quantification of all annotated genes per sample 
simultaneously by imaging of cDNA bound to an array of probes. Microarrays have 25 base-
pair probes synthesised in a grid, with an average of 15-20 probes per gene, which 
collectively are referred to as a probeset. The length and number of probes per probeset means 
that each gene is quantified specifically. As tens of thousands of genes can be quantified per 
sample, microarrays are relatively cheap and use relatively small amounts of RNA per gene 
when compared to RT-qPCR. Unlike RNA-seq, microarrays allow relatively high throughput, 
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are time efficient, less costly (data generation and analysis), data storage requirements are 
more minimal and analysis is both quick and well defined.  
With the advent of sequencing the human genome, probeset design has been based on 
bioinformatically predicted transcripts to achieve “whole transcriptome” microarrays. The 
only limitation is that the arrays are unable to detect novel transcripts such as unknown splice 
variants, fusion genes or mature microRNAs. However because of the high-throughput nature 
of microarrays and as technical and analysis pipelines were well established in the Section of 
Genomic Medicine (NHLI), microarrays were chosen as an efficient first choice to begin to 
address the hypothesis of the study.  
The study hypothesis is that knockdown of IL-33 will result in an alteration of the 
transcriptome thereby confirming and fully defining IL-33’s intracellular role in airway 
epithelium. The aim is to determine which specific genes are altered by IL-33 knockdown 
(Section 4.3.3) in order to add understanding to the intracellular role of IL-33.  
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5.2 Materials and methods 
5.2.1 Cell culture and RNA extraction  
NHBEs were cultured in 24-well plates, transfected with 5 nM IL-33 siRNA for 48 hours (as 
per Section 2.3.1.1). The media was then changed for starving media for 16 hours before a 
24-hour time course of 1 ng/mL IL-1ß stimulation was carried out (Section 2.3). At 0, 2, 4, 6, 
12 and 24 hours of stimulation cells were lysed in situ and extracted using the Qiagen RNeasy 
plus kit (Section 2.4.1). A triplicate time course of RNA from the IL-33 siRNA and IL-1ß 
data (shown in Chapter 4, Figure 4.10) was taken forward for global gene expression analysis 
using microarrays.  
5.2.2 RNA concentration and quality control 
As 10 of the 36 RNA were below the optimal concentration for microarray library preparation 
these were required concentration. To ensure no bias was introduced, all samples were 
therefore concentrated using the Savant Speedvac SC100 concentrator (MN, USA) at medium 
heat for 20 minutes. Care was taken to only reduce samples to half of their original volume 
and after cooling on ice; RNA concentration was quantified using the Nanodrop ND 1000 
UV-Vis spectrophotometer. Once concentrated, RNA quality was assessed using the Agilent 
2100 Bioanalyzer (Section 2.6.1). As microarray profiling requires high quality RNA a 
threshold of a RIN of 7 was applied. 
5.2.3 Microarray library preparation and profiling 
Before starting the library preparation, RNA was randomised and coded in order to avoid 
confounding effects across the batches of preparation and arrays. Library preparation 
converted mRNA to cDNA, each step was done a strand at a time: RNA to single stranded 
DNA, then double stranded DNA, to single stranded cRNA which was then purified and 
sense stranded cDNA was created and purified. cDNA was fragmented, labelled and 
hybridised to complementary probes on the microarray chip and quantified by imaging 
(Sections 2.6.2 and 2.6.3). 
5.2.4 Microarray data analysis 
Quality control of raw data was assessed using the arrayQualityMetrics Package (Version 
3.20.0) in the R environment (Version 3.1.0164) using Bioconductor packages165 (Section 
2.6.4.1). Outlier arrays were excluded and if necessary samples were rerun from library 
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preparation to profiling until all arrays passed quality control. Affymetrix Power Tools 
(Version 1.12.0) was used for Robust Multichip Average (RMA) normalisation167 of all 
arrays together.  
Normalised data were imported into R and control probesets were removed prior to further 
analysis. Batch effects were quantified using the PVCA package (Version 1.6.0169). 
Differential expression between NSC and IL-33 siRNA per time-point was determined using 
Limma (Version 3.20.0). All p values were corrected for multiple testing based on the 
Benjamini and Hochberg method for controlling the false discovery rate171. HOMER (Version 
4.7172) calculated the gene ontology enrichment and was verified by DAVID (Database for 
Annotation, Visualisation and Integrated Discovery)173,174.  
WGCNA is an unbiased approach, defining clusters of co-expressed genes and correlating 
them with traits WGCNA was carried out using the WGCNA package (Version 1.34, see 
Section 2.6.4.3)175. Clusters of genes (modules) were set to a minimum size of 30. Module 
eigengene expression was calculated by a principle component approach and correlated with 
time and transfection. 
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5.3 Results 
5.3.1 Quality control and pre-processing 
Post vacuum concentration, the NHBE IL-33 siRNA experiment’s RNA concentrations 
ranged from 44 – 167 ng/µL and had a RIN range of 7.2 – 8.9 – so were of high quality and 
concentrated enough to be taken forward for microarray analysis. 
Before normalisation, control probe expression was imported into R and the control genes 
added to the sample RNA were analysed. The poly-A controls (Figure 5.1) are poly-
adenylated genes used to show any amplification bias in cDNA generation. These were found 
to be in the expected descending order. The hybridisation controls shown in Figure 5.2 have 
no cross-hybridisation with human genes and thus hybridization bias can be determined by 
examining the intensity values of the spike in genes. These were also found in the expected 
descending order. All arrays passed the control probeset inspection and were taken forward 
for outlier detection using the raw expression data.  
 
Figure 5.1 RNA sample and cDNA preparation controls.  
Raw signal intensity of poly-A spike controls in all microarray samples are shown for the 
controls: thr, phe, lys and trpn. These were in the expected order and showed no bias in 
cDNA generation.  
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Figure 5.2 Hybridisation controls.  
Raw signal intensity of hybridisation controls in all microarray samples are shown for cre, 
bioD, bioC and bioB. These were in expected order and showed no bias in hybridisation. 
Outlier array detection with the arrayQualityMetrics package detected two outliers for the 
NHBE IL-33 siRNA experiment, which were reprocessed. Outlier array detection was rerun 
with the two re-processed arrays and all samples passed. RMA normalisation was carried out 
on these arrays and then the data was loaded into R. Removal of control probesets reduced the 
number of probesets by 5,201 leaving 48,416. A further 15,407 probesets were removed as 
they had below median expression in all samples analysed, leaving 33,009 probesets to be 
taken forward into downstream analyses.  
PVCA (Section 2.6.4.1) showed that the majority of the variance was explained by the 
transfection or time point of stimulation (Figure 5.3). The greatest batch effect was the poly-A 
control batch, which accounted for 3.8% of the variation of the data. This small level of 
variation was taken to be negligible and therefore no correction for batches was carried out in 
order to avoid introducing bias into the data. Transfection, time point of stimulation and the 
interaction between these two factors accounted for 20.3%, 14% and 18% of the variation in 
the data respectively.  
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Figure 5.3 Batch effect quantification using PVCA 
PVCA gives an estimate of the proportion of the data that is explained per batch effect and 
their interactions (depicted by a colon). Transfection explains 20.3% of the variation, and time 
point (time) explains 18%, with the interaction between transfection and time point explaining 
14% of the variation. The largest batch effect was the poly-A control batch, explaining 3.8% 
of the variation of the data. Transfection: transfection status, time: time point in stimulation, 
replicate: replicate of condition (1-3), polya.kit: Batch of polyA control used, block.d1 and 
block.d2: thermocycler block used in the first and second day of the protocol, wt.kit.d1 and 
wt.kit.d2: batch of whole transcriptome kit used per day, array: array plate used, day.1 and 
day.2: date of the copy RNA and single stranded DNA generation respectively, hyb.kit: batch 
of hybridisation kit.  
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5.3.2 Differential gene expression 
A total of 1,920 genes were found to be differentially expressed between NSC and IL-33 
siRNA treated NHBEs, using a p value threshold of < 0.001. When adding the additional 
threshold of > 1.4 fold-change this number decreased to 1,509 transcripts. Of these transcripts 
618 (41%) were up regulated upon IL-33 knockdown and 893 (59%) were down regulated. 
The top 20 of the differentially expressed genes ranked by p value are listed in Table 5.1. 
IL33 had the largest fold change (-20.1) at a p value of 4.8 x 10-20, confirming a successful 
knockdown at the mRNA level. Other genes differentially expressed with a high level of 
significance included KLK5 (kallikrein related peptidase 5; -5.3 fold change, p = 2.1 x 10-17), 
and PCDH18 (protocadherin 18; 15.2 fold change, p = 3 x 10-19), both of which may have 
altered the innate immune response of the NHBEs. In addition, two fibroblast-expressed 
extracellular matrix proteins, COL1A1 (collagen type I alpha 1; 2.5 fold change, p = 4.7 x 10-
15) and FBN1 (Fibrillin-1, 3.0 fold change, p = 8.1 x 10-14), were also increased.  
Volcano plots of the differential expression of genes between NSC and IL-33 siRNA are 
shown in Figure 5.4. The majority of genes remained up or down regulated across the time 
course and did not markedly change their expression over time. From the volcano plots, the 
magnitude of the differential expression appeared to be slightly larger in the genes showing 
decreased expression. A Mann-Whitney U test of the absolute values of increased and 
decreased maximum values shows a significant difference between magnitudes of the fold 
changes (p = 1.5 x10-9). The top 20 down- and up-regulated genes by maximum fold change 
are shown in Table 5.2 and Table 5.3 respectively. The top 250 differentially expressed genes 
are listed in Appendix V. Of the down-regulated genes, KLK6 (-8.4 fold change, p = 5.1 x 10-
11) and KLK5 had a large fold change. ICAM1 (-5.5 fold change, p = 1 x 10-12) was also 
decreased: ICAM-1 is the ligand for the integrin LFA-1 (lymphocyte function-associated 
antigen 1), involved in eosinophil and mast cell chemotaxis. Within the increased genes there 
was large number of adhesion genes: PCDH18, PCDH19, ADGRL3 (adhesion G protein-
coupled receptor L3) and CDH6 (cadherin 6).  
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Table 5.1 Top 20 differentially expressed genes 
Ranked by maximum p value, the top 20 differentially expressed genes in IL-33 siRNA-
treated NHBEs compared to NSC. Genes decreased in IL-33 siRNA have a white background 
and those that increased are shown with a grey background. Median expression determined by 
the average fluorescent units across the probesets for all samples. p values have been 
corrected for multiple testing using Benjamini and Hochberg’s method. 
  
Gene 
Symbol 
Median 
Expression 
Maximum 
Fold 
Change 
p Value 
IL33 35 -20.1 4.8 x 10-20 
PCDH18 32 15.2 3.0 x 10-19 
KLK5 263 -5.3 2.1 x 10-17 
ARPC1A 793 -2.5 2.1 x 10-17 
CDS1 216 -3.7 7.5 x 10-17 
YES1 498 -2.7 1.3 x 10-15 
PAMR1 190 2.6 1.5 x 10-15 
LINC00707 110 -3.5 3.6 x 10-15 
COL1A1 154 2.5 4.7 x 10-15 
EDIL3 324 2.5 5.1 x 10-15 
CRCT1 1284 -5.3 7.6 x 10-15 
KRT75 580 -5.9 7.6 x 10-15 
SEMA4B 162 -2.7 1.5 x 10-14 
LRRN1 45 4.6 1.5 x 10-14 
FAM114A1 407 -2.4 1.8 x 10-14 
ELOVL6 125 -2.2 1.8 x 10-14 
CMTM4 106 -3.4 1.8 x 10-14 
IGFL1 130 -8.0 2.9 x 10-14 
WFDC5 162 -4.9 3.4 x 10-14 
FBN1 61 3.0 8.1 x 10-14 
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Figure 5.4 Volcano plots of differential expression in NHBEs between NSC and IL-33 
siRNA 
Sub-graphs show differential expression per time point in IL-1ß stimulation time course. Each 
point represents the fold change and p value for differential expression of IL-33 siRNA 
treated NHBEs, using NSC treated NHBEs as a reference. Transcripts in light blue were not 
differentially expressed and dark blue transcripts passed the significance threshold of p < 
0.001 and a 1.4 fold-change in expression.  
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Table 5.2 Top 20 down-regulated genes 
Ranked by maximum fold change, the top 20 down-regulated genes in IL-33 siRNA-treated 
NHBEs compared to NSC. Median expression determined by the average fluorescent units 
across the probesets for all samples. p values have been corrected for multiple testing using 
Benjamini and Hochberg’s method.  
 
Gene Symbol Median Expression 
Maximum 
Fold Change p Value 
IL33 35 -20.1 4.8 x 10-20 
KLK6 626 -8.4 5.1 x 10-11 
IGFL1 130 -8.0 2.9 x 10-14 
SPRR2G 33 -7.3 1.2 x 10-08 
KPRP 37 -7.2 3.3 x 10-08 
LCE3D 239 -6.7 1.1 x 10-04 
LCE1F 40 -5.9 1.0 x 10-08 
KRT75 580 -5.9 7.6 x 10-15 
ICAM1 246 -5.5 1.0 x 10-12 
KLK5 263 -5.3 2.1 x 10-17 
CRCT1 1284 -5.3 7.6 x 10-15 
MAL 107 -5.2 1.9 x 10-08 
PRB1 101 -5.1 1.3 x 10-08 
WFDC5 162 -4.9 3.4 x 10-14 
KRT6C 14 -4.6 4.1 x 10-06 
CNFN 860 -4.3 1.1 x 10-06 
SULT2B1 264 -4.2 1.0 x 10-12 
ATP12A 219 -4.2 4.9 x 10-07 
CXCL14 624 -4.2 3.1 x 10-13 
WFDC12 44 -4.0 3.9 x 10-07 
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Table 5.3 Top 20 up-regulated genes 
Ranked by maximum fold change, the top 20 up-regulated genes in IL-33 siRNA-treated 
NHBEs compared to NSC. Median expression determined by the average fluorescent units 
across the probesets for all samples. p values have been corrected for multiple testing using 
Benjamini and Hochberg’s method.  
 
Gene 
Symbol 
Median 
Expression 
Maximum 
Fold 
Change 
p Value 
PCDH18 32 15.2 3.0 x 10-19 
MMP13 104 7.1 1.5 x 10-10 
KRT10 73 5.1 2.8 x 10-04 
PCDH19 46 4.9 1.8 x 10-12 
LRRN1 45 4.6 1.5 x 10-14 
CYP1A1 73 4.1 8.3 x 10-10 
FBXO32 421 3.7 4.5 x 10-13 
CDH6 23 3.7 1.2 x 10-10 
MT1G 201 3.5 2.6 x 10-07 
LUM 14 3.3 3.8 x 10-08 
CYP1B1 106 3.2 8.4 x 10-11 
ZNF608 124 3.1 4.6 x 10-13 
ADGRL3 11 3.1 2.0 x 10-11 
SULT1E1 38 3.0 5.9 x 10-12 
MT1H 15 3.0 4.7 x 10-06 
FBN1 61 3.0 8.1 x 10-14 
GPRC5B 16 2.9 5.3 x 10-07 
PTX3 15 2.9 3.8 x 10-04 
KLRC3 7 2.9 4.6 x 10-05 
PRICKLE2 132 2.8 2.9 x 10-13 
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Inspection of differentially expressed genes found that 8 of the 15 genes in the Kallikrein-
related peptidase family were differentially expressed, along with inhibitors of this family of 
proteins (Table 5.4); the genes SPINK5 (which codes for LEKTI), PI3 (which codes for 
SKALP) and SLPI are tissue kallikrein inhibitors.  
Genes lists were analysed for gene ontology enrichment, and gene ontology terms were 
identified that were biologically relevant, distinct, had a fold-change > 1.5 and a corrected p 
value < 0.05. An enrichment in gene ontology terms related to differentiation, keratinization 
and inflammatory responses was observed for down-regulated genes (Table 5.5). Further to 
this, when chromosome location was tested for enrichment, only the epidermal differentiation 
locus showed weak significant enrichment (chr1q21, 3.9 fold enrichment and p = 0.047). Up-
regulated gene ontology showed roles in extracellular matrix reorganization, cell adhesion and 
collagen metabolism (Table 5.6).  
Due to the large number of genes that were differentially expressed from the single 
knockdown of IL-33, the presence of transcription factors in this set of genes was determined 
using the Animal TFDB database195. Eighty-two transcription factors were present in the 
differential expressed genes. The top 10 ranked by p value are shown in Table 5.7 and 
included SPDEF, PPARD (peroxisome proliferator activated receptor delta), PRDM1 (PR 
domain zinc finger protein 1) and AHR (aryl hydrocarbon receptor). SPDEF is known to be a 
master regulator of goblet cell hyperplasia29 and PPARD, PRDM1 and AHR may affect 
epithelial cell growth and differentiation. Moreover, AHR regulates the cytochrome p450 
enzymes196, which may explain the up regulation of CYP1A1 and CYP1B1 (cytochrome P450 
family 1 subfamily A1 and B1; Table 5.3). 
  
 141 
Table 5.4 Kallikrein-related peptidase genes differentially expressed 
8 of the 15 known tissue kallikreins were down regulated in IL-33 siRNA-treated NHBEs. 
SPINK5, PI3 and SLPI are tissue kallikrein inhibitors and were also down regulated. Median 
expression determined by the average fluorescent units across the probesets for all samples. p 
values have been corrected for multiple testing using Benjamini and Hochberg’s method.  
 
Gene 
Symbol 
Median 
Expression 
Maximum 
Fold 
Change 
p Value 
KLK5 263 -5.3 2.1 x 10-17 
KLK10 449 -3.1 1.3 x 10-13 
KLK7 1626 -4.0 1.0 x 10-12 
KLK6 626 -8.4 5.1 x 10-11 
KLK11 393 -2.2 5.1 x 10-11 
KLK9 104 -3.6 3.8 x 10-08 
SPINK5 170 -2.7 4.4 x 10-07 
SLPI 3972 -1.8 6.8 x 10-07 
KLK13 20 -2.3 9.6 x 10-07 
KLK12 53 -3.1 2.1 x 10-06 
PI3 4040 -1.7 1.2 x 10-05 
 
Table 5.5 Top gene ontology terms of down-regulated genes 
Gene ontology terms with a > 1.5 fold enrichment, and a p value < 0.05 were examined. Of 
the 45 terms initially generated, non-redundant and biologically interesting terms were then 
selected. Top genes are listed by maximum fold-change in differential expression. p values 
have been corrected for multiple testing using Benjamini and Hochberg’s method.  
 
Term ID Term Fold Enrichment p Value Top 5 genes 
GO:0008544 Epidermis development 3.1 3.5 x 10-7 SPRR2G, LCE3D, LCE1F, KLK5, CNFN 
GO:0019432 Triglyceride biosynthetic process 6.8 3.3 x 10
-5 ELOVL6, GPAM, ACSL1, LPCAT1, LPCAT4 
GO:0031424 Keratinization 5.5 2.8 x 10-4 SPRR2G, LCE3D, LCE1F, CNFN, TGM1 
GO:0009913 Epidermal cell differentiation 3.3 6.8 x 10
-4 SPRR2G, LCE3D, LCE1F, CNFN, TGM1 
GO:0050729 Positive regulation of inflammatory response 4.0 5.5 x 10
-3 IL33, IL23A, IL1RL1, TNF, PLA2G7 
GO:0009617 Response to bacterium 2.0 1.8 x 10-2 ICAM1, WFDC12, CXCL10, CCL2, NLRP10 
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Table 5.6 Top gene ontology terms of up-regulated genes 
Gene ontology terms with a > 1.5 fold enrichment, and a p value < 0.05 were examined. Of 
the 25 terms initially generated, non-redundant and biologically interesting terms were then 
selected. Top genes are listed by maximum fold-change in differential expression. p values 
have been corrected for multiple testing using Benjamini and Hochberg’s method. 
 
Term ID Term Fold Enrichment p Value Top 5 genes 
GO:0030198 Extracellular matrix organization 3.3 2.0 x 10
-06 MMP13, LUM, FBN1, RECK, NID1 
GO:0030177 Positive regulation of Wnt signalling pathway 5.1 5.7 x 10
-04 WNT4, COL1A1, TLR2, DACT1, GPC3 
GO:0010811 Positive regulation of cell-substrate adhesion 5.1 9.4 x 10
-04 KDR, WNT4, CD36, CSF1, NID1 
GO:0032963 Collagen metabolic process 4.8 1.2 x 10
-03 MMP13, KRT10, CYP1A1, CXCL10, LUM 
  
Table 5.7 Top 10 Transcription factors in differentially expressed genes 
Within the differentially expressed transcripts, the top 10 transcription factors were selected 
and ordered by p Value (corrected for multiple testing by Benjamini and Hochberg’s method). 
Genes with increased expression are shown with a grey background. Median expression 
determined by the average fluorescent units across the probesets for all samples 
 
Gene Symbol Median Expression 
Maximum Fold 
Change p Value 
SPDEF 317 -1.8 9.3 x 10-12 
PPARD 716 -2.0 6.9 x 10-11 
GLIS3 10 2.6 7.5 x 10-11 
AHR 1435 1.6 2.3 x 10-10 
PRDM1 129 -1.8 3.7 x 10-10 
E2F7 306 1.9 6.2 x 10-10 
ARNTL2 873 -1.7 9.0 x 10-09 
ESRRA 72 -2.2 9.2 x 10-09 
NFATC3 299 1.6 2.3 x 10-08 
TCF7L2 254 1.7 3.0 x 10-08 
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5.3.3 Weighed Gene Co-expression Network Analysis 
Weighed Gene Co-expression Network Analysis (WGCNA)175 is an unbiased approach to 
enrich for genes that are biologically relevant to each other. WGCNA was performed using 
the pre-processed data generated in Section 5.3.1 and the WGCNA package in R175.  
The threshold value was chosen using the pickSoftThreshold function. A power of 9 was 
chosen as the smallest power that gives a Scale Free Topology Model R2 of 0.9. Further 
increases in power did not increase the R2 value, nor decrease the mean connectivity of genes 
(Figure 5.5). In order to reduce computing time, the softConnectivity function was 
implemented to rank the genes by their connectivity and the lowest third (13,539) were 
removed before network construction. This left 19,470 probesets remaining. These were then 
used to create the co-expression tree in which the dynamicMods function split the tree into 
co-expressed modules with a minimum module size of 30 being defined and a deepSplit 
power of 0. This is an arbitrary power that affects how large the modules are, with 0 giving 
the largest module sizes. Modules that were similar were merged using a threshold 
(MEDissThres) of 0.25 resulting in 14 modules based on co-expression, which were 
arbitrarily labelled as colours (by the program) for ease of analysis and reference (Figure 5.6).  
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Figure 5.5 Soft-threshold power choice 
The left panel shows the scale free topology-fitting index, R2 values of a linear regression 
model (x axis) are shown for the corresponding power (y axis). The red line indicates R2 = 
0.9, the lowest power that was closest to this threshold, a power of 9, was chosen for 
subsequent analyses. The right panel shows the mean number of connections per power. As 
the power increases the mean number of connections decreases rapidly, until the power of 8 
and 9 where it stays similar.  
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Figure 5.6 Co-expression dendrogram and modules 
Dendrogram of gene co-expression for the NHBE IL-33 knockdown gene expression. 
Coloured bands below denote the module membership of the genes in the dendrogram above. 
The y-axis is height which denotes the relative similarity of gene co-expression. 
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Each module is summarized by an eigengene which is a vector of the representative 
expression of genes in this module, with a value per sample197. Module eigengenes are then 
correlated with traits to detect biologically relevant modules. Time of stimulation (ranging 
from 0-24 hours) and transfection (NSC or IL-33 siRNA denoted as 0 and 1 respectively) 
were correlated by Pearson correlation as shown in Figure 5.7. Two module eigengenes 
showed a very strong correlation with transfection, with an absolute r > 0.8. The Blue Module 
was positively correlated (r = 0.94, p = 2 x 10-15) whilst the Green Module was negatively 
correlated (r = -0.92, p = 6 x 10-17).  
Two module eigengenes showed a very strong correlation with time of stimulation, 
Lightgreen was positively correlated (r = 0.82, p = 8 x 10-10) with the Brown Module being 
negatively correlated (r = -0.81, p = 1 x 10-9). The majority of module eigengenes that showed 
a strong correlation with transfection had no correlation with the time of stimulation. The 
Black Module showed a strong negative correlation with time of stimulation (r = -0.72, p = 1 
x 10-9) and a positive correlation with transfection (r = 0.58, p = 2 x 10-4). Figure 5.8 shows a 
dendrogram of the module eigengenes with transfection and time variables, the hierarchical 
clustering is based upon the dissimilarity between variables (1- Pearson r). The Blue Module 
eigengene is paired at the end of a branch with transfection alone, being most similar to the 
knockdown status.  
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Figure 5.7 Module eigengene correlation with time and transfection 
Each module eigengene from the NHBE IL-33 knockdown dataset was tested for correlation 
with phenotype data for time of stimulation and transfection status. Module eigengenes are 
shown to the left, with the number of genes per module shown in brackets. Within the 
coloured cells, Pearson correlation coefficient (r) values are shown, with p values in brackets. 
Colours of correlations range from red (r value of 1) to blue (r value of -1) with yellow as an 
intermediate colour to denote no correlation (r value of 0).  
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Figure 5.8 Dendrogram of module eigengenes and phenotype 
Hierarchical clustering of eigengenes and phenotype data (Transfection and Time, shown in 
bold) was carried out using a dissimilarity matrix (1 – Pearson r) to give a dendrogram 
showing the relative relationships.  
  
G
re
en
Sa
lm
on
Li
gh
tg
re
en
Ti
m
e
M
ag
en
ta
Pi
nk
M
id
ni
gh
tb
lu
e
R
ed
Li
gh
tc
ya
n
G
re
en
ye
llo
w
B
lu
e
Tr
an
sf
ec
tio
n
C
ya
n
G
re
y
B
la
ck
B
ro
w
n
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
1.
2
 149 
The individual genes in the Blue and Green Modules were correlated (Pearson) for the 
transfection status and their correlation to their eigengene expression (Module Membership). 
These two values were taken per gene and correlated to investigate the appropriateness of 
each gene per module for the Blue and Green Modules (Figure 5.9 and Figure 5.10). For 
genes in the Blue Module, a very strong positive correlation was found (r = 0.92 and p = < 1 x 
10-200, Figure 5.9), showing that genes that correlate with the eigengene are also correlated 
with transfection status. Similarly, gene correlation with transfection status and eigengene 
expression for the Green Module showed a strongly negative correlation (r = -0.89 and p = < 
1 x 10-200, Figure 5.10). These modules were taken forward as the most related modules to 
transfection status.  
Both the Blue and Green Modules were filtered by a correlation p value of < 0.001 for 
transfection status, > 0.5 module membership and a weighted connectivity of > 0.08, this 
reduced the number of genes to 886 genes in the Blue Module and 184 genes in the Green 
Module. The WGCNA module gene lists and differential expression lists had a high level of 
overlap (Figure 5.11). Fifty two percent of the Green Module genes were present in 11% of 
decreased genes from differential expression analyses. Thirty three percent of the Blue 
Module genes were present in 47% of the increased genes from differential expression. For all 
modules showing a greater than 0.5 Pearson coefficient with transfection (see Figure 5.7) the 
same filtering threshold was applied and the top 25 genes for each of the modules is shown in 
Appendix VI. 
The gene ontology for the Blue Module showed similar terms as the up-regulated genes from 
the differential gene expression analysis (see Table 5.6), with cell projection assembly and 
cell-substrate adhesion being significant terms. Novel terms however were also found in the 
Blue Module and these related to transcription, chromatin modification and specifically 
histone methylation. Table 5.9 shows the gene ontology for the filtered Blue Module genes. 
Gene ontology for the Green Module only found one term that was significant: phospholipid 
metabolic process (Table 5.9), which is a related to the triglyceride biosynthetic process found 
in down-regulated genes.  
For both modules, the data was visualised as co-expression networks in Cytoscape (Version 
3.4.0198) in order to determine important hub genes: genes which are co-expressed with many 
other genes. Upon inspection, there was no clear delineation of hub genes as the majority of 
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transcripts were co-expressed with many other transcripts. These visualisations of the 
networks were not informative and therefore have not been shown.  
 
Figure 5.9 Intra-modular analysis of the Blue Module 
Individual gene correlation with eigengene values (module membership, x axis) and 
expression level correlation with transfection status (y axis) is plotted per gene in the Blue 
Module. Person correlation of these values gives an r of 0.92 and p value < 1 x 10-200. 
 
Figure 5.10 Intra-modular analysis of the Green Module  
Individual gene correlation with eigengene values (module membership, x axis) and 
expression level correlation with transfection status (y axis) is plotted per gene in the Green 
Module. Pearson correlation of these values gives an r of -0.89 and p value < 1 x 10-200.  
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Figure 5.11 Venn diagrams of common genes in differentially expressed genes and 
WGCNA modules 
Gene lists for differential expression and WGCNA modules transformed into co-occurrence 
matrices, which are shown as Venn Diagrams. A) Genes increased from differential 
expression analyses (DE) overlap with Blue Module WGCNA genes. B) Genes decreased 
from DE overlap with Green Module WGCNA genes. Values shown are the numbers of 
genes. 
 
A) 
B) 
525 353296
Increased DE Blue Module
829 9197
Decreased DE Green Module
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Table 5.8 Blue Module gene ontology 
Gene ontology terms with a > 1.5 fold enrichment, a p value < 0.05 and an adjacency 
threshold of > 0.08 were examined. Of the initial 148 terms generated, non-redundant and 
biologically interesting terms were then selected. Top genes were selected by the largest 
correlation with transfection status. p values were corrected for multiple testing using 
Benjamini and Hochberg’s method.  
Term ID Term Fold Enrichment p Value Top 5 genes 
GO:0010468 Regulation of gene expression 1.4 2.7 x 10
-10 COL1A1, EIF4EBP2, NEO1, PTPN14, FZD2 
GO:0016568 Chromatin modification 1.7 3.0 x 10-4 EYA1, RCBTB1, TET3, SMARCC1, PHF8 
GO:0030031 Cell projection assembly 1.9 6.3 x 10
-3 CDH13, LRRC16A, DNM3, TMEM237, S1PR1 
GO:0016571 Histone methylation 2.7 5.5 x 10-3 TET3, SATB1, KMT2A, RTF1, EZH2 
GO:0010810 Regulation of cell-substrate adhesion 2.2 7.4 x 10
-3 COL1A1, CCDC80, EDIL3, CDH13, ABI3BP 
 
Table 5.9 Green Module gene ontology 
Gene ontology terms with a > 1.5 fold enrichment and a p value < 0.05 and an adjacency 
threshold of > 0.08 were examined. Only one term was significantly enriched. Top genes 
were selected by the largest absolute correlation with transfection status. p values have been 
corrected for multiple testing using Benjamini and Hochberg’s method.  
Term ID Term Fold Enrichment p Value Top 5 genes 
GO:0006644 Phospholipid metabolic process 2.3 2.0 x 10
-02 CDS1, PIGS, GPAM, CWH43, SLC44A2 
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5.4 Discussion 
5.4.1 Differential Gene Expression 
One thousand five-hundred and nine transcripts were differentially expressed between NSC 
and IL-33 siRNA-treated NHBEs. By p Value, the top 3 genes differentially expressed were 
IL33, PCDH18 and KLK5 (Table 5.1). By maximum fold change the top genes were similar: 
IL33, PCDH18 and KLK6 (Table 5.2 and Table 5.3).  
Little is known about the role of PCDH18 but studies in mice have shown that both mRNA 
and protein is expressed in many tissues during foetal development and is constitutively 
expressed in the lung and kidneys of adults199. This suggests it may have a role in 
development and differentiation. In CD8+ T cells, PCDH18 inhibits Lck (lymphocyte-specific 
protein tyrosine kinase) signalling and induces a non-lytic phenotype. PCDH18 could interact 
with Lck signalling in the airway epithelium, decreasing inflammatory gene expression. To 
support this, in BEAS-2B cells treated with Lck siRNA, a specific ablation of hexavalent 
chromium induced STAT-3 phosphorylation was observed, but IL-6-induced STAT-3 
phosphorylation was not affected200. It is plausible that the large increase in levels of 
PCDH18 (presuming translated through to the protein level) could result in inhibition of Lck, 
thereby affecting the baseline levels of inflammatory signalling, resulting in a change in the 
expression of inflammatory genes that are not affected by IL-1ß stimulation.  
After IL33, KLK5 and KLK6 were the most significant genes to decrease with IL-33 
knockdown when ranked by p Value and fold change respectively. Eight of the total 15 genes 
in the kallikrein-related peptidases family were differentially expressed due to the knockdown 
of IL-33 (Table 5.4). This family of proteins have a number of innate immune roles. For 
example KLK5 and KLK7 cleave CAP18 (18-kDa cationic antimicrobial protein) into the 
bioactive LL-37 peptide201 which is directly antimicrobial and has been shown to induce 
apoptosis of Pseudomonas aeruginosa infected airway epithelial cells202. KLK5 and KLK6 
also activate PAR-2203, which is the same proteinase-activated receptor that is activated by the 
HDM component Der p1204 and also by A. alternata extract15. It is interesting to note that it 
has been previously reported that HDM triggers TLR4 signalling14 on structural cells, and 
TLR4 in the current study was found to be increased (2 fold change, p = 4.5 x 10-7). The 
TLR4 co-factor for LPS-induced signalling LY96 (lymphocyte antigen 96) was, in contrast, 
decreased (- 1.6 fold change, p = 2.0 x 10-5) upon IL-33 knockdown. This complex interaction 
could lead to protease-mediated HDM signalling being increased in asthma, TLR4-mediated 
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HDM signalling being decreased and perhaps an unchanged responsiveness to LPS. In the 
skin, the main role of KLKs is desquamation during differentiation, which also affects 
intracellular adhesion and membrane integrity by cleaving Desmoglein 1205. Taken together 
this suggests that in asthma, where IL-33 and presumably KLKs are increased there would be 
an increased anti-microbial response with increased apoptosis206, an increased sensitivity to 
protease-mediated signalling74, increased membrane permeability and decreased cellular 
adhesion207,208.  
The differentially expressed gene lists (up-regulated and down-regulated) were enriched for 
the biological processes that make physiological sense in the context of asthmatic airways. 
IL-33 siRNA reduced genes related to cell-substrate adhesion, Wnt signalling, collagen 
catabolism and extracellular matrix organization (Table 5.6). As IL-33 is increased in 
asthmatics, an increase of these terms would be suggestive of the phenotype of asthmatic 
epithelial cells, which have decreased cellular adhesion208, are poorly differentiated and are 
hyper-proliferative206, which may tie in the Wnt signalling pathway. Wnt signalling governs 
cell fate and proliferation during development, however the most convincing evidence for the 
importance of canonical Wnt signalling in bronchial epithelium comes from transgenic mice. 
In a study by Hashimoto et al., increased Wnt signalling in the bronchial epithelium inhibited 
differentiation of epithelial cells into ciliated or goblet cells209. Whilst Wnt signalling is a 
complex network, it is reasonable to infer that if Wnt signalling was inhibited, this could lead 
to a poorly differentiated airway epithelium such as that seen in asthmatics.  
IL-33 siRNA also resulted in increased expression of genes enriched in gene ontology terms 
related to collagen breakdown and extracellular matrix (Table 1.6), which are known to be 
processes involved in airway remodelling in asthma210. Airway smooth muscle or fibroblasts 
are generally accepted as key mediators in airway remodelling, yet the IL-33 knockdown is an 
artificial knockdown model and the gene expression changes may not be specific to the 
airway epithelium alone. For example, in paediatric severe asthma, increased IL-33 in the 
airways has been attributed to fibroblasts154 and intracellular IL-33 in these cells could cause 
some of the pathology seen in asthma. Both extracellular matrix proteases and their substrates 
are differentially expressed, but not in a single direction that would suggest extracellular 
matrix depletion or deposition. For example MMP1 is decreased and MMP2 increased where 
both of these peptidases’ substrates COL1A1 and COL1A2 (Appendix V) are increased. This 
could be due to co-factors required for a cell-type specific role of IL-33, or IL-33 could cause 
a skew in the extracellular matrix dynamic rather than a simple increase or decrease.  
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When gene ontology terms were ranked by p value or fold-change, it appeared that for genes 
decreased in expression, IL-33 regulates differentiation more significantly than inflammation 
(Table 5.5). Other gene ontology terms enriched in the down-regulated genes are related to 
differentiation and development (skin development, keratinization and epidermal cell 
differentiation).  
Of the differentially expressed transcription factors (Table 5.7), SPDEF was the most 
significant when ranked by p Value. SPDEF mRNA is increased in asthmatic airway 
epithelium211, suggesting that the increased SPDEF may be caused by the initial increase in 
IL-33 in asthmatics. SPDEF is a master regulator of airway goblet cell differentiation and in 
mice overexpression of SPDEF has been shown to lead to goblet cell hyperplasia29, a 
physiological change seen in asthmatic airways for which there is currently no treatment. 
Other differentially expressed transcription factors identified in the present study, PPARD, 
PRDM1 (coding for BLIMP-1: B lymphocyte-induced maturation factor 1) and AHR, have 
been shown to have roles in epithelial cell development, differentiation and growth. This 
secondary effect of IL-33 may obscure the direct targets of IL-33, as their differential 
expression would have knock-on effects in gene expression changes. That said, if IL-33 does 
regulate transcription factors, which in turn regulate goblet cell hyperplasia and epithelial 
differentiation, this would imply that IL-33 ultimately has a role in the development and 
maintenance of the airway epithelium’s physiology. 
From the gene ontology analysis IL-33 also appears to increase inflammation, specifically 
responses to bacterium (Table 5.5). Asthmatic airways are hyper-responsive in relation to 
inflammation and an increase in IL-33 would presumably increase the innate inflammatory 
response. Whilst IL-8 was decreased in the supernatant of IL-1ß stimulated NHBEs when IL-
33 was knocked down, at the mRNA level it was only slightly decreased and did not pass the 
threshold for significance (CXCL8, -1.7 maximum fold change at 0 h, p = 0.002). This small 
change could affect IL-8 at the protein level, or the decreased IL-8 in the supernatant could be 
reflecting changes posttranscriptional or interference with the secretion pathway of IL-8.  
Most acute exacerbations in asthmatics are caused by rhinovirus infections; ICAM-1 is the 
receptor used for entry for 90% of these viruses212and is increased in asthmatic epithelium213. 
IL-33 siRNA reduced ICAM1, suggesting that it regulates ICAM1 expression, which may 
explain the increased expression of ICAM-1 and increased severity of infection found in 
asthmatics when infected with rhinovirus. Rhinovirus infection itself increases IL-33 
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expression95, which may further boost ICAM-1 expression and exacerbate the predisposition 
to viral entry. ICAM-1 is also important in asthma because it is the ligand for LFA-1, a 
heterodimeric integrin pair that is key in the chemotaxis of both eosinophils and mast cells.  
5.4.2 Network Analysis 
WGCNA, using an unbiased sample of all genes detected found two major modules (groups 
of co-expressed genes) associated with IL-33 knockdown. When correlating modules with 
time and transfection status, no modules showed strong correlation for both traits (Figure 5.7), 
corroborating the observation that genes that were differentially expressed by IL-33 
knockdown, showed steady levels of expression across the time course of stimulation.  
The Blue Module showed strong association (r = 0.94, p = 6 x 10-17) with IL-33 knockdown. 
These genes had a high overlap with the differentially expressed genes; forty seven percent 
genes increased in differential expression were found and accounted for 33% of the genes in 
the Blue Module (Figure 5.11). Gene ontology terms from this module were similar to those 
for the up-regulated genes from the differential expression analysis, with cell projection 
assembly and cell-substrate adhesion terms being enriched in both groups. WGCNA was able 
to detect novel terms that were not detected by differential gene expression including 
‘covalent chromatin modification’ and more specifically, ‘histone methylation’ (Table 5.8). 
This shows the added benefit of grouping genes based on their co-expression before 
determining differential expression across transfection status, as this method of selection 
showed a biologically distinct set of genes, which have changed upon IL-33 knockdown. The 
apparent alteration of epigenetic factors by IL-33 suggests another layer of complexity in the 
downstream effects of IL-33 when considered alongside the evidence for signalling pathways 
alteration and transcription factor levels.  
The Green Module showed a strong negative association (r = -0.92, p = 2 x 10-15) with IL-33 
knockdown and only one gene ontology term was enriched, phospholipid metabolic process 
(Table 5.9), this was related to the term enriched in down-regulated genes: triglyceride 
biosynthetic process (Table 5.5).  
5.4.3 Comparison to Literature 
All previous studies investigating the intracellular role of IL-33 at the gene and protein level 
have focused on NF-κB targets such as ICAM-1 or CCL2. Consequently the current literature 
suggests that intracellular IL-33 only regulates inflammatory genes. From this present study, 
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novel sets of genes related to differentiation, extracellular matrix reorganization, cell-substrate 
adhesion and histone modification appear to be regulated by IL-33. 
Work in this chapter has validated previous findings of genes altered by IL-33 knockdown or 
over-expression. CCL2121,131(-3.2 fold change, p = 6.4 x 10-8), ICAM1119(-5.5 fold change, p = 
1.0 x 10-12), IL6121,124(-1.8 fold change, p = 2.7 x 10-4), TGFA ( -1.7 fold change, p = 8.6 x 10-
11) and MMP9124( -2.0 fold change, p = 2.1 x 10-7) were all found to be decreased upon IL-33 
siRNA. Two genes showed contrary differential expression than that previously reported: 
TNF (coding for TNF-α) and MMP3. TNF (-1.9 fold change, p = 5.9 x 10-6) has previously be 
reported to be decreased upon overexpression of murine IL-33 in HEK293 cells78, perhaps 
due to a species difference between murine and human IL-33 function, or simply the cell type. 
MMP3 (2.1 fold change, p = 9.7 x 10-5) in TNFα-stimulated rheumatoid arthritic synovial 
fibroblasts did not change upon IL-33 knockdown but was increased when IL-33 was 
overexpressed121. Finally in a contrast to work by Choi et al.119, IL-33 knockdown did not 
alter RELA (p65 of NF-κB) expression. Overall this suggests that IL-33 does have cell-type, 
stimulation or disease specific functions.  
In a yeast two-hybrid screen of human proteins, IL-33 was found to interact with CRMP-1 
(collapsin response mediator protein 1)214. In the same study, CRMP-1 was shown to repress 
the Wnt pathway. Given that the gene ontology term for positive regulation of Wnt signalling 
pathway was increased in the IL-33 knockdown, this suggests that IL-33 may be a co-factor 
increasing CRMP-1’s repression of the Wnt pathway. Wnt signalling mediators and inhibitors 
are gene targets of Wnt signalling215, therefore repression of Wnt signalling would reduce the 
negative feedback loops and could cause the gene expression changes seen. Co-
immunoprecipitation of IL-33 and staining for CRMP-1 would determine whether this 
interaction does indeed exist. 
5.4.4 Limitations 
There are limitations in relation to the present study. As the IL-33 silencing was carried out 
for 48 hours, the primary targets of IL-33 could have their own effect on the transcriptome 
over the incubation period. Transcription factors, RNA-processing factors, non-coding RNA, 
chromatin factors and components of signalling pathways can all create secondary effects in 
terms of gene expression changes. Ideally, following the gene expression over a time-course 
of IL-33 knockdown (i.e. following the course of IL-33 knockdown) would identify the 
primary targets. In addition, determining the gene expression profiles upon knockdown of 
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transcription factors listed above would help in understanding the primary and secondary 
targets of IL-33. Practically this would not change our knowledge of the processes that IL-33 
is involved in, but combined with ChIP-Seq data of IL-33 (Chapter 7) it would give an in 
depth picture of how IL-33 carries out the transcriptional changes.  
Changes at the gene expression level here have not been validated for genes of interest at the 
protein level to show that the changes follow through to phenotypic effects. Moreover, tests 
for phenotypes inferred by gene ontology enrichment or specific genes have not been 
validated using functional assays. This initial study has focused on commercially obtained 
healthy NHBEs and the logical next step would be to validate findings in further NHBEs from 
normal and asthmatics. 
In order to relate the role of IL-33 found in this chapter to that of asthmatic airways, the major 
assumption is that increased IL-33 in asthmatics would have the opposite effect as IL-33 
knockdown. Ideally, this would have been shown by overexpression in NHBEs and carrying 
out global gene expression analyses. Indeed, the specific level of IL-33 may alter gene 
expression in specific ways that may not be reciprocal when over-expression and knockdown 
are compared.  
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6. Effect of ST2 on gene expression in airway epithelium 
6.1 Introduction 
The prior work conducted in Chapter 5 revealed that NHBE gene expression was significantly 
altered in response to IL-33 knockdown during an IL-1ß stimulation time-course. To 
complement this work the purpose of this chapter was to profile and compare the gene 
expression changes of NHBEs upon knockdown of the IL-33 receptor, ST2 (Section 4.3.4). A 
splice variant of the ST2 gene, IL1RL1, encodes soluble ST2 (sST2) that acts as a secreted 
decoy receptor for IL-33, preventing IL-33 from binding to receptor-bound ST2. As with 
IL33, a single nucleotide polymorphism near IL1RL1 has been associated by genome wide 
association studies with asthma55.  
In human studies, there is evidence that IL-33 acts intra-cellularly and independently of ST2. 
In un-stimulated HUVECs, Choi et al. found that IL-33 knockdown reduced ICAM-1 and 
VCAM-1, moreover IL-33 overexpression increased these genes and was not altered by ST2 
knockdown119. In addition, for HOECs (human oesophageal epithelial cells) IL-33 
knockdown decreased IFNγ-induced IL-6 and IL-8 production. In a separate experiment, 
addition of sST2 to block exogenous IL-33 did not affect the secretion of these cytokines in 
response to IFNγ147. These two HOEC experiments may not be completely comparable 
however, as the IL-33 siRNA was carried out in monolayer culture and the sST2 blocking in 
ALI culture. Taken together the current literature suggests that knockdown of IL-33 is likely 
to mediate its effects intra-cellularly, independently of ST2.  
As with the prior chapter, cDNA microarrays were chosen for the preliminary analysis of 
NHBE gene expression upon ST2 knockdown during an IL-1ß stimulation time-course 
(Section 5.1). Based upon the majority of evidence (outlined in Section 1.2.6.2), the 
hypothesis of this current chapter was that the genes altered upon IL-33 knockdown would 
not be shared with those altered by ST2 knockdown. Further to this, an investigation of any 
genes altered by ST2 knockdown may give additional information and insight into the role of 
ST2 in asthma.  
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6.2 Methods 
6.2.1 Cell culture and RNA extraction  
NHBEs were cultured in 24-well plates, transfected with 10 nM ST2 siRNA for 48 hours (as 
per Section 2.3.1.2). Media was replaced with starving media for 16 hours before a 24-hour 
time-course of 1 ng/mL IL-1ß stimulation (Section 2.3). At 0, 2, 4, 6, 12 and 24 hours of 
stimulation, cells were lysed in situ and extracted using the Qiagen RNeasy plus kit (Section 
2.4.1). RNA was extracted in two batches on the same day, the first batch containing samples 
from 0, 4 and 12 hours of stimulation and the second batch containing samples from 2, 6 and 
24 hours of stimulation. A triplicate time course of RNAs from the ST2 siRNA and IL-1ß 
data shown in Chapter 4 Figure 4.12 was used in global gene expression analysis with cDNA 
microarrays. RNA concentration was quantified using the Nanodrop ND 1000 UV-Vis 
spectrophotometer. RNA quality was determined with the Agilent 2100 Bioanalyzer (Section 
2.6.1). As microarray profiling requires high quality RNA, a threshold of a RIN of 7 was 
applied. 
6.2.2 Microarray library preparation and profiling 
RNA samples were randomised and coded in order to avoid introduction of batch effects 
across preparation and arrays, which might confound with knockdown or stimulation. Library 
preparation involved the sequential steps of converting mRNA to single stranded DNA the 
latter then to double stranded DNA then to single stranded cRNA and finally single sense 
stranded cDNA (Section 2.6.2). Next cDNA was fragmented, labelled and hybridised to 
complementary probes on the microarray chip and quantified (Section 2.6.3). 
6.2.3 Microarray data analysis 
Quality control of raw microarray data was determined with the arrayQualityMetrics Package 
(Version 3.20.0) in the R environment (Version 3.1.0164) using Bioconductor packages165 
(Section 2.6.4.1). Any arrays that were outliers were excluded and if necessary samples were 
rerun from library preparation one further time to rule out preparation as the cause of outlier 
status. Affymetrix Power Tools (Version 1.12.0) was used for RMA normalisation167 
simultaneously of all arrays passing QC.  
Normalised data were imported into R and control probesets were removed prior to further 
analysis. Batch effects were quantified using the PVCA package (Version 1.6.0169). 
Differential expression between NSC and ST2 siRNA per time-point was determined using 
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Limma (Version 3.20.0). All p values were corrected for multiple testing based on the 
Benjamini and Hochberg method for controlling the false discovery rate171. HOMER (Version 
4.7172) was applied to calculate the gene ontology enrichment and was verified by 
DAVID173,174.  
6.2.3.1 Genome-wide association study association filtering 
Differentially expressed genes were filtered by their association with traits in GWAS using 
the National Human Genome Research Institute catalogue of published GWAS216. This 
curated database was imported into R and differentially expressed genes were filtered and 
merged with the GWAS information.  
6.2.3.2 Comparison between IL-33 knockdown arrays and ST2 knockdown arrays 
For comparisons between the ST2 knockdown differential expression and the IL-33 
knockdown differential expression, data from Chapter 5 was used.  
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6.3 Results 
6.3.1 Quality control and pre-processing 
RNA concentrations ranged from 40.2 – 85.1 ng/µL and had RIN scores from 8.6 – 10. All 
samples were taken forward for microarray library preparation and profiling. Two arrays 
failed to pass quality control based on ArrayQualityMetrics and still failed after being 
repeated from library preparation through to quantification. These two samples were single 
replicates from NSC-treated cells at 12 hours of stimulation and ST2 siRNA-treated cells at 6 
hours of stimulation. Pseudo-triplicates were therefore made from the two other replicates 
within these conditions, taking an average of their expression thereby allowing their inclusion 
in the differential expression analysis.  
Prior to normalisation, raw expression levels of control probes were imported into R and 
analysed. Controls for cDNA preparation (Figure 6.1) shows the poly-A controls in expected 
descending order, except for one sample where trpn was detected at higher levels than lys. In 
this sample (NSC-treated cells at 6 hours of stimulation), only these two low-expression 
controls were not in the expected descending order in a single array. Figure 6.2 shows the 
hybridisation controls in the expected descending order. All arrays were taken forward for 
differential expression detection.  
Batch effects were quantified using PVCA (Section 2.6.4.1), which determines the proportion 
of variance explained by each factor and their pair-wise interactions (Figure 6.3). Time point 
of stimulation and its interaction with other factors explained the most variation in the data. 
Time point alone explained 19%, and its interaction with RNA extraction batch explained 
22% and transfection explained 10%. Transfection status alone accounted for 5% of the 
variance in the data and the single batch effect that explained the largest variation of the data 
was the RNA extraction batch (1%). Overall this suggested that stimulation played a much 
larger role in explaining the variance of the data than transfection status.  
RNA was extracted in two batches; all samples for 0, 4 and 12 hours of stimulation in one 
batch and another batch with all samples for 2, 6 and 24 hours of stimulation. This was in 
order to avoid confounding RNA extraction batch with the progression of the time course, 
however the expression levels of genes in unstimulated cells (0 hours) or 24 hours of 
stimulation could skew either batch if the gene expression at these time points is widely 
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different from all other time points. This however was not an issue since the purpose of this 
experiment was to determine the differences between transfection status.  
 
Figure 6.1 Poly-A controls for cDNA preparation 
Raw intensity of poly-A controls in all microarray samples: thr, phe, lys and trpn. These were 
in the expected order for all samples except for one where trpn was higher than lys.  
 
 
Figure 6.2 Hybridisation controls for microarray quantification 
Raw intensity for hybridisation controls for all microarrays are shown for cre, bioD, bioC and 
bioB. These were in the expected order and no bias in hybridisation was observed. 
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Figure 6.3 Batch effect quantification using PVCA 
PVCA estimates the proportion of variance that is explained per batch effect given, and their 
interactions (depicted by a colon). Time point explains 19% of the variation, and its 
interaction with RNA batch (22%) and transfection (10%) explain the largest proportion of 
the variance. Transfection alone accounted for 5% of the variance and the single batch effect 
that had the largest impact on variation was RNA batch at 1%. Time: time point of 
stimulation, rna.batch: batch of RNA extraction, transfect: transfection status, resid: residual 
effects that were not attributable to a batch factor, block.day.1 and block.day.2: thermocycler 
block used on day 1 and 2, day.1 and day.2: date of copy RNA and single stranded DNA 
generation, poly.a.kit: polyA control batch, rep: replicate per condition (1-3), array: array 
plate used, wt.kit.d1 and wt.kit.d2: whole transcriptome kit batch used per day. 
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6.3.2 Differential gene expression 
Eighty-seven genes were differentially expressed between NSC- and ST2 siRNA-treated 
cells, using a p value threshold of 0.01. Upon applying the additional threshold of > 1.4 fold 
change this number decreased to 59 genes. As can be seen from the volcano plots (Figure 6.4) 
the fold-change and p values obtained were modest. Of these genes, 44 (75%) were decreased 
upon ST2 knockdown and 15 (25%) were increased. The top 20 genes decreased by ST2 
knockdown (ranked by p value) are listed in Table 6.1. IL1RL1, the gene coding for ST2 had 
the largest fold change (-3.4, p value = 4.4 x 10-13) and as expected was decreased showing a 
reasonable efficiency knockdown. Other down-regulated genes that are of interest include 
those involved in mucin 5AC (MUC5AC) production: S100A12 (S100 calcium-binding 
protein A2) and ANO1 (anoctamin 1) or ceramide synthesis: CERK (ceramide kinase) and 
ORMDL3. 
All genes increased upon ST2 knockdown are detailed in Table 6.2. Genes that may have 
roles in airway remodelling (PLAT: plasminogen activator tissue type, EMP1: epithelial 
membrane protein 1 and PLOD2: procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) were 
found to be significantly increased. Gene ontology analyses were carried out for differentially 
expressed, up-regulated and down-regulated genes but no terms were significantly enriched 
(> 1.4 fold enrichment and p < 0.05). WGCNA was not used, as its key benefit to enrich into 
smaller groupings of genes was not required in this instance due to the small number of 
differentially expressed genes seen.  
The ORMDL3 locus has been identified by GWAS as being associated with asthma and this 
led to the investigation of GWAS-determined genes within the dataset. The IL1RL1 locus has 
been associated with asthma55 and other traits including: serum sST2 levels106, allergic 
sensitisation132, hayfever134, self-reported allergy133, atopic dermatitis135, coeliac disease137, 
Crohn’s disease217 and IBD136. Focusing on these traits, 6 genes were identified that were 
differentially expressed and had a GWAS association with at least one of the traits (Table 
6.3). ORMDL3 was the only gene that was further associated with asthma, with the majority 
being associated with IBD or subset of this, Crohn’s disease. Indeed, IBD patients have 
increased intestinal ST2 which appears to be due to an increase in ST2L, IL-33 also appeared 
to be increased in patients by ELISA but both values were close to the detection threshold91. 
Further, NUPR1 (nuclear protein 1, transcriptional regulator) has been associated with IBD136 
and reduces Mmp9 expression in murine cardiac fibroblasts218. Both NUPR1 and MMP9 were 
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identified and show opposite differential expression upon ST2 knockdown suggesting that 
this regulation may occur in this model. IL24 is increased in IBD intestinal biopsies219, yet 
was also increased upon ST2 knockdown. This suggests that other factors are at play in 
regulating IL24 in IBD epithelium.  
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Figure 6.4 Volcano plots of differential gene expression upon ST2 knockdown 
Sub-graphs show the fold change and p value of each gene analysed per time point in IL-1ß 
stimulation time course when compared to NSC. Genes in mustard yellow did not pass the 
significance threshold of p < 0.01 and a fold change > 1.4.  
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Table 6.1 Top 20 down-regulated genes 
The top 20 down-regulated genes, ranked by p value, of ST2 siRNA-treated cells compared to 
NSC-treated. Median expression was calculated from the fluorescent units across the 
probesets for all samples. p values were corrected for multiple testing using Benjamini and 
Hochberg’s method.  
Gene 
Symbol 
Median 
Expression 
Maximum 
Fold Change p Value 
IL1RL1 21.8 -3.4 4.4 x 10-13 
MMP9 362.2 -1.9 5.0 x 10-8 
MYL9 538.8 -1.9 3.4 x 10-07 
CERK 157.8 -1.7 3.4 x 10-07 
HLA-DOB 62.4 -2.0 3.4 x 10-07 
FAM26E 90.7 -2.1 3.9 x 10-06 
SLURP1 97.4 -2.2 5.5 x 10-06 
RAP2B 837.1 -1.5 1.1 x 10-05 
ANO1 248.2 -1.4 1.1 x 10-05 
PSTPIP2 190.0 -1.7 1.3 x 10-05 
PHLPP2 102.7 -1.8 1.3 x 10-05 
ORMDL3 112.1 -1.5 2.5 x 10-05 
AKR1B10 76.2 -2.2 2.7 x 10-05 
UBAC2 123.7 -1.6 3.3 x 10-05 
KCTD20 141.6 -1.5 5.6 x 10-05 
HS3ST2 73.8 -2.0 6.5 x 10-05 
RHOB 244.2 -1.5 7.3 x 10-05 
S100A12 705.5 -1.6 1.5 x 10-04 
IGFL1 393.3 -1.6 1.6 x 10-04 
OSTF1 240.4 -1.5 3.4 x 10-04 
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Table 6.2 Up-regulated genes 
All up-regulated genes, ranked by p value, of ST2 siRNA-treated cells compared to NSC-
treated. Median expression was calculated from the fluorescent units across the probesets for 
all samples. p values were corrected for multiple testing using Benjamini and Hochberg’s 
method.  
Gene 
Symbol 
Median 
Expression 
Maximum 
Fold Change p Value 
PLAT 186.0 1.9 1.8 x 10-06 
C3 927.3 1.4 2.2 x 10-06 
EMP1 887.0 1.6 2.7 x 10-05 
CPM 132.5 1.5 3.4 x 10-05 
PLOD2 2106.9 1.5 9.9 x 10-05 
TMEM217 59.4 1.7 8.5 x 10-04 
MEST 57.4 1.6 1.0 x 10-03 
IL24 83.7 1.7 1.1 x 10-03 
LOXL2 256.9 1.4 3.3 x 10-03 
LIPH 490.6 1.5 3.3 x 10-03 
MIR4664 20.8 1.7 5.6 x 10-03 
NLRP10 56.9 1.9 5.9 x 10-03 
GABRP 36.0 1.6 6.2 x 10-03 
ZNF138 73.8 2.2 6.7 x 10-03 
MMP3 38.2 1.7 9.9 x 10-03 
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Table 6.3 GWAS genes differentially expressed upon ST2 knockdown 
Differentially expressed genes upon ST2 knockdown, excluding the gene for ST2 (IL1RL1), 
were selected if they have a GWAS association with traits that IL1RL1 have been associated 
with: serum sST2 levels, asthma, allergic sensitisation, asthma and hayfever, self-reported 
allergy, atopic dermatitis, coeliac disease, Crohn’s disease or inflammatory bowel disease. 
Table is sorted by ST2-knockdown p value, which has been corrected for multiple testing 
using Benjamini and Hochberg’s method. Genes that increased in expression upon ST2 
knockdown are shown with a grey background.  
Gene 
Symbol 
ST2 
Knockdown 
Fold Change 
ST2 
Knockdown 
p Value 
GWAS 
Reference GWAS Trait 
GWAS p 
Value 
MMP9 -1.9 5.0 x 10-08 136 Inflammatory bowel disease 1.0 x 10-13 
HLA-
DOB -2.0 3.4 x 10
-07 220 Crohn's disease 9.0 x 10-59 
ORMDL3 -1.5 2.5 x 10-05 136 Inflammatory bowel disease 4.0 x 10-38 
ORMDL3 -1.5 2.5 x 10-05 217 Crohn's disease 2.0 x 10-09 
ORMDL3 -1.5 2.5 x 10-05 55 Asthma (childhood onset) 6.0 x 10-23 
IL24 1.7 1.1 x 10-03 136 Inflammatory bowel disease 7.0 x 10-42 
NUPR1 -1.7 3.3 x 10-03 136 Inflammatory bowel disease 1.0 x 10-21 
NLRP10 1.9 5.9 x 10-03 135 Atopic dermatitis 2.0 x 10-22 
 
6.3.3 Comparison of ST2- and IL-33-knockdown gene expression 
Work in Chapter 5 found 1,509 genes to be differentially expressed upon IL-33 knockdown, 
this is marked contrast to the few genes (N=87) that showed differential expression upon ST2 
knockdown. Any genes that show concordant differential expression for both knockdown 
experiments are likely to be a secondary effect of IL-33 knockdown and mediated by ST2. 
Table 6.4 shows the 15 concordant differentially expressed genes. IL1RL1 decrease was 
common to both experiments; the concordant gene expression changes seen could be due to 
the lack of IL-33 signalling through ST2 or a reduction of ST2 alone. Two matrix 
metalloproteinases, MMP9 and MMP3 were common to both experiments, in addition ANO1 
can induce MMP-9 expression221. Furthermore ANO1 and S100A12 increase mucus 
production (MUC5AC)222,223. Finally, ANO1 and AQP3 (aquaporin 3) may be involved in 
airway differentiation224,225. 
In Chapter 5, gene lists were used to determine gene ontology enrichment. Given that the 
expression of concordant genes in Table 6.4 are likely to be caused by the reduction in ST2, a 
secondary effect of IL-33 knockdown. The gene ontologies were reanalysed for IL-33 
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knockdown and IL-1ß stimulation with concordant genes removed from the differentially 
expressed gene lists and the WGCNA module lists. The majority of gene ontology terms 
retained similar fold-enrichment and p values. The gene ontology terms that showed a 
substantial change (fold enrichment change > 30%, p value change > 5-fold or both) are given 
in Table 6.5. The terms for cell projection assembly and regulation of cell-substrate adhesion 
were the only terms that increased in their fold enrichment and p value after removal of the 
fifteen concordant genes. Positive regulation of inflammatory response decreased in p value 
to 0.036, suggesting a smaller role of nuclear IL-33 in inflammation than inferred in Chapter 
5.  
The IL33 locus has been associated by GWAS with several traits: asthma55, asthma and 
hayfever134, self-reported allergy133, endometriosis226, periodontal microbiota227. Focusing on 
these traits and the data from the IL-33 knockdown and IL-1ß stimulation experiment 
(Chapter 5), 23 genes were differentially expressed and had a GWAS association with at least 
one of the traits (Table 6.6). YES1 (YES proto-oncogene 1) and EDIL3 (EGF like repeats and 
discoidin domains 3) have been shown to effect tight junction formation228 and immune cell 
infiltration into the lung respectively229. Other immune related genes such as IL1RL1, FOS 
(Fos proto-oncogene; coding for a subunit of the transcription factor, AP-1), IL15RA and 
HLA-G (major histocompatibility complex, class I, G) were also found.   
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Table 6.4 Concordant differentially expressed genes upon IL-33 and ST2 knockdown  
Fifteen genes showed concordant differential expression for the IL-33- and ST2-knockdown 
treated cells compared to NSC. Fold Change given is the maximum fold change for the 
experiment and p values have been corrected for multiple testing using Benjamini and 
Hochberg’s method. The table is ordered by ST2-knockdown p value. Genes that were 
increased in response to knockdown are shown with a grey background.  
Gene 
Symbol 
ST2 Knockdown 
Fold Change 
ST2 p 
Value 
IL-33 Knockdown 
Fold Change 
IL-33 p 
Value 
IL-33 
WGCNA 
Module 
IL1RL1 -3.4 4.4E-13 -2.0 1.4E-08 Green 
MMP9 -1.9 5.0E-08 -2.0 2.1E-07 Midnightblue 
C3 1.4 2.2E-06 2.2 1.2E-13 Lightcyan 
FAM26E -2.1 3.9E-06 -2.0 1.2E-07 Lightgreen 
ANO1 -1.4 1.1E-05 -2.3 2.7E-12 Green 
AKR1B10 -2.2 2.7E-05 -1.7 7.1E-05 Brown 
S100A12 -1.6 1.5E-04 -1.7 1.6E-05 Midnightblue 
IGFL1 -1.6 1.6E-04 -8.0 2.9E-14 Green 
MEST 1.6 1.0E-03 1.8 6.3E-08 Black 
CHI3L1 -1.7 2.0E-03 -2.2 7.7E-07 Green 
HSD11B1 -1.6 2.0E-03 -2.3 5.5E-13 Green 
HSD17B2 -1.7 2.2E-03 -2.2 1.7E-06 Green 
AQP3 -1.5 3.6E-03 -1.7 1.4E-04 Green 
GPNMB -1.8 5.9E-03 -1.7 3.0E-04 Midnightblue 
MMP3 1.7 9.9E-03 2.1 9.7E-05 Lightcyan 
 
  
 173 
Table 6.5 Highly changed gene ontology values for IL-33 knockdown gene lists 
Gene lists from IL-33 knockdown and IL-1ß stimulation (Chapter 5) had differentially 
expressed genes from ST2 knockdown removed and then gene ontology was reanalysed. 
Gene ontology terms are shown for terms that changed in fold enrichment by > 30%, changed 
in p value by > 5 fold or both.  
Term ID Term 
 Original 
Fold 
Enrichment 
Original 
p Value 
Corrected 
Fold 
Enrichment 
Corrected 
p Value 
Gene 
List 
GO:0030198 
Extracellular 
matrix 
organization 
3.3 2.0 x 10-06 3.2 2.7 x 10-05 Up 
GO:0032963 
Collagen 
metabolic 
process 
4.8 1.2 x 10-03 3.6 7.6 x 10-02 Up 
GO:0009913 Epidermal cell differentiation 3.3 6.8 x 10
-04 2.1 3.3 x 10-04 Down 
GO:0050729 
Positive 
regulation of 
inflammatory 
response 
4.0 5.5 x 10-03 3.6 3.6 x 10-02 Down 
GO:0010468 
Regulation of 
gene 
expression 
1.4 2.7 x 10-10 1.4 1.3 x 10-06 Blue 
GO:0030031 Cell projection assembly 1.9 6.3 x 10
-03 2.9 3.9 x 10-04 Blue 
GO:0010810 
Regulation of 
cell-substrate 
adhesion 
2.2 7.4 x 10-03 3.5 4.8 x 10-04 Blue 
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Table 6.6 GWAS genes differentially expressed upon IL-33 knockdown 
Differentially expressed genes upon IL-33 knockdown, excluding IL33, were selected if a 
GWAS association with IL33 has been found. The following traits had been reported: asthma, 
asthma and hayfever, self-reported allergy, endometriosis, periodontal microbiota. The table 
is sorted by IL-33 knockdown p value, which has been corrected for multiple testing using 
Benjamini and Hochberg’s method.  
Gene 
Symbol 
IL33 
Knockdown 
Fold Change 
IL33 
Knockdown 
p Value 
GWAS 
Reference GWAS Trait 
GWAS p 
Value 
Increased 
EDIL3 2.5 5.1 x 10-15 134 Asthma and hay fever 5.0 x 10-07 
IL6R 2.0 9.5 x 10-13 230 Asthma 2.0 x 10-08 
WNT4 2.7 7.2 x 10-10 231 Endometriosis 3.0 x 10-11 
TLE4 1.6 5.6 x 10-08 232 Asthma (childhood onset) 7.0 x 10
-07 
ABI3BP 1.8 6.2 x 10-07 233 Asthma (childhood onset) 6.0 x 10
-08 
BCL6 1.8 1.1 x 10-06 133 Self-reported allergy 1.0 x 10-09 
KLHL5 1.4 7.7 x 10-06 233 Asthma (childhood onset) 3.0 x 10
-07 
C11orf30 1.5 3.7 x 10-05 133 Self-reported allergy 2.0 x 10-19 
SYNPO2 2.0 5.0 x 10-05 234 IgE levels in asthmatics 8.0 x 10-06 
TRPS1 1.4 1.5 x 10-04 227 Periodontal microbiota 2.0 x 10-06 
CDKN2B 1.8 2.3 x 10-04 231 Endometriosis 2.0 x 10-09 
FAM19A2 1.5 9.7 x 10-04 134 Asthma and hay fever 2.0 x 10-06 
IL15RA 1.5 9.8 x 10-04 235 Asthma (bronchodilator response) 2.0 x 10
-07 
Decreased 
YES1 -2.7 1.3 x 10-15 236 Pulmonary function in asthmatics 4.0 x 10
-06 
CRCT1 -5.3 7.6 x 10-15 56 Asthma 6.0 x 10-06 
GSDMA -2.9 3.1 x 10-10 55 Asthma 5.0 x 10-09 
IL1RL1 -2.0 1.4 x 10-08 56 Asthma 2.0 x 10-15 
PRKCQ -1.7 4.2 x 10-06 235 Asthma (bronchodilator response) 2.0 x 10
-07 
FOS -1.8 4.9 x 10-06 227 Periodontal microbiota 9.0 x 10-07 
KIAA1715 -1.4 2.5 x 10-05 227 Periodontal microbiota 4.0 x 10-06 
RAB11FIP2 -1.4 5.0 x 10-05 237 Asthma (sex interaction) 4.0 x 10-07 
HLA-G -1.4 2.8 x 10-04 238 IgE levels  4.0 x 10-08 
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6.4 Discussion 
The main focus of this chapter was to compare the impact of ST2 knockdown to IL-33 
knockdown in order to determine the impact of each.  
6.4.1 ST2 knockdown and IL-1ß differential expression 
ST2 knockdown was achieved at a magnitude that altered the global gene expression upon 
ST2 knockdown, with ST2 (IL1RL1) having the largest fold change (-3.4) and smallest p 
value (4.4 x 10-13). Eighty seven genes were differentially expressed across an IL-1ß time-
course in NHBEs, using a p value threshold of > 0.01 (ten-fold higher than the p value 
threshold used for IL-33 knockdown; Chapter 5). Whilst the number of differentially 
expressed genes and their magnitude was modest, biologically relevant genes were affected 
by ST2 knockdown. Many genes identified have the potential to alter MMP-9 expression or 
action, which was also decreased upon ST2 knockdown. Whilst ST2 expression in the 
bronchial epithelium is not altered in asthmatics, increased sputum239 and serum240,241 levels 
of sST2 would alter the baseline of IL-33 signalling in the airway epithelium. Furthermore, 
circulating fibrocytes242 in asthmatics and airway fibroblasts154 in PSTRA have an increased 
expression of ST2. These cells are thought to be important in airway remodelling and the 
gene expression changes upon knockdown may be reversed in these cells. IL-33 is increased 
in the bronchi of asthmatics65, which would then be released upon necrosis, potentially 
leading to an increase in the baseline of IL-33 signalling upon stress.  
LOXL2 was increased upon ST2 knockdown. Work in mice using conditional knockouts and 
over-expression has shown that LOXL2 alters epithelial organisation and increases 
inflammation by inhibiting Notch1 expression in the skin243. This suggests that constitutive 
ST2 or IL-33-signalling may directly alter the airway epithelium organisation. In addition, 
EMP1 (another gene that showed increased expression) may have a role in airway 
remodelling. In nasal polyps, EMP1 is decreased where goblet cell hyperplasia is observed244, 
yet it is unknown whether this is in response to goblet cell hyperplasia or part of the cause. 
Other potential genes of interest are PLOD2 that crosslinks collagen, which is important in 
fibrosis and PLAT, which converts plasminogen to plasmin. Active plasmin is then able to 
degrade the extracellular matrix. It is difficult to deduce the outcome of these two products on 
the extracellular matrix.  
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The IL1RL1 locus codes for ST2 and has been previously shown to be robustly associated 
with asthma. Notably ST2 knockdown caused ORMDL3, a major asthma gene determined by 
GWAS55 to be involved in asthma, to decrease in expression. ORMDL3 negatively regulates 
sphingolipid synthesis, yet when over-expressed in a bronchial epithelium cell line, 
sphingolipid synthesis was largely unaltered suggesting a complex network of regulation245. 
Similar over-expression in the A549 cell line increased MMP9, IL8 and CXCL11246. Whilst 
MMP9 did decrease in this Chapter, no other ORMDL3-induced genes found by Miller et 
al.246 were differentially expressed. This however may be due to the cell type as A549 cells 
are type II pneumocytes.  
Both S100A12 and ANO1 gene expression were decreased with ST2 knockdown and IL-33 
knockdown. Both genes have been shown to have a role in MUC5AC expression by the 
airway epithelium. S100A12 is an anti-microbial peptide which represses bacterial growth by 
zinc chelation247. Additionally, NHBEs grown in air-liquid interface had increased MUC5AC 
expression upon the addition of recombinant S100A12223. ANO1 codes for TMEM16A, a 
calcium activated chloride channel. Knockdown of ANO1 and over-expression of the gene in 
the 16HBE bronchial epithelial cell line, revealed that TMEM16A increased IL-13 induced 
MUC5AC secretion222. Both proteins can affect MMP-9 expression. Transfection of ANO1 in 
glial cell lines revealed that it induced MMP-9 expression221 whilst S100A12 inhibits MMP-9 
activity, presumably by chelating zinc ions248. Nupr1 in murine cardiac fibroblasts also has 
been shown to reduce TNFα-induced Mmp9 expression218. As MMP9 was decreased in ST2-
knocked down cells, it is possible that this was due to the reduction of ANO1 or increased 
NUPR1 caused by the ST2 knockdown. Yet, if there is less S100A12, the lower expression of 
MMP-9 may be balanced by the lack of MMP-9 inhibition making it difficult to predict the 
final phenotype.  
Two genes that showed altered expression by ST2 and IL-33 knockdown may affect airway 
differentiation. In a murine kidney epithelium cell line, ANO1 has been shown to be important 
for the early stages of ciliogenesis224 whilst AQP3 codes for a water channel, that in murine 
models is only expressed in basal airway epithelium and delays differentiation225. Both genes 
were decreased upon ST2 or IL-33 knockdown suggesting a delayed differentiation and 
altered ciliogenesis.  
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6.4.2 Re-analysis of IL-33 knockdown and IL-1ß gene expression data 
Re-analysis of the gene ontology terms for IL-33 knockdown and IL-1ß stimulation, 
removing concordant genes from ST2 knockdown and IL-1ß stimulation, did not lead to a 
dramatic change in most terms by their enrichment and p values. Gene ontology terms ‘Cell 
projection assembly’ and ‘Regulation of cell-substrate adhesion’ were the only ones that 
increased in both fold-enrichment and p value. These terms were present in the Blue module 
from the WGCNA analysis and give weight to the role of nuclear IL-33 in epithelial 
remodelling. In contrast, terms for ‘Extracellular matrix organization’ and ‘Collagen 
metabolic process’ (up-regulated gene list) decreased in terms of p value and fold-enrichment 
respectively. The reduction in the significance of these terms suggests that ST2 was 
responsible for a proportion of the response seen. It is noteworthy that the gene ontology term 
for ‘Positive regulation of inflammatory response’ (down-regulated gene list) had a higher p 
value, from 0.0055 to 0.036, upon removal of the concordant genes. Whilst the threshold of p 
< 0.05 was chosen, making it still a significant term, this does increase the chances of these 
genes for this term being enriched by chance from ~1/200 to ~1/30. Ultimately these gene 
ontologies are biased by what has been researched and are used as an overview. Nonetheless 
it does suggest that the main effect of nuclear IL-33 is less involved with inflammation. A 
complex network of interactions affects gene expression and mapping secondary effects of 
IL-33, such as shown in this chapter, will allow for the immediate targets of IL-33 to become 
more apparent. 	
Investigation of the ST2 siRNA differentially expressed genes highlighted ORMDL3 which, 
in addition to IL1RL1 had been associated with asthma by GWAS55. This led to a re-analysis 
of differentially expressed genes from Chapter 5 for GWAS genes. YES1 in Table 6.6 was the 
most significant gene (IL-33 knockdown p value = 1.3 x 10-15) down-regulated and was 
associated with pulmonary function in asthmatics by GWAS. Evidence from inhibition of 
YES1 and pull-down in canine kidney epithelial cells shows that YES1 promotes tight 
junction formation by phosphorylating occludin, increasing membrane integrity measured by 
trans-epithelial electrical resistance228. This work has not been followed up in airway 
epithelium, but would suggest that asthmatics would have higher YES1 expression, perhaps 
partially restoring membrane integrity. The most significantly (IL-33 knockdown p value = 
5.1 x 10-15, Table 6.6) up-regulated gene associated with asthma and hayfever was EDIL3. 
The gene codes for DEL1 (developmental endothelial locus-1), is expressed on endothelial 
cells and binds with low strength to LFA-1 on neutrophils. In physiological flow conditions of 
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the vasculature, this adhesion is weaker than the shear forces and DEL1 inhibits neutrophil 
infiltration; as shown in mice by Edil3 knockout, or anti-ICAM-1 injection increasing LPS-
induced neutrophil BAL infiltration229. Further, dosing mice with Del-1-Fc prior to LPS 
stimulation was found to cause a decrease in neutrophil influx229. The focus of the mouse 
studies was the role of Del-1 in the endothelium, whether Del-1 has the same role in the 
airway epithelium remains to be seen.  
From the IL-33 differentially expressed and GWAS-associated inflammatory genes, IL1RL1 
and FOS are well studied and involved in pro-inflammatory responses. Increased levels of 
these products could set up a hyper-inflammatory environment in the airways as seen in 
asthma. Although the in vitro work conducted in Chapter 4 (Section 4.3.2) revealed NHBEs 
to be unresponsive to IL-33 stimulation, it is possible that co-stimulation may be required in 
these cells or that cell culture does not recapitulate the true in vivo environment. HLA-G was 
found to be decreased by IL-33 knockdown and further to its GWAS association, has been 
found to be increased in atopic asthmatic serum249. Matrix metalloproteinases can cleave 
HLA-G from the membrane to make soluble HLA-G, which inhibits natural killer (NK) cell 
cytotoxic responses250. Stromal cell IL-15RA also has a role in inhibiting NK and T cells; IL-
15RA can bind IL-15 and recycle it to the surface without degradation. This allows IL-15 
trans-signalling to occur with the stromal cells presenting IL-15 to immune cells that undergo 
prolonged IL-15 stimulation and proliferate251. IL15RA however was found to be increased 
(Table 6.6) making it difficult to draw any firm conclusions about the effect this might have 
in terms of the innate immune response.  
6.4.3 Conclusion 
This chapter has shown that ST2 knockdown modestly altered the expression of several genes 
of interest. The majority of differentially expressed genes upon IL-33 knockdown were not 
affected by ST2 knockdown, showing that the receptor is not involved in the expression 
changes observed in Chapter 5. Exogenous stimulation using IL-33 in NHBEs (in Chapter 4) 
did not cause any IL-6 or IL-8 secretion, suggesting that the expression changes upon ST2 
knockdown could be evidence of an IL-33 independent role of ST2 or that IL-33 signalling 
alters cytokine secretion when co-stimulated with IL-1ß. 
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7. ChIP-Seq of IL-33 
7.1 Introduction 
The investigations in Chapters 5 and 6 have shown that intracellular IL-33 influences the 
transcriptome of bronchial epithelial cells. The direct mechanisms behind this effect however 
have not been elucidated.  
It has previously been reported using over-expression of short IL-33 peptide sequences and 
epitope-tag pull-down, that IL-3340-58 binds to the acidic pocket of the H2A-H2B histone 
dimer77. Whilst this interaction was robustly demonstrated, this was not carried out for full-
length IL-33, making it unclear whether full length acts in the same manner as the smaller 
chromatin binding peptide. Other protein binding capacities have been reported with murine 
IL-33 immunoprecipitating with p65 and p50 of the NF-κB complex78. When this interaction 
was further investigated, murine IL-33 reduced NF-κB binding to DNA (determined by 
EMSA) as well as its in vitro activity (determined by a luciferase assay). Furthermore, over-
expression of murine IL-33 led to a slight delay in the inflammatory response of HEK293 
cells upon IL-1ß stimulation78. Finally, Shao et al. showed that human IL-33 co-
immunoprecipitates with the histone methyltransferase SUV39H1117. These studies appear to 
suggest that IL-33 acts as a repressor, either through chromatin organisation or through 
inhibiting NF-κB binding (see Section 1.2.6.1 for some potential roles proteins in the 
nucleus).  
Homology studies of IL-33 have revealed a helix-turn-helix domain64 and along with its 
constitutive localisation in the nucleus, this has led to the presumption that IL-33 binds 
directly to DNA. Shao et al. reported enrichment of IL-33 by ChIP-qPCR at the promoter of 
IL1RL1117, demonstrating a 2-3 fold enrichment. Ni et al.118 have shown that over-expressed 
IL-33 binds at a 4-6 fold enrichment to the IL13 promoter region. ENCODE guidelines 
suggest that an enrichment threshold of 4-fold for any ChIP-Seq120. It logically follows that 
this threshold should be applied to ChIP-qPCR experiments. The enrichment at the promoter 
of IL1RL1 does not attain this recommended threshold, either due to a lack of ChIP 
optimisation or the enrichment itself being an artefact of the assay. There is currently a 
paucity of data and understanding of the nuclear role of IL-33. This may be due to much of 
the interest in IL-33 being focused on its role as a cytokine. Alternatively, it may be due to 
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technical issues such as the lack of specific antibodies suitable for ChIP. A final reason for 
this may be that that IL-33 does not bind to DNA.  
There are several methods available to determine or validate the DNA-binding sites of 
proteins. If a binding site is known, this could be validated in an EMSA. The putative binding 
site DNA is radiolabelled and incubated with increasing amount of the protein of interest. 
These mixtures are migrated by gel electrophoresis and imaged, where mixtures with 
increasing amount of protein should slow the migration of the DNA. Imaging of these gels 
validates that the protein is sufficient to bind to DNA alone however as the DNA binding site 
needs to be known in advance the method is not useful for finding new binding sites.  
New DNA-binding sites of a protein are based upon chromatin immunoprecipitation. Here, 
the cells are fixed with formaldehyde to form a reversible bond between the DNA and the 
protein. The nuclei are extracted, lysed and the chromatin sheared to form small fragments of 
DNA (ideally 100-500 bp in size) with the proteins still fixed. Sheared chromatin is then 
added to magnetic beads the latter being coated with antibodies for the protein of interest, and 
left to bind at 4ºC. A series of washes then removes any chromatin that is non-specifically 
bound to the beads, leaving just the chromatin that is bound by the antibody. Formaldehyde 
cross-links are reversed upon heating and proteinase K is used to degrade residual proteins in 
order to elute DNA from the beads.  
DNA eluted from the immunoprecipitation can be quantified by RT-qPCR (ChIP-qPCR), 
microarray (ChIP on Chip) or next generation sequencing (ChIP-Seq). RT-qPCR can be used 
to validate the ChIP efficiency by determining the enrichment of DNA for a known binding 
site compared to a negative locus. The relative enrichment is calculated by dividing the 
enrichment of the pull-down by the negative control pull-down (usually a non-immunised IgG 
of the same isotype as the pull-down antibody). This technique however, does not lend itself 
to high throughput novel binding site detection, as all primers must be designed per locus.  
ChIP on chip has largely been surpassed by ChIP-Seq with the decrease in the cost of 
sequencing. For ChIP-Seq, libraries are made from the ChIP and from DNA purified from the 
input chromatin, and both libraries are then sequenced. After mapping to the reference 
genome, enrichment of reads is determined relative to the input control and is known as peak 
calling. Peaks are loci where there is enrichment of ChIP DNA reads and have a characteristic 
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normal distribution when read density is plotted against the genomic location. ChIP-Seq is 
therefore an ideal technique to measure the global binding sites of IL-33 and was used.  
The aim of this chapter was to determine the DNA binding sites of IL-33, if they exist, and 
thereby determine globally the genes that may be directly altered by IL-33. The use of ChIP-
Seq will additionally allow for potential co-factors to be identified, if a motif similar to a 
binding motif of a known transcription factor is found.   
 182 
7.2 Methods  
7.2.1 Cell culture 
Cells were seeded in 100 mm tissue culture dishes (Nunc). For chromatin harvesting using 
Normal Human Bronchial Epithelial cells (NHBEs), cells were seeded at 1.5 x 106 cells per 
dish and 4 hours after seeding, the media was changed for un-supplemented basal growth 
epithelial media before harvesting 16 hours later when cells were at 80% confluence. For 
experiments involving the 16HBE cell line overexpressing fl-IL33-HA, cells were seeded at 
1.4 x 106 per dish and left for 16 hours in growth media. At ~70% confluence cells were 
transfected with 1 µg of fl-IL33-HA plasmid as per Section 2.3.1.3 for 24 hours.  
NHBE samples were harvested at passage 3 and 16HBE cells were harvested between 
passages 11 and 17.  
7.2.2 Chromatin immunoprecipitation  
Chromatin immunoprecipitation was initially carried out using the Millipore EZ-Magna ChIP 
HiSens kit and then later using the Millipore EZ-Magna ChIP A/G kit. For both, the kit 
instructions were followed with the same modifications (Section 2.7).  
7.2.2.1 Fixation and chromatin shearing 
Cells were grown and fixed in 100 mm dishes; one dish was reserved and a cell count 
performed in order to provide a representative total cell number per dish. The other dishes 
were fixed using a final concentration of 1% formaldehyde, quenched using glycine and 
harvested as per Section 2.7.1. Chromatin was extracted at 2 x 107 cell equivalents per mL 
and sheared using the Covaris S2 for NHBE samples or Covaris M220 for 16HBE samples. 
Optimum shearing conditions for NHBEs using the Covaris S2 were 10 minutes of shearing 
at 20% duty cycle, an intensity of 5 and 200 cycles per burst. Optimum shearing for 16HBE 
chromatin using the Covaris M220 was 10 minutes of shearing with an average incident 
power of 3.8 Watts, peak incident power at 75 Watts, duty factor of 5% and 200 cycles per 
burst. Sheared DNA was then centrifuged at 10,000 g for 10 minutes at 4ºC, to pellet any 
insoluble material, before being carefully transferred to a new tube.  
To validate that chromatin shearing had been achieved 10 µL (2 x 105 cell equivalents) of un-
sheared DNA and 10 µL of sheared DNA (2 x 105 cell equivalents) were treated with RNase 
A and Proteinase K. Each sample was made up to 25 µL in kit-supplied ChIP Elution buffer 
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with 500 ng of RNase A (Roche) and 1 µL of kit-supplied Proteinase K added. After mixing 
well these were incubated on a thermocycler set to 62ºC for 2 hours before running an aliquot 
(10 µL) on a 1.2% agarose gel (Section 2.2.1). The NEB purple loading dye without SDS was 
used in these gels as the dye does not absorb light and therefore the entire shearing size could 
be resolved without any shadowing issues. Shearing was optimised to produce DNA that had 
a length between 100 – 500 bp.  
7.2.2.2 Immuno-precipitation  
Immuno-precipitation (IP) was carried out using 1 x 106 cell equivalents of sheared chromatin 
per IP as described in Section 2.7.3. The IP of interest as well as a positive control 
(H3K4me3) and negative control (normal rabbit IgG) was carried out. Chromatin was 
incubated with kit-supplied protein A/G beads and 1µg of monoclonal antibody or 6 µg of 
polyclonal antibodies (see Appendix III for antibodies used). The same amount of sheared 
chromatin was taken through the protocol without magnetic bead separation or washes to act 
as an input control. After beads were washed by resuspension and separation on a magnetic 
stand (using kit supplied buffers in order: low salt wash buffer, high salt wash buffer, LiCl 
wash buffer and TE buffer) the beads were resuspended in ChIP elution buffer. Next 
following addition of RNase A, samples were incubated shaking at 62ºC for 16 hours in order 
to reverse formaldehyde crosslinks and remove RNA contamination. After this Proteinase K 
was added to the samples followed by a 2 hour incubation at 62ºC in order to digest residual 
protein in the sample and aid additional reversal of crosslinks. Beads were then separated 
using the magnetic stand and the eluted DNA purified using the kit supplied spin columns 
with a final elution in 50 µL of kit-supplied Elution Buffer “C”. Purified ChIP DNA was kept 
on ice for RT-qPCR validation of successful ChIP and DNA quantification by PicoGreen 
(Thermo Fisher) (Section 2.7.4). The ChIP DNA was then frozen at -80ºC until library 
preparation.  
7.2.2.3 RT-qPCR validation of Immuno-precipitation  
Relative standard curve RT-qPCR using 2 µL of sample in a total reaction volume of 10 µL 
(Section 2.4.4) was used to determine that the ChIP was successful for the positive control 
(H3K4me3 pull-down) compared to the negative control (normal rabbit IgG pull-down). 
Primers were designed and tested for the promoters of a positive control region (GAPDH, see 
Appendix I) and negative control region (HBB, ß-globin, see Appendix I). Input DNA was 
serially diluted (1/10) ranging from 1/5 to 1/50,000 and used as a standard for quantification. 
ChIP DNA for both control-IPs were diluted 1/5 and these were quantified as a fraction of the 
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input DNA for the positive and negative control regions. The enrichment for each antibody 
was determined by dividing the quantity at the positive control region by the quantity at the 
negative control region. The relative enrichment was then determined by dividing the positive 
control-IP enrichment by the negative control-IP enrichment.  
7.2.3 ChIP sequencing 
7.2.3.1 Library preparation 
Library preparation was carried out using 5 ng of DNA, as per Section 2.7.5.1. For NHBE and 
16HBE samples with Cook-3 antibody pull-down, 15 rounds of PCR were used. For 16HBE 
experiments where fl-IL33-HA (Section 3.3.4.1) was overexpressed in conjunction with a HA 
pull-down, 14 rounds of PCR were used. Bioo Scientific adapter barcodes 4 and 6 (Illumina 
barcodes AR006 and AR012 respectively) were used for the pull-down and input libraries 
respectively. These barcodes were chosen for use together as they allow for optimum 
discrimination for de-multiplexing reads after sequencing 
7.2.3.2 Determination of library concentration 
The average sizes of libraries were determined by running 1 µL of library on the High 
Sensitivity kit for the 2100 Bioanalyzer (Section 2.7.5.2). Using this in combination with RT-
qPCR quantification using the KAPA Library Quantification Kit (Section 2.7.5.3) the 
concentration of each library could be determined. This was then used to allow equi-molar 
pooling of libraries with the concentration of the pooled library then determined in the same 
manner on the day of the sequencing run.  
7.2.3.3 Sequencing run 
Sequencing was done using 150 cycle (2x75 paired-end) V3 MiSeq kits on an in-house 
MiSeq sequencer as per Section 2.7.5.4. A 5% PhiX spike was used in order to help with 
library diversity and initial focusing, as well as acting as a control for identifying if any 
sequencing problems arose. The loading concentration of libraries aimed to achieve cluster 
densities, 800-1,000 x103 clusters per mm2.  
7.2.4 ChIP-Seq analysis 
Analysis of reads was done using a custom pipeline and an overview of the ChIP-Seq analysis 
is given in Figure 7.1.  
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Figure 7.1 Schematic of ChIP-Seq analysis pipeline 
Main processing steps in analysis pipeline are shown from with programs used in parentheses. 
Arrows show flow of processing steps, when these change colour the processing starts at the 
beginning of the next section (left to right).  
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7.2.4.1 Quality control and pre-processing 
De-multiplexed reads were transferred from the MiSeq sequencer for analysis. FastQC 
(Version 0.3.11252) was run to evaluate the read quality and potential sources of 
contamination or error. Samples found to have adapters in their sequence were trimmed using 
Trim Galore! with paired end and default settings (Version 0.4.1253). This ensures that the 
parts of any sequence that contain Illumina adapter sequence or have a Phred score of less 
than 20 are trimmed. The Phred score is the logarithmic probability of a base call being 
wrong, where a score of 10 gives a 1/100 chance of the base call being incorrect. Furthermore 
it ensures that only paired sequences that each have a minimum read length of 20 bp are 
retained.  
7.2.4.2 Mapping of reads 
Bowtie 2 (Version 2.2.3254) was used to map trimmed reads to the GRCh38/Hg19 reference 
genome with settings for paired reads. Additional parameters included allowance for two 
alignments per read to be reported, with one mismatch in the seed region as well as a 
maximum-paired end span-length of 1,000 bp. 
Next Samtools (Version 1.2255) was used to remove the secondary alignments and low 
mapping-quality reads (using the samflag 256 and a Bowtie2 MAPQ score of 2) and the result 
was output as a BAM file. This involved the multiple sequencing runs of a library being 
merged using the Samtools merge function. Next, mate-pair reads spanning more than 1,000 
bp or different chromosomes were removed. This was achieved by creating two files: reads 
where only one of the mate pairs mapped (singletons) and reads where both mate pairs were 
mapped within 1 Kb of each other (properly paired reads). These two files were then merged 
to obtain a final BAM file that was indexed using the Samtools index function. 
7.2.4.3 Peak calling and analyses 
Peak calling was carried out using MACS (Version 1.4.2256) with the Homo sapiens genome 
size, comparing the ChIP library to the Input library. PeakAnalyzer (Version 1.4257) was used 
to split any large peaks that consisted of distinct peaks that were overlapping or in tandem. 
Peaks may map to contigs where there is not sufficient evidence to place them on a specific 
chromosome (ChrUn or ChrN) These ambiguous mapping peaks were  removed by 
PeakAnalyzer. For visualisation of reads, a Bedgraph was created from each BAM file using 
the genomeCoverageBed (BEDTools Version 2.25.0258) program, and this was then converted 
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into a BigWig file by bedGraphToBigWig (BEDTools) using the Hg19 reference genome. 
Finally IGV (Version 2.1.24259) was used to visualise called peaks and mapped reads.  
HOMER (Version 4.8172) was used to determine whether the peaks contained any motif 
enrichment, i.e. transcription factor motifs. De novo motif enrichment was chosen with a peak 
size extension of 50 bp, this was done at a motif size of 6-9 bp.  The HOMER program suite 
was used for genomic region enrichment analyses (running annotatePeaks with the 
genomeOntology setting), within 1 Kb of a ChIP-Seq peak.  
GOSeq (Version 1.24260) was used to determine gene ontology of genes within 200 bp of 
ChIP-Seq peaks. This is achieved by use of a Wallenius approximation to adjust the 
weighting of each gene for the hypergeometric distribution. GOSeq was used instead of 
HOMER because GOSeq weights transcripts by their length. This is important because in 
contrast to microarray quantification, larger transcripts are more likely to overlap with ChIP-
Seq peaks by chance due to their size260.  
  
 188 
7.3 Results 
7.3.1 Preliminary ChIP-Seq experiments 
Here, preliminary experiments are described briefly, but are not discussed in detail in order to 
focus on the final successful ChIP-Seq (Section 7.3.2). ChIP experiments were carried out 
using NHBEs with Cook-3 and Nessy-1 antibodies (Appendix III). Using 5 ng of DNA from 
the input control and Cook-3 pull-down, library preparation yielded sufficient material for 
sequencing. The Nessy-1 pull-down was not successful, with the same input amount of DNA. 
Consequently, the input and Cook-3 libraries were sequenced using an in-house MiSeq 
machine (Section 7.2.3). The read depth achieved was not sufficient to show valid ChIP-Seq 
peaks, but allowed for preliminary analysis and determination as to whether more sequencing 
was warranted. The total numbers of reads from the input and Cook-3 pull-down libraries 
were 8.3 x 106 and 6 x 106 reads respectively. Analysis of the sequencing (Section 7.2.4) 
showed no significant peak enrichment. It appeared that either the Cook-3 antibody had too 
low affinity for ChIP with endogenous levels of IL-33 or IL-33 did not directly interact with 
DNA.  
In order to increase the chance of a successful pull-down, fl-IL33-HA plasmid (full length IL-
33 with an HA-tag at the C’ terminus, developed in Section 3.2.3.1) overexpression was 
carried out in 16HBEs. Here again, Cook-3 antibody pull-down was used and library 
preparation was successful. Sequencing was carried out over two runs where the total reads 
from the input and Cook-3 pull-down libraries yielded 25 x 106 paired end reads and 12.8 x 
106 paired end reads respectively. Here again, analysis did not yield significant peak 
enrichment. As it appeared that Cook-3 and Nessy-1 may be unsuitable for ChIP, experiments 
were carried out using the 16HBEs overexpressing fl-IL33-HA in conjunction with an HA 
pull-down. 
7.3.2 IL-33 overexpression and HA pull-down ChIP-Seq 
7.3.2.1 Chromatin shearing and ChIP 
16HBE overexpression of HA-tagged full length IL-33 was taken forward for pull-down 
using the HA antibody. Chromatin was extracted from the cells and sheared as detailed in 
Section 7.2.2.1. Optimal shearing was achieved as shown in Figure 7.2. Here, the largest 
detectable fragment in the sheared chromatin was 1 Kb in size and the majority of the DNA 
was sheared to 100-300 bp.  
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Using this chromatin, ChIP was performed (Section 7.2.2.2) with RT-qPCR of the positive 
control pull-down (H3K4 methylation) and negative control pull-down (normal rabbit IgG) 
showing a technically successful ChIP (Figure 7.3). Whilst IL-33 has been shown to be 
enriched at the promoter of IL13118, at the time of experimentation this was not published and 
therefore only technical success of ChIP could be shown using other pull-downs. Another 
complication of not having a direct assessment of successful ChIP for IL-33 was that 
optimisation of ChIP, a critical part of getting high quality enrichment, could not be done. 
The RT-qPCR revealed that H3K4 methylation pull-down, when compared to the normal IgG 
control, had a median enrichment of 14.9 (12.7 – 16.1) fold at the GAPDH promoter. The 
median enrichment at the HBB (ß-globin) promoter was 1.1 (0.6 – 1.3) fold showing no 
enrichment at the negative control locus as expected. The relative enrichment of the ChIP for 
H3K4 methylation pull-down was therefore 13.5-fold showing a technically successful ChIP, 
HA-pull down IP was taken forwards with the input DNA for library preparation.  
 
Figure 7.2 Optimal shearing of 16HBE chromatin 
16HBE cells were transfected with the overexpression plasmid containing HA-tagged full 
length IL-33. The chromatin from these cells were harvested and sheared before running on 
an agarose gel and imaged. Labels above lanes indicate the ladder used, DNA from untreated 
chromatin or DNA from optimally sheared-chromatin. The majority of the sheared chromatin 
DNA was between 100 and 300 bp in size, with a maximum size of 1,000 bp detected.  
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Figure 7.3 RT-qPCR validation of ChIP 
Enrichment at the promoter of GAPDH (positive locus) and HBB (negative locus) of 
H3K4me3 pull-down compared to the relative levels using normal rabbit IgG pull-down. The 
median relative enrichment at the promoter of GAPDH is 13.5 fold when compared to the 
HBB (ß-actin) promoter, confirming that the ChIP has been successful. Median and range is 
shown for three technical replicates. 
7.3.2.2 Library preparation and sequencing 
Library preparation was carried out using Bioo Scientific adapters (Section 7.2.3.1).  Running 
1 µL of each prepared library on a high sensitivity dsDNA Bioanalyzer chip (Section 2.7.5.2) 
revealed two peaks for the input library (Figure 7.4-A), with maxima at 354 and 715 bp. The 
354 bp peak was the expected peak since the bead size-selection enriches for DNA between 
300-400 bp. The second peak was approximately double the size of the first with two-thirds 
its intensity. A doublet peak can occur when the adapters bind two separate amplicons 
together (known as bubble-products). These bubble products do not affect the sequencing 
however261. For the HA pull-down library, two peaks were seen (Figure 7.4-B) at 500 bp and 
715 bp, with a shoulder at 350 bp. The shoulder was a fifth of the intensity of the other two 
peaks and as for the input library it was likely that the adapters binding separate amplicons 
together could have caused the two larger peaks.  
Consequently in order to determine whether the larger peaks were bubble-products, the 
libraries were denatured for two minutes at 70ºC and then run on a Bioanalyzer RNA pico 
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chip. The denaturation separates a large proportion of the double strand DNA libraries to 
single stranded DNA (which is detected by the RNA pico chip) that should make the smaller-
sized peak the most abundant. For the input library (Figure 7.5-A), the doublet peak decreased 
to a third the intensity of the singleton peak. The singleton peak of the HA pull-down library 
(Figure 7.5-B) was the most abundant peak, with a doublet peak at about two-thirds the 
intensity. Both of these results suggested that the larger peak on the DNA chip (double 
stranded library) was composed of amplicon-dimers and the heat denaturation did not 
completely convert all double-stranded DNA to single stranded DNA. As a part of the loading 
process of sequencing preparation, the libraries are denatured into single strands and therefore 
this did not pose a problem.  
Both libraries appeared to be the correct size and were quantified by RT-qPCR (Section 
7.2.3.2) to enable equi-molar pooling at 3.2 nM.  On the day of sequencing pooled libraries 
were quantified by RT-qPCR to allow for optimum cluster density. Sequencing was 
performed over two runs in order to have sequencing depth, loading 12.5 pM libraries per run 
to achieve optimal cluster density (Section 7.2.3.3).  
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Figure 7.4 Bioanalyzer traces of 16HBE-HA ChIP libraries 
Size distributions of libraries are shown with markers at 35 and 10,380 bp on a high 
sensitivity dsDNA chip. Fluorescence units (FU) are the raw intensity values from the 
Bioanalyzer. Markers are shown at 35 and 10,380 bp. A) Input library has two peaks at 354 
and 715 bp. B) HA pull-down library has three features: a shoulder (small peak) a fifth of the 
intensity of the other peaks at 350 bp, a peak at 550 bp and the largest peak at 750 bp.  
A) 
B) 
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Figure 7.5 RNA Bioanalyzer traces of denatured 16HBE-HA ChIP libraries 
Libraries were denatured at 70ºC for 2 minutes followed by analysis on the Bioanalyzer Pico 
RNA chips. Fluorescence units (FU) are the raw intensity values of the Bioanalyzer and a 
marker is shown at 25 bp. A) Input library has one main peak at ~400 bp and a larger peak at 
a third of the intensity at ~1,000 bp. B) HA pull-down library has a largest peak at ~300 bp 
and a second at two-thirds the intensity at ~1,000 bp.   
A) 
B) 
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7.3.2.3 Sequencing quality control and mapping 
Sequencing yielded 16.7 and 16.8 million paired-end (total of 33.5 million paired end reads, 
i.e. 67 million total reads), 75 bp reads passing the MiSeq quality filter. The MiSeq de-
multiplexing was successful for 95% of the read pairs, with 3.5% of sequences accounting for 
the PhiX spike. The total read number throughout the quality control and mapping is shown in 
Table 7.1. A quarter of the reads from the HA pull-down library and 23% of the input library 
reads could not be mapped to the reference genome. Using Trim Galore! to trim any bases 
that had a Phred score less than 20 and to remove any adapters in sequencing reads (Section 
7.2.4.1), resulted in 300,000 reads being discarded. The Phred score for the sequencing of 
each library (i.e. HA pull-down and input), both before and after trimming was high, as 
shown in Figure 7.6. Paired-end mapping using Bowtie2 successfully mapped 48.4 million 
reads to the reference genome (GRCh38/Hg19). Further analysis using Samtools identified 
that 40% of the sequences from both libraries (HA pull-down and input) were mate-pairs that 
spanned chromosomes or more than 1 Kb. For ease of reference these were called “>1Kb 
mate-pairs”. This could have been due to an artefact of PCR amplification or concatamers 
formed in ligation. Alternatively, the 16HBE cells have undergone SV40 transformation and 
cell culture passage that may have caused chromosomal crossovers and rearrangement. In 
order to avoid possible confounding of the results, the >1Kb mate-pairs were removed from 
the analysis. 
 
Table 7.1 ChIP-Seq read number through analysis pipeline 
Total numbers of reads are shown per each stage of the analysis pipeline. Of note, 25% of HA 
pull-down reads could not be mapped and 23% of input reads could not be mapped. Of these 
mapped sequences, 40% of the HA pull-down and input sequences contained a mate-pair that 
spanned different chromosomes or more than 1 Kb; these were removed to avoid potential 
bias. 
Pipeline Stage HA pull-down reads (x106) 
Input reads 
(x106) 
De-multiplexed 28.2 35.7 
Trimmed 28.0 35.6 
Mapped 21.1 27.3 
Removed >1Kb mate-
pairs 12.6 16.3 
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Figure 7.6 Sequencing quality  
Phred score is shown per library before and after trimming by sub-graph. Per sequencing 
read, the mean (black point) and range between the 10th and 90th percentile is shown (grey 
bar). Graphs show that the majority of reads have base-calls of high certainty, before and after 
trimming.  
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7.3.2.4 Peak calling and down-stream analysis 
The reads remaining after pre-processing (12.6 million and 16.3 million for the HA pull-down 
and input respectively) to identify ChIP-Seq peaks using MACS. This resulted in 3,541 peaks 
being identified the HA pull-down compared to the input control, with default threshold 
values: p value threshold of 1 x 10-5, at least 5-fold enrichment above background and an 
FDR of > 20%. Individual peaks that overlap or are in tandem may be called as a single peak 
by MACS and PeakAnalyzer was used to split these into distinct peaks. PeakAnalyzer also 
removed any peaks that mapped to ambiguous contigs (Section 7.2.4.3), reducing the total 
number of peaks to 3,485.  
To determine if any features of the genome were enriched with ChIP-Seq peaks, the 
hypergeometric algorithm in HOMER was used to analyse for genomic region enrichment 
within 200 bp of a ChIP-Seq peak (Table 7.2). HOMER defines the promoter region as 1,000 
bp upstream to 100 bp downstream of the transcription start site. This showed enrichment for 
exons, genes and promoters when compared to a random model, suggesting the peaks 
identified have a potential role in gene regulation. This was supported by the fact that 
conversely, there was a depletion of intergenic, intronic and 3’ untranslated regions. Areas 
with increased CpG content and 5’ UTRs we also enriched. ChIP-Seq peaks that were within 
200 bp of exons, gene bodies and promoters were determined in R. This showed 1,739 gene 
bodies overlapped with peaks, 739 genes where exons overlapped (of these, 249 were the first 
exon) and 521 promoters overlapped.  
In order to further investigate the genes that had a ChIP-Seq peak within 200 bp, gene 
ontology enrichment analysis was performed using GOSeq (Section 7.2.4.3). GOSeq accounts 
for the increased chance of an overlap of a ChIP-Seq peak for longer transcripts; an un-
adjusted hypergeometric method was used for promoters, as their size was constant. The 
results of gene ontology enrichment by overlap with genes, promoters and exons are shown in 
Table 7.3. Similar gene ontology terms were found between genomic features. For example, 
overlap with genes and exons enriched for central nervous system development related terms. 
A potential role in development was observed; exons were enriched for morphogenesis of 
branching epithelium, where genes were enriched for tube development and cell-cell 
adhesion.  
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Table 7.2 ChIP-Seq peak genomic region 
HOMER-derived genome ontology values of genomic regions within 200 bp of peaks are 
shown, ordered by p value. Fold enrichment was calculated by dividing the number of base-
pairs in genomic regions by the expected number of base-pairs if peaks were randomly 
allocated throughout the genome. All p values are corrected for multiple testing using 
Benjamini and Hochberg’s method.    
 
Genomic 
Region 
Fold 
Enrichment 
Percent 
Base-pair 
Overlap 
p Value 
CpG Islands 24.7 27.0 < 1 x 10-300 
Intergenic -2.1 42.1 < 1 x 10-300 
Exons 3.4 13.2 2.4 x 10-114 
Introns -1.4 42.8 4.1 x 10-112 
Gene 4.0 9.3 1.3 x 10-96 
5' UTRs 12.4 3.7 1.8 x 10-93 
Promoters 4.3 7.1 1.1 x 10-78 
3' UTRs -2.5 0.6 9.4 x 10-7 
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Table 7.3 Gene ontology of genes overlapping with ChIP-Seq peaks 
GOSeq was used to calculate the gene ontology of genes within 200 bp per genomic feature. 
The most specific and enriched terms are shown with a fold enrichment > 1.5 and p < 0.05. 
For transcripts and exons, an adjusted hypergeometric test was used that takes into account 
the transcript length; for promoters (1,000 bp upstream to 100 bp downstream of the 
transcription start site) an unadjusted hypergeometric test was used. All p values are corrected 
for multiple testing using Benjamini and Hochberg’s method.   
  
Feature 
Overlap Term ID Term 
Fold 
Enrichment p Value 
Gene GO:0007156 Homophilic cell adhesion via plasma membrane adhesion molecules 3.1 2.4 x 10
-5 
Gene GO:0098742 Cell-cell adhesion via plasma-membrane adhesion molecules 2.5 1.6 x 10
-4 
Gene GO:0007417 Central nervous system development 1.6 1.1 x 10-3 
Gene GO:0035295 Tube development 1.6 2.6 x 10-2 
Promoter GO:0098655 Cation transmembrane transport 2.0 8.5 x 10-3 
Promoter GO:0071805 Potassium ion transmembrane transport 3.2 2.0 x 10-2 
Exon GO:0007417 Central nervous system development 2.1 4.5 x 10-4 
Exon GO:0042127 Regulation of cell proliferation 1.5 1.6 x 10-2 
Exon GO:0010941 Regulation of cell death 1.5 3.2 x 10-2 
Exon GO:0061138 Morphogenesis of a branching epithelium 2.7 4.4 x 10-2 
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Next, in order to identify peaks containing transcription factor motifs, de novo motif analysis 
was carried out in HOMER. Peak sequences were extended by 50 bp for both de novo and 
known motif databases, with lengths of de novo motifs being set from 6-9 nucleotides. For 
motif analysis the ChIP-Seq peaks were filtered the MACS-derived false discovery rate of 5% 
or less, leaving 614 peaks. Only one known motif was detected with an enrichment of more 
than 4 above background, PU.1:IRF (i.e. the motif of PU.1 interacting with IRF [interferon 
regulatory factor]; 6.9 fold, p =1 x 10-28). The transcription factor PU.1 is known to interact 
with members of the IRF family262 (which are involved the JAK-STAT signalling pathway), 
suggesting a possible binding site involved in regulating inflammatory genes. From de novo 
detection, 14 motifs were found above the HOMER-suggested false discovery threshold of p 
= 1 x 10-12 and these are shown in Figure 7.7-A. Of these, motifs (2, 3 and 4) similar to GLIS 
(Figure 7.7-B), STAT3 (Figure 7.7-C) and SP4 (Figure 7.7-D) had fold enrichments greater 
than 10-fold, p values less than 1 x 10-150 and a known motif match of greater than 0.7. Motif 
5 had a high fold change (41 fold, p = 1 x 10-114) with a high match score for a known motif 
(0.73), yet upon inspection the matching motif was not a convincing match. Motif 12 had a p 
value of 1 x 10-24 and a fold enrichment of 4.8, yet it had a motif similarity score of 0.95 to 
ZBTB3. Little is known about the ZBTB3 transcription factor except for its role in the 
regulation of oxidative stress and apoptosis263.  
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Figure 7.7 De novo motifs and the most similar known motif 
A) The 14 HOMER-derived de novo motifs within 50bp of ChIP-Seq peaks are shown by 
their p value, motif match score (ranging from 0-1) and fold enrichment compared to a 
randomised set of peaks (colour scale). (B-D) De novo motifs logos and their best match from 
known motif databases. The height of each nucleotide corresponds to the proportion of the 
nucleotide per position.  
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In Chapter 5, where IL-33 knockdown upon IL-1ß stimulation was investigated, a total of 
1,509 genes were differentially expressed. Overlap between this gene list and genes that had 
ChIP-Seq peaks within 1 Kb identified 147 common genes, the top 20 genes are shown in 
Table 7.4 (see Appendix VII for all genes that met this criteria). Of these EDIL3 had the 
lowest p value for differential expression and was increased along with MMP13 and 
EIF4EBP2 (eukaryotic translation initiation factor 4E-binding protein 2). Other genes of 
interest were decreased upon IL-33 knockdown, such as ANO1, PPARD and MUC1. Two of 
these products would directly alter gene expression, PPARD is a transcription factor that 
appears to be involved in airway epithelial inflammatory responses264 and inhibits PPARG, 
which is involved in murine lung development265,266. EIF4EBP2 inhibits translation initiation 
and is implicated cell proliferation267. 
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Table 7.4 Top 20 differentially expressed genes upon IL-33 knockdown overlapping with 
ChIP-Seq peaks 
Differentially expressed genes from IL-33 knockdown and IL-1ß stimulation in Chapter 5 
were filtered by their transcripts being within 1,000 bp of a ChIP-Seq peak and of these, the 
top 20 by differential gene expression p value are shown. Median expression was calculated 
from the fluorescence units across the probesets for all samples. The table is separated by 
increased or decreased expression upon IL-33 knockdown across the stimulation time course. 
Multiple testing correction for p values was done using Benjamini and Hochberg’s method.  
 
Gene 
Symbol 
Median 
Expression 
Maximum 
Fold 
change 
p Value 
Increased 
EDIL3 324.0 2.5 5.1 x 10-15 
FBN1 61.1 3.0 8.1 x 10-14 
SESN1 69.1 2.0 5.5 x 10-13 
TP53INP1 836.4 1.8 7.8 x 10-13 
INPP5D 225.9 1.9 1.8 x 10-11 
SFRP1 133.9 1.9 4.3 x 10-11 
SLC39A8 82.6 2.2 5.2 x 10-11 
MMP13 104.1 7.1 1.5 x 10-10 
EIF4EBP2 2429.4 1.4 3.1 x 10-10 
EPS8 166.8 2.1 3.2 x 10-10 
MBNL2 753.1 1.6 5.2 x 10-10 
Decreased 
AP1G1 1086.7 -1.8 4.1 x 10-13 
GPD2 215.6 -2.6 5.5 x 10-13 
MUC1 131.5 -2.8 1.5 x 10-12 
ANO1 165.4 -2.3 2.7 x 10-12 
RELL1 102.5 -2.2 9.6 x 10-12 
PPARD 716.7 -2.0 6.9 x 10-11 
MROH6 57.3 -1.8 6.7 x 10-10 
OSBP2 35.2 -1.9 7.0 x 10-10 
GPC4 128.7 2.6 8.4 x 10-10 
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7.4 Discussion 
ChIP-Seq relies on robust pull-down using antibodies that are specific for the factor of 
interest. Unfortunately, initial experiments on NHBEs and 16HBEs overexpressing fl-IL33-
HA showed that the Cook-3 and Nessy-1 antibodies were unsuitable for ChIP, despite 
working well for native IL-33 by confocal and semi-native IL-33 by Western blot (Sections 
3.3.4 and 3.3.5). Therefore an HA pull-down was carried out on chromatin from 16HBEs 
over-expressing HA-tagged IL-33. Library preparation was successful, yet there was a large 
amount of doublet peaks, where the Illumina adapters hydrogen-bond two amplicons together 
to form a loop (known as a bubble product), importantly this does not interfere with 
downstream sequencing261 
The two sequencing runs of equimolar-pooled libraries resulted in a total of 63.6 million high 
quality reads. It was notable however that upon mapping, 40% of read mate-pairs spanned 
1Kb or different chromosomes. Whether this was due to artefacts creating fusion amplicons 
or if the 16HBE genome has many chromosomal rearrangements was not clear. Single-end 
sequencing is the default for ChIP-Seq but because paired-end sequencing was used in this 
present study, it was possible to detect the span of mate-pairs. Removing these reads was the 
most stringent approach to avoid introducing bias into the analysis. In future work (discussed 
in Chapter 8), after ChIP optimisation has been carried out, an increased amount of DNA at 
the start of the library preparation and a reduced number of PCR cycles would be used to try 
and avoid this.  
Peak calling and splitting identified a total of 3,485 peaks, which were enriched for genomic 
regions that suggest gene regulation: promoters, exons and genes. Gene ontology showed that 
central nervous system development and potassium ion transport genes were enriched. This 
fits with the literature as IL-33 is expressed in glial cells268 and intracellular IL-33 has been 
shown to promote glioma cell growth124. Gene ontology terms related to asthmatic lungs were 
also enriched cell-cell adhesion, cell proliferation and morphogenesis of branching 
epithelium. This suggests that IL-33 may directly alter the expression of genes and thereby 
alter the physiology of the airway epithelium in asthma. It is interesting to note that IL-33 is 
constitutively expressed in barrier tissues115 and the cell-adhesion and proliferation 
enrichment observed would be supportive of IL-33 having a potential role in maintaining the 
tight junctions important in these barrier tissues.  
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The nervous system has previously been implicated in asthma. In a mouse model of airway 
inflammation using OVA as the inflammatory trigger, selective ablation of sensory neurones 
had no effect on the inflammatory response but these neurones were required for airway 
hyper-responsiveness269. Neurones express many receptors for sphingosine-1-phosphate 
(S1P). Mice that have been dosed with agonists to S1PR3 (a receptor for S1P) exhibit an 
increase in airway hyper-responsiveness269. As this response was absent in mice lacking 
sensory neurones the authors suggested that this is a mechanism for airway hyper-
responsiveness. This might explain the role of the major asthma gene, ORMDL3, involved in 
sphingolipid synthesis and as S1P is a sphingolipid there may be an increased propensity for 
airway hyper-responsiveness due to local S1P levels and perhaps sensory neuron activation.  
Transcription factor motif analysis of the identified ChIP-Seq peaks implicated similar 
pathways as the gene ontology analysis. Of the known motifs similar to de novo motifs, 
GLIS2 and SP4 are both involved in neuronal differentiation, further suggesting that IL-33 
may have a nervous system-specific role. A motif similar to STAT3, a mediator of 
inflammatory signalling was also found. This is of relevance as in a HDM-induced mouse 
model of asthma epithelial knockout of Stat3 resulted in a decrease in airway hyper-
responsiveness and reduction in inflammatory cell influx13. It is further interesting to note that 
eight of the top 20 overlapping genes in Table 7.4 are targets of STAT3 in mice (INPP5D, 
EPS8, MBNL2, AP1G1, GPD2, MUC1, ANO1 and PPARD270), suggesting that it is an 
important cofactor for IL-33’s nuclear role in the airway epithelium.  
One hundred and forty-seven genes were common to the differentially expressed genes upon 
IL-33 knockdown (Chapter 5) and genes with ChIP-Seq peaks nearby. Of these genes, EDIL3 
and ANO1 have been discussed in Section 6.4.2. EDIL3 may be important for immune cell 
infiltration229 and is associated with asthma and hayfever134. ANO1 is important for 
MUC5AC and MMP-9 expression and may be involved in airway remodelling221. As noted in 
Chapter 1 Section 1.1.2.1, MUC5AC is a predominant component of mucus that is produced 
by goblet cells, so is of inherent interest in asthma28. MUC1 was found to be common to 
differentially expressed genes and ChIP-Seq peaks. MUC1 appears to decrease epithelial 
barrier function in unstimulated corneal epithelial cells271. Furthermore, in NHBEs in ALI 
culture MUC1 is involved in responses to cigarette smoke that disrupt the barrier function, 
binding to ß-catenin and localising to the nucleus272.  
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Another gene in common between the differentially expressed genes (and discussed in 
Section 5.4.1) and ChIP-Seq peaks was PPARD. This encodes a transcription factor that 
notably has been reported to reduce smoke-induced TNF-α and IL-1ß release in 16HBEs264 as 
well as inhibiting PPARG265. PPARG is involved in normal airway differentiation in mice, 
with extracellular matrix gene expression being altered in Pparg knockout mice266. 
Furthermore investigations using PPARG agonists show these increase tight junction 
expression and barrier function in nasal epithelium273. Collectively this suggests that IL-33 
directly alters PPARD expression, which in turn has downstream effects altering 
inflammatory responses, extracellular matrix and epithelial adhesion.  
A final notable gene in common to the differentially expressed and ChIP-Seq peak gene lists 
was MMP13. MMP13 was increased upon IL-33 knockdown and has been shown to be pro-
inflammatory in small airway epithelial cells274. It is important to highlight that the IL-33 
knockdown and IL-1ß stimulation was carried out in NHBEs and the IL-33 overexpression in 
16HBEs.  Consequently there may be differences in the chromatin architecture or co-factors 
between these two cell types and therefore the overlap between the differentially expressed 
genes and ChIP-Seq peaks may not be truly representative but nonetheless is worth further 
exploration.  
The immunoprecipitation of over-expressed IL-33 in HEK293 cells and RT-qPCR enrichment 
at the promoter of IL13118 (Section 7.1) was not observed by the ChIP-Seq experiments in this 
chapter. This could be due to a difference in signalling, presence of co-factors or chromatin 
environment, between HEK293 cells and 16HBE cells. The two proteins shown to interact 
with IL-33 are the H2A-H2B histone dimer77 and SUV39H1117 (Section 7.1). IL-33 may 
recruit SUV39H1 to promoters or gene bodies and methylate H3K9 to repress transcription or 
directly interact with histones through the H2A-H2B acidic pocket binding. Why this is of 
note is in light of the finding in this present study, is that IL-33 was enriched at promoters, 
exons and the gene-body (Section 7.1). This could be indicative that IL33 is regulating gene 
expression by DNA methylation or histone modification over the gene-body. This is further 
supported by the function of SUV39H1, which silences gene expression by tri-methylating 
H3K9 and may suggest interaction with other epigenetic remodellers to methylate DNA275.  
A cautionary note however is that a single biological replicate is not sufficient to draw strong 
conclusions on genomic region, gene ontology and motif enrichment. This does support the 
hypothesis that IL-33  binds to DNA in a functional and specific manner although there is 
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some uncertainty in the reliability of the peaks. A large proportion of ChIP-Seq peaks may be 
due more to chance enrichment therefore finding the intersection of peaks between at least 
two biological replicates should be done for certainty (see Chapter 8). This work gives loci 
where IL-33 would be expected to be enriched and therefore would allow for ChIP 
optimisation by RT-qPCR for a higher level of signal to background reads in ChIP-Seq. A 
final limitation is that IL-33 was overexpressed and therefore some binding sites in the 
genome may not be altered at physiological levels.   
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8. Discussion  
8.1 General discussion 
The IL33 locus has shown a robust association with asthma55,56 and IL-33 is increased in 
asthmatic airway epithelium20,58. Given that IL-33 resides in the nucleus and acts extra-
cellularly via the ST2 receptor57, it has been proposed to have a dual role as a nuclear factor 
and a cytokine. The majority of research into the role of IL-33 has however focused on its 
cytokine role and little is known about its nuclear action beyond affecting the expression of a 
handful of inflammatory genes. This thesis aimed to investigate the hypothesis that nuclear 
IL-33 alters gene expression in the airway epithelium in ways that relate to asthmatic airways 
and this was investigated with three main aims.  
Chapter 3 has addressed the first aim of the project, identifying the appropriate cell lines for 
use in downstream experiments. This chapter also established optimal assays for detection of 
IL-33 at the RNA and protein level. The second aim to determine the role of IL-33 in the 
inflammatory response of the airway epithelium has been addressed by the work conducted in 
Chapters 4 to 6 inclusive by conducting knockdown of IL-33 knockdown, and its receptor 
(ST2) knockdown in NHBEs. Here, IL-33 knockdown decreased cytokine secretion upon IL-
1ß stimulation where ST2 knockdown increased cytokine secretion. Moreover, using 
microarray transcriptional profiling, the majority of gene expression changes found upon IL-
33 knockdown were not observed upon ST2 knockdown. Finally, Chapter 7 used ChIP-Seq to 
determine the DNA-binding sites of IL-33 and whilst the data is not complete enough to be 
conclusive, this adds further evidence that the transcriptional changes seen upon IL-33 
knockdown are likely due to IL-33 interacting with DNA. These final chapters (5 – 7) 
partially addressed the third aim of the project in determining the global gene expression 
targets of IL-33 and its binding sites.  
In Chapter 3, NHBEs and A549 cells were found to only express full length IL-33 by PCR 
and sequencing, whereas this was not found for two SV40-transformed cell lines (16HBE and 
BEAS-2B). This showed that the cell type used for studies is important as variants of IL-33 
would lack known domains important to the nuclear or cytokine roles (Section 1.2.3). The 
A549 cell line was selected for preliminary work that was continued in NHBEs (Chapter 4). 
An assessment of two commercial and three custom-made IL-33 antibodies found that Nessy-
1 (commercial) and Cook-3 (custom) were able to specifically detect full length IL-33 by 
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confocal microscopy and Western blot (Section 3.3.5), with Nessy-1 also detecting the 
cytokine fragment of IL-33. This was done by construction of an over-expression plasmid of 
full length and the cytokine fragment of IL-33. Both Western blots and confocal microscopy 
showed that full length IL-33 was predominantly nuclear and that the cytokine-fragment was 
cytoplasmic, as was anticipated based on the majority of the published literature for IL-33 
(Section 1.2.1).  
Investigations of the commercial IL-33 ELISAs available (Section 1.2.4) identified the 
previously unreported phenomenon of preferential detection of the cytokine fragment of IL-
33 and a lack of sensitivity to full length IL-33. This would suggest that full length IL-33 
would not be detected. Furthermore cleaved IL-33 could have enhanced cytokine activity or 
be an inactivated degradation product making the biological interpretation difficult.  In 
addition, the lack of detection of over-expressed IL-33 in cell lysate by ELISA suggests a 
failure to distinguish IL-33 over other intracellular proteins. If this is correct then IL-33 
ELISAs may only be indicative of cell death, irrespective of IL-33 concentrations. Given that 
IL-33 is released upon necrosis70,71 this is particularly concerning if correct, as it is likely that 
the ELISAs may simply measure another product of cell death. Future work using both 
recombinant and over-expression of the full length and cytokine fragment IL-33 could be 
used to design and validate an ELISA that was able to detect full-length IL-33 at the same 
sensitivity as the cytokine fragment.  
Although the recombinant cytokine fragment of IL-33 has been reported to induce cytokine 
secretion in NHBEs187, this was not found upon stimulation with 100 ng/mL in these cells 
(Section 4.3.2). Whether this was due to cell culture conditions or if there is heterogeneity in 
IL-33 responsiveness is unknown. It is interesting to note that in a different cell type, 
fibroblasts, either the age of the donor or disease status appears to affect responsiveness to IL-
33 stimulation. Airway fibroblasts from paediatric severe therapy resistant asthmatics 
(PSTRA) secreted collagen upon IL-33 stimulation, where those from healthy adults did 
not154. This variability suggests either a predisposition to IL-33 responsiveness or perhaps a 
specific stage in development where IL-33 inflammation may affect the structural cell 
populations.  Alternatively, the lack of NHBE responsiveness to IL-33 stimulation could be 
due to only studying IL-6 and IL-8 secretion, future work using a global profiling method of 
gene expression such as microarray would show if there is a response that is not related to the 
cytokine secretion.  
 209 
Though not the focus of this thesis, it is interesting to note that IL33 decreased in NHBEs 
across an IL-1ß stimulation time-course whereas it did not in the A549 cells line (Section 
4.3.6). This was abrogated when the stimulation was carried out in fully supplemented growth 
media. The expression of IL-33 in other cell types has been shown to require EGF184 or 
retinoic acid194 which are present in the supplemented growth media used. Any future work 
investigating the intracellular role of IL-33 should be carried out in supplemented media 
rather than conditioning the cells in un-supplemented media, in order to avoid this 
constitutive decrease in IL-33.   
Cytokine secretion (IL-6 and IL-8) upon IL-33 knockdown and IL-1ß stimulation in the A549 
cell line and NHBEs showed that nuclear IL-33 acts in a pro-inflammatory manner (Chapter 
4). This contrasts with HEK293 cells transfected with murine IL-3378 and knockdown in 
human epidermal keratinocytes123. This could be due to the cell type used and may suggest 
that murine and human IL-33 act differently. In Chapter 5, taking total RNA prepared from 
the NHBE IL-33 knockdown and IL-1ß stimulation (Section 4.3.3.2), global gene expression 
analysis was conducted. This identified differential expression of 1,509 genes, of which 618 
were up regulated and 893 were down regulated. Overall, IL-33 knockdown appeared to 
affect the expression of genes involved in differentiation, cell-substrate adhesion and the 
extracellular matrix. SPDEF was also decreased upon IL-33 knockdown, this codes for a 
transcription factor which is crucial in goblet cell hyperplasia29 and therefore of great interest 
in asthma. This work showed that the alteration of NF-κB targets is a small part of its role. 
Previous studies of the nuclear role of IL-33, which have focused on a small number of genes, 
most likely have missed novel functions of nuclear IL-33 in the cell types studied. Consistent 
IL-33 targets shown in synovial fibroblasts121 and endothelium119 have been validated in this 
work using NHBEs. Furthermore, the majority of gene expression changes upon IL-33 
knockdown were not found upon ST2 knockdown (Chapter 6), ruling out an autocrine 
signalling of IL-33 in airway epithelium to be the cause of differential gene expression.  
As found in Chapter 5, IL-33 knockdown caused the IL-33 receptor, ST2 (IL1RL1) to 
decrease at the mRNA level. ST2-knockdown alone appears to have an effect on a small 
number of genes (Chapter 6). IL1RL1 has been associated with asthma along with ORMDL355 
which was also decreased by ST2 knockdown. Whilst it appears that an autocrine-route for 
IL-33 signalling in NHBEs seems unlikely, it is interesting that the lack of receptor may alter 
gene expression. This has been seen in Il1rl1 knockout mice and HEK293 overexpressing 
IL1RL1, where ST2 was hypothesised to be sequestering intracellular signalling molecules in 
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unproductive associations193. This work may suggest a more complex role of resting ST2, 
with overexpression of ST2 being required to fully determine whether the gene expression 
changes are not an artefact.  
A logical route of immediate investigation from the gene expression results upon IL-33 
knockdown would be to determine whether these affect the bronchial epithelium in a 
physiological manner. In order to investigate goblet cell hyperplasia, basal cell hyperplasia 
and differentiated epithelium integrity, an ALI culture would need to be used as detailed in 
Section 8.2. Monolayer culture models can be used to investigate cell-substrate adhesion, 
wound healing and TLR4 signalling upon HDM and LPS stimulation. Cell adhesion could be 
measured by pre-coating tissue culture plates with collagen IV and seeding cells for a limited 
amount of time, followed by aspiration of the media where cells can then be quantified using 
a fluorescent live and dead cell quantification assay (for example the MultiTox-Flour Assay 
from Promega). Cells would be pre-treated with IL-33 siRNA or control siRNA before 
seeding and the relative number of cells adhered at 30, 60 and 90 minutes of adhering time 
would be an ideal starting point. Similarly, a microscopy tracked wound-healing assay276 
could be used to determine whether IL-33 alters the capacity for migration and proliferation 
into the cleared area. There may be some differential sensitivity to LPS and HDM as upon IL-
33 knockdown TLR4 was increased and its co-factor LY96 was decreased. From mouse 
studies it has been shown that LPS requires both TLR4 and LY96 for signalling whereas 
HDM only requires TLR4277. LPS and HDM sensitivity could be assessed using both of these 
as stimulations and comparing their cytokine secretion.  
Work in Chapter 7 supports the hypothesis that IL-33 binds to DNA in order to mediate its 
effects on gene expression (shown in Chapter 5), yet the evidence is not sufficient to make a 
strong claim. The ChIP should be optimised by RT-qPCR, using loci from the ChIP-Seq to 
determine optimal conditions for enrichment of IL-33 pull-down DNA. Once a high level of 
ChIP efficiency has been achieved this could then be taken forward for library preparation 
and sequencing, using at least two biological replicates and finding an intersection between 
the peaks called. From here an in depth analysis of ChIP-Seq peaks and any binding motifs 
could be performed with more certainty. Binding motifs could be cloned into a reporter 
construct; co-transfecting IL-33 into this system should then alter the reporter assay (e.g. 
luciferase) readout compared to control plasmid transfection. If a positive result is found here 
with a binding motif, the direct DNA binding could be mediated by a co-factor. This would 
be followed up by an EMSA with IL-33 alone to show whether IL-33 is sufficient to bind 
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DNA. Co-immunoprecipitation followed by mass-spectrometry would allow interacting 
partners of IL-33 to be elucidated.  This could be done by an HA pull-down of over-
expressing (HA-tagged) full length IL-33 and comparing to the cytokine-fragment over-
expression.  
The network analyses from IL-33 knockdown data (Chapter 5) were enriched for genes 
involved in histone methylation and would suggest that IL-33 knockdown may alter the 
chromatin environment through these factors. Moreover, ChIP-Seq peaks (Chapter 7) were 
enriched in promoter and intergenic regions which further suggests a possible chromatin 
modifying role, perhaps via the histone methyltransferase SUV39H1, which co-
immunoprecipitates with IL-33117. ChIP sequencing of NHBEs upon IL-33 knockdown for 
common histone methylation that are broadly associated with activation (H3K4) or silencing 
(H3K9 and H3K27) would determine whether histone modification occurs. In particular, 
SUV39H1 methylates H3K9 and therefore if an interaction with IL-33 alters the role of this 
protein then differential H3K9 methylation would be expected between the control and IL-33 
knockdown cells. 
Gene expression upon IL-33 knockdown combined with IL-33 ChIP-Seq suggests that IL-33 
has a nuclear role that affects genes that are important in other cell types. IL-33 is expressed 
in keratinocytes, and gene ontology terms relating to keratinocyte and epidermis development 
were enriched upon IL-33 knockdown in NHBEs. Genes related to asthmatic fibroblasts were 
also affected, for example COL1A1, COL1A2 and MMP2. Fibroblasts have been shown to 
have increased IL-33 expression in PSTRA patients157 and therefore these gene expression 
changes may be indicative of a key role of this cell type in asthma. Glial cells express IL-33 
and as ChIP-Seq peaks were enriched for genes involved in central nervous system 
development, IL-33 may play a key role in glial cell differentiation. Not all targets were 
suggestive of other cell types, for example SPDEF was decreased upon IL-33 knockdown. 
SPDEF is a key regulator of goblet cell differentiation and is thought to be epithelial-specific.  
The airway epithelium was chosen as the first route of investigation as it is the first barrier 
that any noxious agent comes into contact with in the lung and it has a clear role in priming 
the immune response. It may be worth pursuing further work in other IL-33 expressing cell 
types involved in the asthmatic airways such as fibroblasts, endothelium, mast cells and 
airway smooth muscle.   
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8.2 New routes of investigation 
ALI culture is a more appropriate model for the airway epithelium than submerged monolayer 
culture. This is because ALI culture gives a pseudo-stratified differentiated epithelium with 
the apical aspect exposed to the air, as is the case with the epithelium in the airways. Yet 
knockdown using siRNA in ALI culture is not generally effective278 and work from 
colleagues has proved unsuccessful in the knockdown of IL-33 in ALI culture (data 
unpublished). A lentiviral IL-33 knockdown should be possible and if so, the effect of IL-33 
knockdown during the differentiation process and following differentiation could be 
compared. Indeed, relative levels of ciliated, goblet and basal cells could be determined by 
microscopy. The trans-epithelial airway resistance (TEER) can be measured, which gives the 
electrical resistance of the barrier and therefore its relative permeability. These phenotypes 
are all relevant in asthma and it is reasonable to suggest that IL-33 may affect them. Finally, 
there is some discrepancy in which cell types in healthy bronchial epithelium express IL-33, 
basal epithelium82 or both the basal and apical epithelium86. Using the validated Nessy-1 and 
Cook-3 antibodies would allow the determination of whether IL-33 expression is altered in 
differentiated epithelium.  
In the context of asthmatic airway remodelling, fibroblasts are thought to cause sub-epithelial 
fibrosis. As PSTRA patients have increased bronchial IL-33 expression, specifically increased 
fibroblast IL-33 expression, the nuclear role in these cells may be important. This is further 
reinforced when combined with the differential expression of genes upon IL-33 knockdown 
(Chapter 5) that have been altered in asthmatic fibroblasts (MMP2, COL1A1 and COL1A2). 
Carrying out IL-33 knockdown and over-expression in fibroblasts would be an ideal further 
step to determine the effects of nuclear IL-33 in another asthma-relevant cell type. This would 
have the advantage of elucidating cell-type specific and common changes in gene expression.  
As highlighted at the start of the discussion, GWAS have identified several loci associated 
with asthma and in particular key SNPs near the IL33 gene55.  It is not known whether these 
SNPs (or linked variants) directly cause the increased levels of IL-33 in the bronchial 
epithelium of asthmatics20,58. Indeed, the increase in IL-33 may be due to the asthmatic lung 
microenvironment. Using the antibodies from Section 3.3.5 and either RNA-Seq or PCR 
followed by sequencing (as in Section 3.3.1), the baseline levels of IL-33 expression in 
normal and asthmatic airway epithelium could be determined: in monolayer and ALI culture. 
This would determine whether asthmatic epithelia are predisposed to express more IL-33 or 
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different splice variants. Indeed, Gordon and colleagues279 have shown that brushings from 
human airways express a variety of isoforms of IL-33, with variants lacking exons 3 and 4 
being cytoplasmic and non-nuclear. Moreover the particular isoform was found to be 
associated with a transcriptome-determined TH2 inflammation in asthmatic patient airway 
brushings and could be actively secreted in BEAS-2B cells. Whether the source of the IL-33 
variants is epithelial is not clear as immune cells can express IL-33, however it would prove 
to be an interesting route to follow if a cytokine-only variant plays a role.  
Further to this, with the advance of the CRISPR-CAS9 system, there has been recent success 
in inducing single point mutations280. Though the clonal seeding after gene editing would 
require a cell line to be used, this would allow for the introduction of the SNP associated with 
asthma (rs1342326) in a cell line, which can be compared with the non-mutated-control cell 
line. Investigating the expression of IL-33 in both of these cell lines in stimulated and 
unstimulated cells would determine whether the SNP does directly play a role in the 
expression of IL-33. If this is not found then the SNP associated with asthma is likely to be in 
linkage disequilibrium with the variant that does play a role in the risk of developing asthma. 
As asthma is a complex disease, it is assumed that relatively common polymorphisms all have 
a small contribution to the likelihood of developing disease and therefore a relatively modest 
change in IL-33 may be expected. Another potential use of the CRISPR-CAS9 gene editing 
technique would be to follow up the ChIP-Seq experiments by editing the gene of IL33 and 
creating a fusion with an epitope tag. This would allow for physiological expression levels 
and allow for a successful ChIP-Seq, as current antibodies are not amenable for ChIP (Section 
7.3.1) 
From current evidence in mouse models (see Section 1.2.7.1.1) it appears that murine IL-33 
predominantly functions as a cytokine. This may be due to the modes of investigation used: 
mouse models of asthma that induce large cytokine concentrations, immune cell infiltration, 
airway hyperresponsiveness and airway remodelling as readouts. This may miss subtle 
changes, or there could be compensation for the loss of IL-33’s nuclear role. Carrying out 
murine epithelial cell culture and taking a functional genomics approach as was done in 
Chapters 3, 4 and 5 would determine whether IL-33 in mice does have a nuclear role.  
The work conducted in this thesis has provided new insights into the nuclear role of IL-33 in 
the context of asthma that are worthy of further investigation and may be of relevance in other 
inflammatory diseases.  
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Appendix I – Primer Sequences 
Table shows all primer sequences used and the annealing temperatures 
Target Forward Sequence Reverse Sequence Annealing 
Temperature  
(ºC) 
IL33 (all 
variants) 
TGAGTCTCAACACCCCTCAA TCCTTGTTGTTGGCATGCAA 53 
IL1RL1 
(ST2) 
TGTTCTGGATTGAGGCCACT GGCCCCATCTGTACTGGATT 54 
fl-IL33-HA ATACGAATTCATGAAGCCTAAA
ATGAAGTA 
AGACGATATCAGTTTCAGAGAG
CTTAAAC 
51 
GFP-fl-IL33 ATACCCATGGCTATGGAAATGA
AGCC 
AGACGGATCCCTAAGTTTCAGA
GAGCT 
54 
fl-IL33-GFP ATACCTCGAGATGGAAATGAAG
CCTAA 
AGACGGATCCATAGTTTCAGAG
AGCTTAA 
53 
nn-IL33-HA ATACGAATTCATGAAAAGGCCT
TCAC 
AGACGATATCAGTTTCAGAGAG
CTTAAAC 
51 
GFP-nn-
IL33 
ATACCTCGAGCTAAAAGGCCTT
CAC 
AGACGGATCCCTAAGTTTCAGA
GAGCT 
54 
nn-IL33-
GFP 
ATACCTCGAGATGAAAAGGCCT
TCA 
AGACGGATCCATAGTTTCAGAG
AGCTTAA 
53 
cf-IL33-HA ATACGAATTCATGAGTATCACA
GGAATTTC 
AGACGATATCAGTTTCAGAGAG
CTTAAAC 
51 
GFP-cf-
IL33 
ATACCTCGAGCTAGTATCACAG
GAATTT 
AGACGGATCCCTAAGTTTCAGA
GAGCT 
54 
cf-IL33-
GFP 
ATACCTCGAGATGAGTATCACA
GGAAT 
AGACGGATCCATAGTTTCAGAG
AGCTTAA 
53 
HBB 
promoter 
AGGACAGGTACGGCTGTCATC TTTATGCCCAGCCCTGGCTC 57 
GAPDH 
promoter 
TACTAGCGGTTTTACGGGCG CGAACAGGAGGAGCAGAGAG 55 
RPS13 CTTTACCCTATCGACGCAGC TCTGTGAAGGAGTAAGGCCC 54 
GATA3  CCTCCCTGAGCCACATCTC CCTGACCGAGTTTCCGTAGT 54 
IL33 E2:3 CCAACAAAATTTCCACAGCA TTTCAGTGAAGGCCTTTTGG 54 
IL33 E3:4 CAAAGAAGTTTGCCCCATGT AAGGCAAAGCACTCCACAGT 54 
IL33 E4:5 ATCTGGTACTCGCTGCCTGT TTTCATCCTCCAAAGCAAAA 54 
IL33 E5:6 TTGCTTCTCTAAGCACATACAAT
G 
GATTCATTTGAGGGGTGTTGA 54 
IL33 E6:7 TGAGTCTCAACACCCCTCAA TCCTTGTTGTTGGCATGCAA 53 
IL33 E7:8 AAGACTTCTGGTTGCATGCC AACACTCCAGGATCAGTCTTG 54 
IL33 (5' 
UTR to 3' 
UTR) 
ACAGACTCCTCCGAACACAG TCCAGTGGTAGCATTTGGGT 54 
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Appendix II – Cell Culture and Solutions 
Cell culture media 
A549 and 16HBE cells were grown in Dulbecco’s Modified Eagle’s Medium (GIBCO BRL, 
Gaithersburg, MD) containing 10% v/v foetal calf serum (Sigma) and 2mM L-Glutamine 
(Sigma). BEAS-2B cells were grown in keratinocyte serum-free medium (GIBCO BRL) 
supplemented with recombinant human epidermal growth factor (GIBCO BRL) and bovine 
pituitary extract (GIBCO BRL). HUVECs were grown in Endothelial Cell Medium 
(Promocell) with foetal calf serum (2% v/v), endothelial cell growth supplement (0.4 % v/v), 
epidermal growth factor (0.1 ng/mL), fibroblast growth factor (1ng/mL), heparin (90 µg/mL) 
and hydrocortisone (1 µg/mL). NHBEs were grown in Airway Epithelial Cell Medium 
(Promocell) and supplemented with bovine pituitary extract (0.4 % v/v), epidermal growth 
factor (10 ng/mL), insulin (5 µg/mL), hydrocortisone (0.5 µg/mL), epinephrine (0.5 µg/mL), 
triiodo-L-thyronine (6.7 ng/mL), transferrin (10 µg/mL) and retinoic acid (0.1 ng/mL). 
Starving media for all cell types was the unsupplemented basal medium.  
Optimal seeding density:  
Optimal seeding density for A549 cell in 24-well plates was 1.5 x 105 cells per well. NHBE 
optimal seeding per well of 24-well plates and 100 mm dishes were 1 x 105 and 1.5 x 106 cells 
respectively. 16HBEs were seeded at 1 x 105 cells per 24-well dish, 1 x 105 cells per LabTek 
well and 1.5 x 106 cells per 100 mm dish.  
Buffers 
Permeabilisation buffer for confocal fixation was 1X TBS with 10% goat serum (v/v, Sigma) 
and 0.5% Triton X-100 (v/v, Sigma) 
FACS buffer was 1X PBS with 0.5 % bovine serum albumin (Sigma, w/v) with 0.1% sodium 
azide (Sigma, w/v). 
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Appendix III – Antibody Concentrations 
 
Antibody Name Supplier and Code Species Antibody 
Target 
Technique Concentration  
ß-actin Abcam, AB6276 Mouse, 
mAb 
ß-actin Western 
Blot 
1/20,000 
R&D mAb R&D, MAB3625 Ra, mAb IL-33112-270 Western 
Blot 
1/1,000 
Confocal 1/100 
Lamin A + C Abcam, AB108595 Rabbit, 
mAb 
Lamin A + 
C 
Western 
Blot 
1/20,000 
Normal Rabbit 
IgG 
Millipore, CS200581 Rabbit, 
pAb 
None ChIP 1 µg per IP 
Nessy-1 Enzo, ALX-804-840-
C100 
Mouse, 
mAb 
IL-33112-270 Western 
Blot 
1/1,000 
Confocal 1/100 
ChIP 1 µg per IP 
H3K4me3 Millipore, CS200580 Rabbit, 
mAb 
H3K4me3 ChIP 1 µg per IP 
Cook-5 Cambridge Research 
Biochemicals, custom 
Rabbit, 
pAb 
IL-33243-258 Western 
Blot 
1/1,000 
Confocal 1/100 
Cook-4 Cambridge Research 
Biochemicals, custom 
Rabbit, 
pAb 
IL-3358-74 Western 
Blot 
1/1,000 
Confocal 1/100 
Cook-3 Cambridge Research 
Biochemicals, custom 
Rabbit, 
pAb 
IL-332-17 Western 
Blot 
1/1,000 
Confocal 1/100 
ChIP 6 µg per IP 
anti-Rat (Cy5) ThermoFisher, 
A10525 
Goat, 
pAb 
Rat IgG Confocal 1/250 
anti-Rat (Alkaline 
Phosphatase) 
Millipore, AP136A Goat, 
pAb 
Rat IgG Western 
Blot 
1/20,000 
anti-Rabbit 
(Alkaline 
Phosphatase) 
Millipore, AP132A Goat, 
pAb 
Rabbit IgG Western 
Blot 
1/20,000 
anti-Rabbit (Alexa 
594) 
ThermoFisher, 
A11037 
Goat, 
pAb 
Rabbit IgG Confocal 1/250 
anti-Mouse 
(Alkaline 
Phosphatase) 
Millipore, AP160A Rabbit, 
pAb 
Mouse IgG Western 
Blot 
1/20,000 
anti-Mouse (Alexa 
568) 
ThermoFisher, 
A11031 
Goat, 
pAb 
Mouse IgG Confocal 1/250 
anti-HA Abcam, AB9110 Rabbit, 
pAb 
HA Western 
Blot 
1/4,000 
ChIP 6 µg per IP 
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Appendix IV – Images of IL-33 R&D mAb Staining 
Figure shows images from IL-33 staining with R&D in the one replicate where positive 
staining appeared to be detected. Nuclei (DAPI in A), GFP-fl-IL33 (B), R&D staining (C) and 
a merge of all channels are shown (D).  
 
  
A) DAPI B) GFP 
C) R&D D) Merge 
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Appendix V – Top 250 Differentially Expressed Genes 
upon IL-33 Knockdown and IL-1ß Stimulation 
Ranked by p Value, the top 250 genes differentially expressed upon IL-33 knockdown and 
IL-1ß stimulation. Average expression is the median fluorescent units across the probeset for 
all samples. p Values have been corrected for multiple testing using Benjamini and 
Hochberg’s method.  
Transcript 
Cluster 
Average 
Expression 
Gene 
Symbol 
Maximum 
Fold 
Change 
p Value 
17083433 35 IL33 -20.1 4.8E-20 
16979875 32 PCDH18 15.2 3.0E-19 
16874683 263 KLK5 -5.3 2.1E-17 
17048859 793 ARPC1A -2.5 2.1E-17 
16968468 216 CDS1 -3.7 7.5E-17 
16853445 498 YES1 -2.7 1.3E-15 
16737344 190 PAMR1 2.6 1.5E-15 
16702257 110 LINC00707 -3.5 3.6E-15 
16846587 154 COL1A1 2.5 4.7E-15 
16997816 324 EDIL3 2.5 5.1E-15 
16671023 1284 CRCT1 -5.3 7.6E-15 
16764882 580 KRT75 -5.9 7.6E-15 
16804716 162 SEMA4B -2.7 1.5E-14 
16936925 45 LRRN1 4.6 1.5E-14 
16966026 407 FAM114A1 -2.4 1.8E-14 
16978995 125 ELOVL6 -2.2 1.8E-14 
16827123 106 CMTM4 -3.4 1.8E-14 
16863419 130 IGFL1 -8.0 2.9E-14 
16919531 162 WFDC5 -4.9 3.4E-14 
16808793 61 FBN1 3.0 8.1E-14 
16859643 127 B3GNT3 -2.2 1.0E-13 
16819064 845 MMP2 2.4 1.2E-13 
16867784 1660 C3 2.2 1.2E-13 
17015084 685 SERPINB1 -2.0 1.3E-13 
16874731 449 KLK10 -3.1 1.3E-13 
16717452 701 ERLIN1 -2.3 1.3E-13 
16791219 699 TGM1 -3.6 1.4E-13 
16827041 319 CDH11 -2.2 2.9E-13 
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Transcript 
Cluster 
Average 
Expression 
Gene 
Symbol 
Maximum 
Fold 
Change 
p Value 
16955800 132 PRICKLE2 2.8 2.9E-13 
17000168 624 CXCL14 -4.2 3.1E-13 
16854437 55 CDH2 2.6 4.1E-13 
16828074 1087 AP1G1 -1.8 4.1E-13 
16913681 94 FAM83D -2.5 4.3E-13 
17080788 421 FBXO32 3.7 4.5E-13 
16819689 92 NDRG4 -2.6 4.5E-13 
16999321 124 ZNF608 3.1 4.6E-13 
16980974 23 FAM198B 2.3 5.4E-13 
16676988 149 HSD11B1 -2.3 5.5E-13 
16763295 95 PRICKLE1 2.3 5.5E-13 
16886677 216 GPD2 -2.6 5.5E-13 
17022362 69 SESN1 2.0 5.5E-13 
16966621 86 CWH43 -3.3 6.0E-13 
16807772 135 PLA2G4E -3.9 6.0E-13 
16834785 72 FZD2 2.8 7.2E-13 
17079317 836 TP53INP1 1.8 7.8E-13 
16942648 137 GXYLT2 2.5 8.2E-13 
16880669 2283 LGALSL -2.3 9.4E-13 
16671457 577 IL6R 2.0 9.5E-13 
17115271 77 L1CAM -2.2 1.0E-12 
16858137 246 ICAM1 -5.5 1.0E-12 
16863820 264 SULT2B1 -4.2 1.0E-12 
16906352 49 COL5A2 2.2 1.0E-12 
16662317 154 GJB4 -2.2 1.0E-12 
16874702 1626 KLK7 -4.0 1.0E-12 
16747835 77 NECAP1 -2.3 1.3E-12 
16873104 133 LYPD5 -3.4 1.3E-12 
16785938 351 TTC9 -2.7 1.4E-12 
16766822 253 LRIG3 2.0 1.4E-12 
16706906 58 ADIRF -3.5 1.4E-12 
16693976 131 MUC1 -2.8 1.5E-12 
17112596 46 PCDH19 4.9 1.8E-12 
16714965 150 RUFY2 -2.1 2.4E-12 
16872796 1056 CXCL17 -2.5 2.7E-12 
16728287 165 ANO1 -2.3 2.7E-12 
16842637 516 PIGS -2.0 2.9E-12 
17108816 159 MXRA5 2.8 3.0E-12 
16726336 354 PLCB3 -1.8 3.1E-12 
17008867 99 CUL9 2.0 3.5E-12 
16801179 187 MAPK6 -1.9 4.7E-12 
 
 242 
Transcript 
Cluster 
Average 
Expression 
Gene 
Symbol 
Maximum 
Fold 
Change 
p Value 
16728261 821 CCND1 -2.1 4.8E-12 
16976615 38 SULT1E1 3.0 5.9E-12 
16979225 138 PRSS12 1.8 6.2E-12 
16990862 149 ABLIM3 -2.2 6.4E-12 
16671632 100 EFNA3 -2.2 7.7E-12 
16957396 123 CCDC80 2.0 7.7E-12 
17093949 567 RNF38 1.6 8.0E-12 
16708161 989 ENTPD7 1.7 8.1E-12 
17107309 211 VGLL1 -2.1 9.2E-12 
17018408 317 SPDEF -1.8 9.4E-12 
16975157 102 RELL1 -2.2 9.6E-12 
16728778 156 P2RY2 -2.2 9.6E-12 
17045198 255 ANLN -2.4 1.1E-11 
16668420 79 CSF1 2.6 1.2E-11 
16731773 126 TMPRSS4 -3.1 1.3E-11 
16754536 31 SYT1 2.2 1.3E-11 
17062460 641 WASL -1.9 1.4E-11 
16844200 302 MIEN1 -1.8 1.5E-11 
16996605 243 SMIM15 -2.0 1.5E-11 
16884629 517 IL1RN -2.0 1.6E-11 
16892446 226 INPP5D 1.9 1.8E-11 
17071584 568 ATP6V1C1 -1.5 1.8E-11 
16967202 11 LPHN3 3.1 2.0E-11 
16821398 367 HSBP1 -1.8 2.2E-11 
16754935 1020 TMTC3 -2.1 3.1E-11 
16850294 223 ZNF750 -3.1 3.1E-11 
16855196 551 MYO5B -1.7 4.1E-11 
17076609 134 SFRP1 1.9 4.3E-11 
17009193 141 SLC29A1 -1.9 4.6E-11 
17104332 202 YIPF6 -2.0 4.7E-11 
16733421 233 TMEM45B -2.6 4.7E-11 
17024285 540 CITED2 2.3 5.1E-11 
16874693 626 KLK6 -8.4 5.1E-11 
17092712 16 PLIN2 2.5 5.1E-11 
16742963 19 SYTL2 2.3 5.1E-11 
16874740 393 KLK11 -2.2 5.1E-11 
16978417 83 SLC39A8 2.2 5.2E-11 
16808401 119 FRMD5 2.4 6.4E-11 
16875599 31 TNNT1 -2.5 6.6E-11 
17078134 41 EYA1 2.2 6.9E-11 
17107919 756 ZNF185 -1.8 6.9E-11 
  
 243 
Transcript 
Cluster 
Average 
Expression 
Gene 
Symbol 
Maximum 
Fold 
Change 
p Value 
17007810 717 PPARD -2.0 6.9E-11 
16944325 741 UPK1B -2.3 6.9E-11 
16976438 273 TMPRSS11D -2.0 6.9E-11 
16940260 270 NBEAL2 -1.8 7.4E-11 
16998293 97 GLRX -1.9 7.5E-11 
17092081 11 GLIS3 2.6 7.5E-11 
16672027 177 TMEM79 -2.2 7.9E-11 
16896561 106 CYP1B1 3.2 8.4E-11 
16898788 348 TGFA -1.7 8.6E-11 
16670574 214 ECM1 -1.9 9.2E-11 
16857886 323 ANGPTL4 -2.8 1.1E-10 
16791371 36 RIPK3 -2.0 1.2E-10 
16983652 23 CDH6 3.7 1.2E-10 
16907198 75 FAM126B -1.7 1.3E-10 
16720077 223 IFITM2 -2.5 1.4E-10 
16743764 104 MMP13 7.1 1.5E-10 
16847841 1271 SMURF2 -1.5 1.6E-10 
16682989 509 ECE1 -1.7 1.8E-10 
16863063 357 CBLC -1.8 1.9E-10 
17051860 833 BPGM -1.9 1.9E-10 
16825647 104 GDPD3 -2.9 2.1E-10 
16848902 72 UNC13D -2.7 2.2E-10 
17043856 1435 AHR 1.6 2.3E-10 
17097869 474 MEGF9 1.5 2.3E-10 
16790143 53 NDRG2 -2.3 2.6E-10 
16706499 1721 PPIF -1.6 2.9E-10 
16833921 66 GSDMA -2.9 3.1E-10 
16724061 74 CD82 -1.8 3.1E-10 
17077774 263 PDE7A 1.8 3.1E-10 
17096285 385 CTSV -2.3 3.1E-10 
16705715 2429 EIF4EBP2 1.4 3.1E-10 
16761877 167 EPS8 2.1 3.2E-10 
16881838 214 HK2 -2.0 3.3E-10 
16862563 392 CEACAM6 -2.4 3.3E-10 
17081106 123 GSDMC -2.2 3.3E-10 
17014442 62 SLC22A3 -2.6 3.4E-10 
16884335 31 BCL2L11 2.4 3.6E-10 
17011279 129 PRDM1 -1.8 3.8E-10 
16826779 209 DOK4 -1.7 3.8E-10 
16827131 239 DYNC1LI2 -1.7 4.1E-10 
16696295 244 KIFAP3 -1.6 4.3E-10 
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Transcript 
Cluster 
Average 
Expression 
Gene 
Symbol 
Maximum 
Fold 
Change 
p Value 
16885199 151 TSN -1.9 4.4E-10 
16683960 142 MAP3K6 -1.8 4.9E-10 
16714699 90 RHOBTB1 2.1 5.1E-10 
16775883 753 MBNL2 1.6 5.2E-10 
16683920 119 FAM46B -2.5 6.3E-10 
16767851 307 E2F7 1.9 6.3E-10 
16971631 42 TLR2 2.3 6.3E-10 
16703036 472 PLXDC2 1.8 6.3E-10 
17004903 1757 EDN1 -1.8 6.4E-10 
17082109 57 MROH6 -1.8 6.7E-10 
16839710 38 TRPV3 -2.5 6.8E-10 
16999180 46 LOX 2.2 7.0E-10 
16929015 35 OSBP2 -1.9 7.0E-10 
16683221 137 WNT4 2.7 7.2E-10 
16921268 141 PTK6 -2.0 7.2E-10 
16802795 143 NEO1 1.6 7.7E-10 
16883624 20 IL1R2 -3.1 7.8E-10 
17012963 54 KIAA1244 -1.7 7.8E-10 
16774303 150 RGCC 2.7 7.8E-10 
17084838 83 RECK 2.8 8.1E-10 
16811684 73 CYP1A1 4.1 8.3E-10 
16819892 594 CES2 -1.7 8.3E-10 
16839352 1363 MYO1C -1.6 8.3E-10 
16911040 196 CDC25B -1.9 8.3E-10 
16667346 129 SLC44A3 -1.5 8.3E-10 
17114272 129 GPC4 2.6 8.4E-10 
16855184 319 ACAA2 1.9 8.5E-10 
16994002 127 LPCAT1 -1.8 8.5E-10 
16873632 471 SLC1A5 -1.9 8.8E-10 
16954401 38 HYAL1 -2.9 9.7E-10 
16676983 421 G0S2 -1.8 9.8E-10 
16786872 59 TMEM63C -2.3 9.9E-10 
16748304 67 GABARAPL1 2.1 1.0E-09 
16675763 1314 PKP1 -1.7 1.0E-09 
17059828 201 TFPI2 -2.1 1.0E-09 
17000650 164 TMEM173 -1.7 1.0E-09 
16865590 110 EPS8L1 -2.2 1.0E-09 
17047918 182 CROT 2.0 1.0E-09 
16782818 102 LTB4R -2.0 1.2E-09 
16735738 125 RNF141 -1.8 1.2E-09 
17012047 525 DCBLD1 1.9 1.3E-09 
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Average 
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16854425 83 CHST9 2.3 1.3E-09 
16827574 467 ESRP2 -2.0 1.4E-09 
16863864 102 FUT2 -2.1 1.4E-09 
16774053 102 CCNA1 -3.1 1.4E-09 
16695602 155 B4GALT3 -1.7 1.4E-09 
17100201 108 CLIC3 -2.4 1.5E-09 
17048473 15 COL1A2 2.3 1.5E-09 
16834700 664 G6PC3 -1.6 1.6E-09 
16722143 238 MICALCL -2.0 1.6E-09 
16780808 76 KDELC1 1.9 1.7E-09 
17001901 697 FAT2 1.6 1.7E-09 
17047795 8 CD36 2.6 1.7E-09 
16956532 586 VGLL3 1.6 1.8E-09 
16887237 17 DHRS9 -2.8 1.9E-09 
16884607 40 IL36RN -3.1 1.9E-09 
16938935 258 GOLGA4 -2.0 2.0E-09 
16952769 1382 CDCP1 -1.4 2.1E-09 
16852445 116 C18orf54 -1.9 2.2E-09 
16716341 76 ANKRD22 -3.1 2.3E-09 
16745563 237 CLMP -1.8 2.3E-09 
16662322 978 GJB3 -1.5 2.6E-09 
16852726 142 KIAA1468 -1.7 2.7E-09 
16968122 97 FRAS1 1.7 2.8E-09 
17007910 431 MAPK13 -1.6 2.8E-09 
16929368 39 SLC5A1 -3.6 2.8E-09 
16959871 217 TFDP2 1.5 2.8E-09 
16937137 68 LMCD1 2.0 3.0E-09 
16791898 180 CFL2 -2.1 3.0E-09 
16793299 83 LINC00520 -2.6 3.0E-09 
17045806 104 ADCY1 2.2 3.1E-09 
16844663 39 KRT34 -2.3 3.1E-09 
16735332 48 NLRP10 -2.8 3.2E-09 
16785897 114 SMOC1 2.1 3.4E-09 
16680034 66 RNF223 -2.1 3.5E-09 
16861945 683 NCCRP1 -2.4 3.7E-09 
16768270 103 KITLG 1.9 3.8E-09 
16850063 567 STRA13 -1.6 3.9E-09 
16733883 168 ANO9 -1.8 3.9E-09 
16660360 1442 CDA -1.6 4.1E-09 
16813112 587 RHCG -2.2 4.1E-09 
16992467 46 CREBRF 2.2 4.2E-09 
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16808609 200 DUOXA1 -2.0 4.3E-09 
16672457 120 DUSP23 -2.2 4.3E-09 
16869803 176 EPHX3 -2.6 4.3E-09 
16775546 336 SCEL -2.4 4.5E-09 
16979163 130 ARSJ -1.8 4.6E-09 
16844674 155 KRT31 -2.0 4.8E-09 
16795128 122 TMED8 -1.8 4.8E-09 
17019029 98 TREM2 -2.4 4.8E-09 
16705507 88 SRGN 2.4 4.8E-09 
16986583 153 JMY 1.6 5.3E-09 
16829139 544 MVD -1.6 5.5E-09 
16817824 184 CORO1A -2.1 5.6E-09 
17090296 556 ASS1 -2.0 5.6E-09 
16687352 123 LRP8 -1.7 5.8E-09 
16976468 59 TMPRSS11F -3.0 6.3E-09 
16869023 46 ACP5 -2.4 7.3E-09 
16972663 72 TENM3 1.9 7.7E-09 
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Appendix VI – Top 25 Genes from WGCNA Modules 
Correlated with Transfection  
Top 25 Black Module genes (out of 169 filtered genes) 
Pearson r values for correlations between the gene and transfection status (Transfection r) and 
between the gene and module eigengene (Module Membership) with corresponding p Values. 
p Values have been corrected for multiple testing by Benjamini and Hochberg’s method.  
Gene Symbol Transfection r 
Transfection 
p Value 
Module 
Membership 
Module 
p Value 
DNALI1 0.81 1.5E-09 0.76 7.0E-08 
CHST9 0.80 6.3E-09 0.80 4.5E-09 
MOV10 0.78 2.4E-08 0.80 3.2E-09 
LOX 0.77 2.9E-08 0.85 6.0E-11 
CRISPLD1 0.77 4.0E-08 0.80 3.7E-09 
PTPRM 0.77 5.1E-08 0.92 1.7E-15 
COL4A6 0.76 8.5E-08 0.78 1.9E-08 
HMGN3 0.75 1.3E-07 0.88 1.6E-12 
CFI 0.74 2.2E-07 0.73 5.0E-07 
ZNF738 0.73 4.9E-07 0.74 3.1E-07 
PLAGL1 0.73 5.6E-07 0.84 1.0E-10 
HERC2P9 0.72 7.6E-07 0.67 6.5E-06 
CBY1 0.72 8.1E-07 0.66 1.3E-05 
TWSG1 0.72 9.4E-07 0.77 5.4E-08 
PEX1 0.71 1.1E-06 0.76 7.4E-08 
GPX7 0.71 1.5E-06 0.83 2.9E-10 
AADAT 0.70 1.7E-06 0.83 4.4E-10 
CNN2 0.70 1.8E-06 0.68 4.9E-06 
SFRP1 0.70 2.1E-06 0.85 6.4E-11 
TMEM245 0.69 3.0E-06 0.78 2.2E-08 
ATXN10 0.69 3.2E-06 0.86 2.9E-11 
CBX6 0.69 3.4E-06 0.62 4.9E-05 
MAP4K5 0.69 3.5E-06 0.72 8.8E-07 
TLK1 0.69 3.5E-06 0.76 8.4E-08 
MAP3K7CL 0.69 3.8E-06 0.66 1.4E-05 
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Top 25 Blue Module genes (out of 886 filtered genes) 
Pearson r values for correlations between the gene and transfection status (Transfection r) and 
between the gene and module eigengene (Module Membership) with corresponding p Values. 
p Values have been corrected for multiple testing by Benjamini and Hochberg’s method.  
Gene Symbol Transfection r 
Transfection 
p Value 
Module 
Membership 
Module p 
Value 
COL1A1 0.98 2.7E-24 0.94 3.8E-17 
MMP2 0.97 3.5E-22 0.92 4.4E-15 
EIF4EBP2 0.96 3.6E-21 0.91 3.5E-14 
PAMR1 0.96 3.9E-20 0.87 7.5E-12 
PCDH18 0.96 8.9E-20 0.96 4.4E-20 
GXYLT2 0.96 1.1E-19 0.94 1.6E-17 
COL5A2 0.95 1.9E-19 0.90 8.4E-14 
CCDC80 0.95 2.1E-18 0.87 8.8E-12 
FBN1 0.94 5.2E-18 0.88 1.1E-12 
EDIL3 0.94 1.8E-17 0.90 1.1E-13 
LRRN1 0.94 1.9E-17 0.89 3.2E-13 
SYTL2 0.94 4.8E-17 0.92 3.2E-15 
NEO1 0.94 5.4E-17 0.94 3.5E-17 
SESN1 0.93 9.0E-17 0.95 4.4E-19 
PTPN14 0.93 3.2E-16 0.93 1.1E-16 
SIDT2 0.92 2.5E-15 0.84 1.3E-10 
PXDN 0.92 3.0E-15 0.90 5.9E-14 
CDH6 0.92 3.1E-15 0.85 6.3E-11 
PRSS12 0.92 4.4E-15 0.90 6.9E-14 
FZD2 0.91 6.0E-15 0.92 4.9E-15 
LRIG3 0.91 1.6E-14 0.91 2.1E-14 
CROT 0.91 2.3E-14 0.87 3.5E-12 
ACAA2 0.91 3.1E-14 0.77 3.9E-08 
EYA1 0.91 3.6E-14 0.94 5.4E-17 
FRMD5 0.90 3.6E-14 0.91 7.3E-15 
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Top 25 Green Module genes (out of 184 filtered genes) 
Pearson r values for correlations between the gene and transfection status (Transfection r) and 
between the gene and module eigengene (Module Membership) with corresponding p Values. 
p Values have been corrected for multiple testing by Benjamini and Hochberg’s method.  
Gene 
Symbol 
Transfection 
r 
Transfection 
p Value 
Module 
Membership 
Module p 
Value 
SPDEF -0.94 4.0E-17 0.86 1.5E-11 
ELOVL6 -0.93 2.1E-16 0.94 4.5E-18 
RUFY2 -0.93 2.8E-16 0.79 1.2E-08 
ECE1 -0.91 2.2E-14 0.89 5.4E-13 
CDCP1 -0.90 6.3E-14 0.89 3.0E-13 
RRBP1 -0.89 1.8E-13 0.87 8.1E-12 
MAPKAPK3 -0.89 3.5E-13 0.92 4.7E-15 
LGALSL -0.88 8.2E-13 0.87 7.1E-12 
ITPR3 -0.88 1.2E-12 0.84 1.3E-10 
ANO9 -0.88 1.9E-12 0.70 1.9E-06 
WIPF2 -0.87 5.9E-12 0.87 8.1E-12 
EFNA3 -0.86 1.3E-11 0.95 7.3E-19 
FKBP10 -0.86 1.7E-11 0.77 3.9E-08 
KIAA1244 -0.86 2.2E-11 0.88 9.6E-13 
C18orf54 -0.86 2.3E-11 0.80 4.6E-09 
ATP2C2 -0.86 2.5E-11 0.86 2.8E-11 
KLK11 -0.85 3.4E-11 0.95 3.2E-19 
EPB41L5 -0.85 3.9E-11 0.83 3.4E-10 
OSGIN1 -0.85 6.3E-11 0.74 2.8E-07 
TLCD2 -0.84 1.5E-10 0.88 1.3E-12 
EHBP1L1 -0.84 2.3E-10 0.85 7.0E-11 
SLC29A1 -0.84 2.3E-10 0.82 6.6E-10 
BCAP31 -0.83 2.7E-10 0.82 1.0E-09 
HLA-G -0.83 3.4E-10 0.76 8.2E-08 
LATS2 -0.83 3.5E-10 0.68 6.2E-06 
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Top 25 Greenyellow Module genes (out of 100 filtered genes) 
Pearson r values for correlations between the gene and transfection status (Transfection r) and 
between the gene and module eigengene (Module Membership) with corresponding p Values. 
p Values have been corrected for multiple testing by Benjamini and Hochberg’s method.  
Gene Symbol Transfection r 
Transfection 
p Value 
Module 
Membership 
Module p 
Value 
ZKSCAN7 0.80 5.6E-09 0.85 3.6E-11 
B3GALNT2 0.79 8.0E-09 0.71 1.1E-06 
SYNRG 0.79 1.2E-08 0.79 8.5E-09 
ABCC5 0.78 1.5E-08 0.82 1.3E-09 
BCAS3 0.75 1.5E-07 0.82 1.1E-09 
HINFP 0.75 1.5E-07 0.74 2.3E-07 
PAXIP1-AS2 0.74 1.9E-07 0.75 1.1E-07 
CCDC146 0.74 2.9E-07 0.78 1.8E-08 
NACC2 0.72 8.0E-07 0.83 3.3E-10 
BMPER 0.72 8.3E-07 0.78 1.6E-08 
PROS1 0.71 1.1E-06 0.77 3.7E-08 
PRRC1 0.71 1.5E-06 0.69 3.6E-06 
S100PBP 0.69 2.6E-06 0.71 1.4E-06 
LRP1 0.69 2.9E-06 0.78 1.6E-08 
TTC30A 0.68 5.5E-06 0.78 1.7E-08 
TUG1 0.68 6.0E-06 0.72 5.7E-07 
ARID2 0.67 7.3E-06 0.87 4.3E-12 
SPOCK3 0.67 9.3E-06 0.78 2.6E-08 
ZMYM2 0.66 1.0E-05 0.71 1.2E-06 
C9orf69 0.66 1.2E-05 0.74 3.0E-07 
ADCY1 0.66 1.3E-05 0.87 7.5E-12 
CDK19 0.66 1.4E-05 0.79 1.4E-08 
EPHB4 0.64 2.4E-05 0.83 3.2E-10 
CHD7 0.64 2.9E-05 0.79 1.3E-08 
CYP26B1 0.63 3.2E-05 0.68 5.4E-06 
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Top 25 Lightcyan Module genes (out of 395 filtered genes) 
Pearson r values for correlations between the gene and transfection status (Transfection r) and 
between the gene and module eigengene (Module Membership) with corresponding p Values. 
p Values have been corrected for multiple testing by Benjamini and Hochberg’s method.  
Gene Symbol Transfection r 
Transfection 
p Value 
Module 
Membership 
Module p 
Value 
C3 0.92 4.0E-15 0.79 7.6E-09 
MEGF9 0.91 3.1E-14 0.79 1.2E-08 
RNF38 0.90 1.2E-13 0.89 6.0E-13 
ENTPD7 0.89 5.1E-13 0.90 1.0E-13 
SULT1E1 0.88 8.2E-13 0.85 7.3E-11 
TP53INP1 0.88 9.6E-13 0.95 2.7E-18 
TFDP2 0.87 3.7E-12 0.88 2.4E-12 
FAM160B1 0.87 7.2E-12 0.86 1.6E-11 
CSNK1G1 0.86 1.0E-11 0.85 8.0E-11 
PDE7A 0.86 1.2E-11 0.77 5.5E-08 
ERAP1 0.86 2.4E-11 0.82 1.1E-09 
NCOA2 0.86 2.7E-11 0.87 3.5E-12 
TLE4 0.85 3.5E-11 0.83 3.5E-10 
BAZ2B 0.85 5.4E-11 0.90 3.8E-14 
FN1 0.85 6.9E-11 0.73 4.9E-07 
TCF7L2 0.85 8.5E-11 0.80 4.9E-09 
FBXO32 0.83 3.8E-10 0.81 2.6E-09 
RAB8B 0.83 3.9E-10 0.85 9.0E-11 
MANBA 0.83 4.7E-10 0.79 8.7E-09 
CITED2 0.82 1.2E-09 0.77 3.3E-08 
LOC644794 0.81 1.4E-09 0.79 1.4E-08 
CLASP1 0.81 1.5E-09 0.82 1.3E-09 
TLR2 0.81 1.8E-09 0.81 2.6E-09 
SORBS2 0.81 1.8E-09 0.83 3.6E-10 
JAK1 0.81 1.9E-09 0.83 4.2E-10 
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Appendix VII – Overlap of IL-33 Knockdown 
Differentially Expressed Genes and IL-33 ChIP-Seq Peaks  
Average expression is the median fluorescent units across the probeset for all samples. p 
Values have been corrected for multiple testing using Benjamini and Hochberg’s method. 
Transcript 
Cluster 
Average 
Expression 
Gene 
Symbol 
Maximum 
Fold 
Change 
p Value 
16997816 324.0 EDIL3 2.5 5.1E-15 
16808793 61.1 FBN1 3.0 8.1E-14 
16828074 1086.7 AP1G1 -1.8 4.1E-13 
16886677 215.6 GPD2 -2.6 5.5E-13 
17022362 69.1 SESN1 2.0 5.5E-13 
17079317 836.4 TP53INP1 1.8 7.8E-13 
16693976 131.5 MUC1 -2.8 1.5E-12 
16728287 165.4 ANO1 -2.3 2.7E-12 
16975157 102.5 RELL1 -2.2 9.6E-12 
16892446 225.9 INPP5D 1.9 1.8E-11 
17076609 133.9 SFRP1 1.9 4.3E-11 
16978417 82.6 SLC39A8 2.2 5.2E-11 
17007810 716.7 PPARD -2.0 6.9E-11 
16743764 104.1 MMP13 7.1 1.5E-10 
16705715 2429.4 EIF4EBP2 1.4 3.1E-10 
16761877 166.8 EPS8 2.1 3.2E-10 
16775883 753.1 MBNL2 1.6 5.2E-10 
17082109 57.3 MROH6 -1.8 6.7E-10 
16929015 35.2 OSBP2 -1.9 7.0E-10 
17114272 128.7 GPC4 2.6 8.4E-10 
16994002 127.1 LPCAT1 -1.8 8.5E-10 
16954401 38.3 HYAL1 -2.9 9.7E-10 
16865590 110.0 EPS8L1 -2.2 1.0E-09 
16782818 101.6 LTB4R -2.0 1.2E-09 
16968122 96.7 FRAS1 1.7 2.8E-09 
17007910 431.3 MAPK13 -1.6 2.8E-09 
16959871 216.6 TFDP2 1.5 2.8E-09 
16785897 114.3 SMOC1 2.1 3.4E-09 
16869023 46.2 ACP5 -2.4 7.3E-09 
16972663 72.3 TENM3 1.9 7.7E-09 
16831013 45.1 NTN1 2.5 7.9E-09 
16730429 221.4 ARHGAP42 1.8 8.4E-09 
16964027 177.9 FGFR3 -2.4 9.2E-09 
16961501 27.9 TNIK 1.9 1.8E-08 
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Transcript 
Cluster 
Average 
Expression 
Gene 
Symbol 
Maximum 
Fold 
Change 
p Value 
16842618 134.5 SLC46A1 1.9 2.8E-08 
16920169 809.4 B4GALT5 -1.6 2.8E-08 
16951756 448.2 SLC4A7 1.5 3.2E-08 
16877225 112.8 LPIN1 -1.5 3.9E-08 
17005281 24.5 CASC15 2.1 5.5E-08 
16716547 365.6 IDE -1.5 6.1E-08 
16743517 168.2 MAML2 1.8 7.3E-08 
16673842 47.5 DNM3 1.9 8.3E-08 
16839177 65.4 METRNL -2.3 1.1E-07 
16664978 44.8 ACOT11 -1.8 1.3E-07 
16722720 110.9 NAV2 1.5 1.3E-07 
16662234 142.3 ZNF362 1.6 1.5E-07 
16810523 438.0 CSNK1G1 1.5 1.8E-07 
16795582 417.0 PTPN21 1.5 2.8E-07 
17001800 523.2 ANXA6 -1.7 3.8E-07 
16813799 251.2 CERS3 -1.9 3.9E-07 
16686557 95.6 PIK3R3 1.6 4.0E-07 
16694617 40.2 IQGAP3 -1.8 4.6E-07 
16755908 594.7 DRAM1 1.5 4.8E-07 
16785155 189.1 SYNE2 1.6 1.0E-06 
17111366 82.3 PHF8 1.5 1.1E-06 
16852296 971.9 LIPG -1.4 1.2E-06 
17069250 147.5 RAB2A -1.5 1.6E-06 
16853716 53.3 LAMA1 1.6 1.6E-06 
16754808 24.0 TMTC2 -1.7 2.0E-06 
16687208 203.2 ZCCHC11 1.4 2.4E-06 
16935703 293.7 ARFGAP3 -1.4 2.8E-06 
16809687 677.7 NEDD4 1.4 2.8E-06 
17099816 137.6 NACC2 1.7 2.9E-06 
17020317 266.6 DST 1.5 2.9E-06 
16665901 26.4 IL12RB2 2.3 3.0E-06 
16977196 199.7 CNOT6L 1.5 3.2E-06 
17057478 115.5 IGFBP3 -2.1 3.9E-06 
16775811 70.6 GPC6 2.0 5.4E-06 
17046982 14.0 CLDN4 -1.8 5.7E-06 
17078330 46.9 UBE2W -1.6 7.0E-06 
17089003 494.7 OLFML2A 1.9 7.2E-06 
16811359 54.4 GRAMD2 1.6 7.7E-06 
16881634 110.0 TET3 1.7 8.2E-06 
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16954641 268.0 PCBP4 -1.5 8.2E-06 
17008750 736.0 KLHDC3 1.6 1.0E-05 
17104217 622.2 ZXDB 1.6 1.0E-05 
16819678 110.8 GINS3 -1.7 1.1E-05 
16713614 135.3 MARCH8 1.4 1.3E-05 
16972198 17.5 TLL1 1.6 1.3E-05 
17111413 22.4 FAM120C 1.7 1.4E-05 
16729789 314.9 PRSS23 1.5 1.6E-05 
16898911 24.8 CYP26B1 2.1 1.6E-05 
16847578 160.3 LIMD2 1.5 1.9E-05 
16923239 55.5 PDE9A -1.6 2.0E-05 
16737669 158.2 PHF21A 1.4 2.0E-05 
16719254 70.4 NKX1-2 1.8 2.1E-05 
16928867 277.5 MTMR3 1.5 2.1E-05 
16664748 78.2 GPX7 1.8 2.2E-05 
16823825 291.8 EMP2 -1.5 2.2E-05 
16920299 25.2 KCNG1 -1.7 2.4E-05 
16744524 143.2 USP28 1.5 2.5E-05 
17088100 485.8 UGCG -1.5 2.8E-05 
16974830 9.4 PPARGC1A 2.0 2.8E-05 
16801512 99.3 FAM63B -1.5 2.9E-05 
16661544 432.9 SESN2 1.6 3.1E-05 
16661351 457.2 WDTC1 1.5 3.1E-05 
16995339 60.2 C5orf42 1.5 3.5E-05 
16993746 27.5 TPPP -1.8 3.6E-05 
16991527 39.7 CYFIP2 1.4 3.9E-05 
16795368 301.0 STON2 1.4 4.3E-05 
16740828 28.7 CTSF 1.7 5.0E-05 
17001404 33.8 SH3TC2 -1.6 6.8E-05 
17001063 123.0 SPRY4 -1.8 6.9E-05 
17053100 46.6 ZNF783 1.6 7.5E-05 
16752825 17.8 NXPH4 -2.0 7.6E-05 
16777143 74.2 PSPC1 1.4 7.8E-05 
16969495 49.7 NPNT 1.8 8.7E-05 
17123306 26.2 PROS1 1.7 9.2E-05 
17094761 69.2 KLF9 1.4 1.0E-04 
16776117 83.4 PCCA 1.6 1.1E-04 
16827833 341.5 MTSS1L 1.5 1.1E-04 
16910284 21.2 C2orf54 -2.2 1.1E-04 
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17088300 148.3 ZNF618 1.4 1.3E-04 
16814915 206.8 SLC9A3R2 -1.5 1.3E-04 
16999475 527.8 FBN2 1.5 1.4E-04 
16934568 42.7 FOXRED2 1.7 1.4E-04 
16887360 165.8 UBR3 -1.5 1.5E-04 
16974096 256.3 GRPEL1 -1.6 1.5E-04 
16689969 58.2 DPYD 1.5 1.6E-04 
16710245 51.9 ACADSB 1.9 1.8E-04 
16762978 43.0 AMN1 -1.7 1.8E-04 
16795508 39.8 GALC -1.4 2.8E-04 
16736120 11.7 SOX6 1.5 2.9E-04 
16882895 17.8 KCNIP3 -1.6 2.9E-04 
16914925 46.9 TSHZ2 1.5 3.4E-04 
16975954 276.4 SCFD2 -1.4 3.5E-04 
16795664 94.3 FOXN3 1.4 3.5E-04 
16937505 64.6 FANCD2 -1.6 3.8E-04 
16782805 26.7 LTB4R2 -1.6 4.4E-04 
16917004 343.2 GPCPD1 1.4 4.5E-04 
16658390 48.0 ESPN -1.7 4.5E-04 
16707379 620.4 TNKS2 1.4 4.6E-04 
17019365 220.5 ZNF318 1.4 4.6E-04 
17069272 159.4 CHD7 1.4 4.9E-04 
17045917 127.5 UPP1 -1.5 5.6E-04 
16992989 214.3 NSD1 1.4 5.7E-04 
16985704 261.0 OCLN -1.4 5.7E-04 
17123310 30.4 PROS1 1.8 6.3E-04 
16889475 22.1 CASP8 -1.4 7.2E-04 
16737543 14.6 TP53I11 -1.6 7.4E-04 
16684429 14.5 FABP3 -1.9 7.5E-04 
16937626 63.2 SLC6A11 -1.6 7.8E-04 
16902437 37.3 CYP27C1 -1.9 8.1E-04 
16681323 252.7 RERE 1.4 8.7E-04 
16859611 16.8 FCHO1 -1.6 9.0E-04 
16708089 10.4 GOLGA7B -2.2 9.1E-04 
16984056 25.1 SLC1A3 1.4 9.6E-04 
17123802 13.0 LINC01088 -1.5 9.7E-04 
 
 
